

# CITATION REPORT

List of articles citing

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

DOI: 10.1056/nejm199011083231901

New England Journal of Medicine, 1990, 323, 1289-98.

**Source:** <https://exaly.com/paper-pdf/21782127/citation-report.pdf>

**Version:** 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2012	Evolution and Progression of Atherosclerotic Lesions in the first Forty Years of Life. <b>1992</b> , 1-8		
2011	Herzinfarkt - und wie geht es weiter?.		
2010	LDL Immunoapheresis (LDL-Therasorb): Efficacy, Safety, and Effects on Coronary Heart Disease. <b>1993</b> , 129-138		
2009	Regression of coronary atherosclerosis. <i>New England Journal of Medicine</i> , <b>1990</b> , 323, 1337-9	59.2	35
2008	Cholesterol Redux. <b>1990</b> , 264, 3060		2
2007	Regression of Coronary Atherosclerosis During Treatment of Familial Hypercholesterolemia With Combined Drug Regimens. <b>1990</b> , 264, 3007		476
2006	Clinical considerations regarding treatment of hypercholesterolemia in the elderly. <b>1991</b> , 91 Suppl, S35-57		16
2005	Relationship of skeletal muscle fiber type to serum high density lipoprotein cholesterol and apolipoprotein A-I levels. <b>1991</b> , 90, 49-57		28
2004	Predictability and coronary disease. <b>1991</b> , 338, 1364-1365		
2003	Why screen children for blood cholesterol levels?. <b>1991</b> , 1, 571-4		0
2002	MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. <b>1991</b> , 337, 1235-1243		2919
2001	Coronary disease and stroke in patients with large-vessel peripheral arterial disease. <b>1991</b> , 42 Suppl 5, 16-21		39
2000	Rational therapy to reduce mortality and reinfarction following myocardial infarction. <b>1991</b> , 122, 1740-50		6
1999	Should we diagnose early coronary artery disease and how?. <b>1991</b> , 122, 1798-9		
1998	Workshop VI--Regression of atherosclerosis: what does it mean?. <b>1991</b> , 90, 53S-55S		3
1997	Regression of coronary atherosclerosis: an achievable goal? Review of results from recent clinical trials. <b>1991</b> , 91, 10S-17S		14
1996	Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia. <b>1991</b> , 91, 18S-24S		33

1995	Rationale for treatment. <b>1991</b> , 91, 31S-36S	6
1994	Niacin revisited: clinical observations on an important but underutilized drug. <b>1991</b> , 91, 239-46	65
1993	Possible role of macrophages in regression of atherosclerosis. <b>1991</b> , 30, 237-43	11
1992	Intravascular ultrasound imaging: a current perspective. <b>1991</b> , 18, 1811-23	69
1991	Fate of venous grafts: the past, the present and the future. <b>1991</b> , 17, 1081-3	103
1990	Low-dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation. <b>1991</b> , 33, 241-6	33
1989	Screening and intervention for cholesterol. <b>1991</b> , 21, 393-5	1
1988	Physician response to screening for hypercholesterolaemia in a coronary care unit. <b>1991</b> , 21, 401-4	1
1987	Hypercholesterolaemia and vascular disease after transplantation. <b>1991</b> , 5, 131-149	15
1986	Regression of atherosclerosis in humans by lowering serum cholesterol. <b>1991</b> , 89, 1-10	32
1985	Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apo B levels. <b>1991</b> , 89, 109-16	61
1984	Rediscovery of crystalline niacin. <b>1991</b> , 66, 112-3	3
1983	Limits to Human Life Expectancy: Evidence, Prospects, and Implications. <b>1991</b> , 17, 603	116
1982	Cholesterol, primary and secondary prevention, and all-cause mortality. <b>1991</b> , 115, 973-6	28
1981	Guidelines for the detection and treatment of elevated serum cholesterol: which is the baby and which is the bathwater?. <b>1991</b> , 115, 324-6	3
1980	Evaluation of human panelists in assessing coronary atherosclerosis. <b>1991</b> , 11, 385-94	22
1979	Uncomplicated acute myocardial infarction. Methods of nonlytic management. <b>1991</b> , 90, 71-2, 77-9, 82	
1978	Can life-style changes reverse coronary atherosclerosis?. <b>1991</b> , 26, 123-6, 129-32	9

1977	The Effect of Pravastatin on Plasma Lipoprotein and Apolipoprotein Levels in Primary Hypercholesterolemia. <b>1991</b> , 151, 2234	10
1976	Hyperlipidemia. What to do when life-style changes aren't enough. <b>1991</b> , 90, 213-7, 220-4	
1975	Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. <b>1991</b> , 115, 687-93	123
1974	On Jumbo and Junk Trials. A fumbled affair, a jungle, or the ultimate solution?. <b>1991</b> , 12, 103-103	
1973	Serum cholesterol and coronary heart disease. <b>1991</b> , 20, 226	
1972	The effects of lipid lowering on diabetic retinopathy. <b>1991</b> , 112, 385-91	118
1971	How much testing is needed after myocardial infarction?. <b>1991</b> , 90, 74-81, 84	1
1970	Treating serum lipid abnormalities in high-priority patients. <b>1991</b> , 89, 81-2, 87-90, 93-6	2
1969	Usefulness of the total cholesterol to high-density lipoprotein cholesterol ratio in predicting angiographic coronary artery disease in women. <b>1991</b> , 68, 1646-50	49
1968	National Cholesterol Education Program's recommendations, and implications of "missing" high-density lipoprotein cholesterol in cardiac rehabilitation programs. <b>1991</b> , 68, 1087-8	46
1967	On jumbo and junk trials: a fumbled affair, a jungle, or the ultimate solution?. <b>1991</b> , 67, 763-4	2
1966	Management of hypertriglyceridemic patients. A. Treatment classifications and goals. <b>1991</b> , 68, 30A-34A	22
1965	Long-term complications of cardiac transplantation. <b>1991</b> , 33, 229-82	71
1964	Noninvasive and invasive testing after myocardial infarction. <b>1991</b> , 16, 721-63	1
1963	Drug intervention trials in dyslipidemia: the past and the future. <b>1991</b> , 14, 148-52	2
1962	Can percutaneous transluminal coronary angioplasty be considered successful for managing coronary artery disease?. <b>1991</b> , 4, 257-60	2
1961	On lowering lipids in the post-infarction patient. <b>1991</b> , 229, 483-8	3
1960	Extracorporeal methods in lipid reduction pursuant to improvement in risk factors associated with atherosclerosis. <b>1991</b> , 6, 211-5	

1959 Detection and Treatment of Elevated Blood Cholesterol. **1991**, 151, 25

1958 Regression of femoral atherosclerosis. **1991**, 83, 698-700

6

1957 Clinical implications of late proven patency after successful coronary angioplasty. **1991**, 84, 572-82

48

1956 Regression of coronary artery disease as a result of intensive lipid-lowering therapy. *New England Journal of Medicine*, **1991**, 324, 1133-5

59.2

1955 Quantitative coronary angiography to measure progression and regression of coronary atherosclerosis. Value, limitations, and implications for clinical trials. **1991**, 84, 412-23

164

1954 Heparin as a therapy for atherosclerosis: preliminary observations on the intrapulmonary administration of low-dose heparin in the morning versus evening gauged by its effect on blood variables. **1991**, 8, 210-33

4

1953 Atherosclerosis: inhibition of regression as therapeutic possibilities. **1991**, 65, 302-10

35

1952 Measuring and Knowing. **1991**, 266, 1696

3

1951 Cost-effectiveness of HMG-CoA Reductase Inhibition for Primary and Secondary Prevention of Coronary Heart Disease. **1991**, 265, 1145

193

1950 Randomized trials to assess the long-term effects of therapies on angiographic end points. **1991**, 99, 1243-7

3

1949 Progression and regression of atherosclerosis, what roles for LDL-cholesterol and HDL-cholesterol: a perspective. **1991**, 12, 952-7

22

1948 Ischaemic heart disease: risk stratification and intervention. Risk of progression of coronary artery disease. **1992**, 13 Suppl C, 3-13

3

1947 Molecular genetics of familial hypercholesterolaemia: common and rare mutations of the low density lipoprotein receptor gene. **1992**, 24, 363-7

18

1946 Direct measurement of low density lipoprotein in whole blood by silver-enhanced gold-labelled immunoassay. **1992**, 29 ( Pt 3), 283-6

2

1945 Effect of a single oat bran cereal breakfast on serum cholesterol, lipoproteins, and apolipoproteins in patients with hyperlipoproteinemia type IIa. **1992**, 16, 533-7

16

1944 Desirable serum total cholesterol with low HDL cholesterol levels. An undesirable situation in coronary heart disease. **1992**, 86, 1341-4

4

1943 Joint lipid risk factors and coronary heart disease. **1992**, 85, 365-7

13

1942 Laboratory facilities for investigating lipid disorders in the United Kingdom: results of the British Hyperlipidaemia Association survey. **1992**, 45, 102-5

5

1941	Cardiovascular disease and high cholesterol in old age. <b>1992</b> , 2, 1-2	1
1940	Changes in Sequential Coronary Arteriograms and Subsequent Coronary Events. <b>1992</b> , 268, 1429	108
1939	The Benefits of Treating Hyperlipidemia to Prevent Coronary Heart Disease. <b>1992</b> , 267, 816	41
1938	Lipoprotein(a). <b>1992</b> , 267, 1109	44
1937	Evaluation of colestipol/niacin therapy with computer-derived coronary end point measures. A comparison of different measures of treatment effect. <b>1992</b> , 86, 1701-9	35
1936	Anatomical progression of coronary artery disease in humans as seen by prospective, repeated, quantitated coronary angiography. Relation to clinical events and risk factors. The INTACT Study Group. <b>1992</b> , 86, 828-38	99
1935	Blood Lipid Measurements. <b>1992</b> , 267, 1652	56
1934	Comparison of Gemfibrozil and Lovastatin in Patients With High Low-Density Lipoprotein and Low High-Density Lipoprotein Cholesterol Levels. <b>1992</b> , 152, 1781	3
1933	Comparison of computer- and human-derived coronary angiographic end-point measures for controlled therapy trials. <b>1992</b> , 12, 348-56	17
1932	Cholesterol and cost-effectiveness. Implications for practice, policy, and research. <b>1992</b> , 85, 1939-41	7
1931	Effects of exposure to carbon disulphide on low density lipoprotein cholesterol concentration and diastolic blood pressure. <b>1992</b> , 49, 287-93	6
1930	Report of the Conference on Low Blood Cholesterol: Mortality Associations. <b>1992</b> , 86, 1046-60	539
1929	Distribution of Lipid Phenotypes in Community-Living Men With Coronary Heart Disease. <b>1992</b> , 152, 2412	16
1928	Polymeric Sorbents for Bile Acids. III. Hydrophilic and Hydrophobic Models Of Cholestyramine. <b>1992</b> , 29, 1129-1140	3
1927	Assessment and management of carotid disease. <b>1992</b> , 43, 301-16	5
1926	Screening college students for hypercholesterolemia. <b>1992</b> , 40, 272-5	6
1925	The pathogenesis of coronary artery disease and the acute coronary syndromes (2). <i>New England Journal of Medicine</i> , <b>1992</b> , 326, 310-8	59.2 1511
1924	Genetic epidemiology of low-density lipoprotein subclass phenotypes. <b>1992</b> , 24, 477-81	44

1923	Antiatherosclerotic effects of calcium channel blockers. <b>1992</b> , 92, 265-8	3
1922	Medical treatment after myocardial infarction. Results of studies using various methods. <b>1992</b> , 92, 84-90	
1921	Drug therapy for hyperlipidemia. When reducing cardiovascular risk is a priority. <b>1992</b> , 91, 162-4, 167-8, 171-2 passim	1
1920	Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine. <b>1992</b> , 304, 1335-8	31
1919	Frequency of citation and outcome of cholesterol lowering trials. <b>1992</b> , 305, 422	2
1918	The cholesterol controversy. <b>1992</b> , 304, 713	4
1917	Lovastatin alters blood rheology in primary hyperlipoproteinemia: dependence on lipoprotein(a)?. <b>1992</b> , 32, 539-45	24
1916	Long-term predictors of subsequent cardiovascular events with coronary artery disease and 'desirable' levels of plasma total cholesterol. <b>1992</b> , 86, 1165-70	113
1915	Controlling ventricular dilation in the compromised myocardium. <b>1992</b> , 32, 680-4	
1914	Effect of lovastatin or niacin combined with colestipol and regression of coronary atherosclerosis. <b>1992</b> , 13 Suppl B, 17-20	67
1913	Advances in Cardiovascular Pharmacology: Protocol Design and Methodology. Proceedings of the 11th annual symposium. Atherosclerosis and Drug Development for Ischemic Heart Disease. <b>1992</b> , 32, 848-66	1
1912	Cholesterol lowering as a treatment for established coronary heart disease. <b>1992</b> , 85, 1229-35	53
1911	Accurate measurement of serum total cholesterol: the need for standardization. <b>1992</b> , 11 Suppl, 8S-15S	8
1910	Asymptomatic coronary artery disease in patients with stroke. Prevalence, prognosis, diagnosis, and treatment. <b>1992</b> , 23, 433-6	39
1909	Low-dose, time-release nicotinic acid: effects in selected patients with low concentrations of high-density lipoprotein cholesterol. <b>1992</b> , 67, 855-60	16
1908	The relationship between cholesterol level and myocardial infarction or mortality risk in patients with coronary artery disease. A report from the Coronary Artery Surgery Study (CASS) registry. <b>1992</b> , 2, 129-36	5
1907	Effects of HMG Co-A Reductase Inhibitors on Lipids and Lipoprotein(a) in Hypercholesterolaemia. <b>1992</b> , 4, 227-231	7
1906	Overview: ACAT Inhibitors: A Potential New Approach to the Treatment of Hypercholesterolaemia and Atherosclerosis. <b>1992</b> , 2, 507-526	19

1905	Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease. <b>1992</b> , 1, 124-45	19
1904	Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. <b>1992</b> , 340, 1111-5	3776
1903	A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia. <b>1992</b> , 33, 451-3	25
1902	Effectiveness and tolerability of simvastatin versus pravastatin. <b>1992</b> , 52, 1-6	1
1901	Effect of simvastatin treatment on high-density lipoprotein cholesterol. <b>1992</b> , 52, 98-105	1
1900	Treatment of severe hypercholesterolemia with heparin-induced LDL apheresis. <b>1992</b> , 52, 317-329	6
1899	Treatment of children with homozygous familial hypercholesterolemia: safety and efficacy of low-density lipoprotein apheresis. <b>1992</b> , 120, 892-8	33
1898	Short-term interruption of training affects both fasting and post-prandial lipoproteins. <b>1992</b> , 95, 181-9	39
1897	Combination drug therapy in the treatment of severe hyperlipidaemia. <b>1992</b> , 97, S21-S26	5
1896	Comparison of simvastatin and ciprofibrate in the treatment of primary hypercholesterolaemia <sup>Ⓛ</sup> French multicentre study. <b>1992</b> , 97, S59-S66	3
1895	Regression of atherosclerosis. <b>1992</b> , 97, S81-S89	
1894	Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. The LARS Investigators. <b>1992</b> , 95, 1-13	134
1893	Poland-US collaborative study on cardiovascular epidemiology: classification agreement between US National Cholesterol Education Program and European Atherosclerosis Society hyperlipidemia guidelines in selected Polish and US populations. <b>1992</b> , 95, 43-50	1
1892	Differential effects of nicotinic acid in subjects with different LDL subclass patterns. <b>1992</b> , 95, 69-76	128
1891	Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733). <b>1992</b> , 95, 87-94	89
1890	Mechanism of grass-pollen-induced asthma. <b>1992</b> , 339, 569-72	307
1889	A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group. <b>1992</b> , 45, 849-60	82
1888	Heart disease in patients with diabetes mellitus. <b>1992</b> , 45, 1357-70	23



1887	Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). <b>1992</b> , 339, 563-9	727
1886	Coronary atheroma regression trials. <b>1992</b> , 339, 1241-1243	6
1885	Aneurysmal enlargement of the aorta during regression of experimental atherosclerosis. <b>1992</b> , 15, 90-101	29
1884	Evolution of revascularization strategies for single-vessel coronary artery disease. <b>1992</b> , 67, 389-91	2
1883	Plasma lipid and lipoprotein effects of transdermal administration of estradiol and estradiol/norethisterone acetate. <b>1992</b> , 47, 213-21	13
1882	Culprit coronary artery lesion. <b>1992</b> , 339, 242	5
1881	Lowering cholesterol: effects on trauma death, cancer death and total mortality. <b>1992</b> , 22, 580-2	14
1880	Summary. <b>1992</b> , 37, S3-S11	1
1879	General perspective. <b>1992</b> , 37, S12-S13	
1878	Does positron emission tomography improve patient selection for coronary revascularization?. <b>1992</b> , 20, 566-8	12
1877	Myocardial perfusion and regression of coronary artery disease in patients on a regimen of intensive physical exercise and low fat diet. <b>1992</b> , 19, 34-42	130
1876	Quantitative analysis of coronary artery restenosis after coronary angioplasty--has the rose lost its bloom?. <b>1992</b> , 19, 946-7	16
1875	The role of lipid regulation in the prevention of coronary heart disease. <b>1992</b> , 13 Suppl B, 23-8	5
1874	Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. <b>1992</b> , 86, 1-11	1549
1873	The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes. <b>1992</b> , 41, 768-71	135
1872	Correlation between computer-assisted femoral arteriography and physiological tests in hypercholesterolaemic patients: a methodological study with special reference to clinical trials. <b>1992</b> , 12, 53-68	3
1871	Mortality over a period of 10 years in patients with peripheral arterial disease. <i>New England Journal of Medicine</i> , <b>1992</b> , 326, 381-6	59.2 1986
1870	Efficacy of lipid profiles in prediction of coronary disease. <b>1992</b> , 124, 768-74	111

1869 Reply. **1992**, 123, 1725

1868 Atherogenesis and thrombosis: mechanisms, pathogenesis, and therapeutic implications. **1992**, 123, 1106-9

9

1867 A clinical overview of dyslipidemias: treatment strategies. **1992**, 93, 187-98

9

1866 Cost and health implications of cholesterol lowering. **1992**, 85, 1960-8

181

1865 Frequency of citation and outcome of cholesterol lowering trials. **1992**, 305, 422

1864 Progression and Regression of Atherosclerotic Coronary Artery Disease. **1992**, 5, 11-25

1863 A Quest For the Relief of Atherosclerosis: Potential Role of Intrapulmonary Heparin<sup>A</sup> Hypothesis. **1992**,

1862 Dyslipoproteinemia in the Elderly: Should It Be Treated?. **1992**, 8, 89-102

10

1861 Frequency of citation and outcome of cholesterol lowering trials: Author's reply. **1992**, 305, 422-422

1860 Frequency of citation and outcome of cholesterol lowering trials. **1992**, 305, 421-2

1859 The cholesterol controversy. **1992**, 304, 712-3

1858 Limits of Current Therapy in Coronary Artery Disease: Treatment Effects on Progression and Regression of Atherosclerosis. **1992**, 59-84

1857 Treatment of primary hypercholesterolaemia with pravastatin: efficacy and safety over three years. **1992**, 157, 584-9

10

1856 Fr?herkennung von Hyperlipoprotein?mien und Intervention. **1992**, 50, 19-27

1855 Long-term experience with extracorporeal low-density lipoprotein cholesterol removal by dextran sulfate cellulose adsorption. **1992**, 70, 99-104

11

1854 Cholesterol biosynthesis and metabolism. **1992**, 6, 103-10

131

1853 Cholesterol and coronary disease--outstanding questions. **1992**, 6, 131-6

3

1852 Fatty acid composition of the diet: impact on serum lipids and atherosclerosis. **1992**, 70, 968-1009

27

1851	Measuring progression and regression of coronary atherosclerosis in clinical trials: problems and progress. <b>1992</b> , 8, 165-73	32
1850	Does griseofulvin alter serum lipids?. <b>1992</b> , 126, 202-4	
1849	New insights into the management of myocardial ischemia. <b>1992</b> , 70, 8G-12G; discussion 12G-13G	6
1848	Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. The Liposorber Study Group. <b>1992</b> , 70, 1010-6	85
1847	A comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia. <b>1992</b> , 69, 28-34	18
1846	Improved stenosis geometry by quantitative coronary arteriography after vigorous risk factor modification. <b>1992</b> , 69, 845-53	83
1845	Marked benefit with sustained-release niacin therapy in patients with "isolated" very low levels of high-density lipoprotein cholesterol and coronary artery disease. <b>1992</b> , 69, 1083-5	49
1844	Comparative clinical consequences of aggressive lipid management, coronary angioplasty and bypass surgery in coronary artery disease. <b>1992</b> , 69, 1229-33	11
1843	Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. <b>1992</b> , 69, 1251-4	157
1842	Quantitative angiographic and statistical methods to assess serial changes in coronary luminal diameter and implications for atherosclerosis regression trials. <b>1992</b> , 69, 1286-90	91
1841	Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia. <b>1992</b> , 70, 135-40	32
1840	Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery disease in postmenopausal women. <b>1992</b> , 69, 176-8	157
1839	Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias. <b>1992</b> , 70, 1-9	61
1838	The prevention of atherosclerosis with antioxidants. <b>1992</b> , 15, 636-40	26
1837	Cholesterol and cardiovascular disease: hOw strong is the evidence?. <b>1992</b> , 15, 2-7	9
1836	Issues and answers: curreNt challenges of treatment. <b>1992</b> , 15, 8-9	
1835	When do we treat hypercholesterolemia?. <b>1992</b> , 15, 10-14	1
1834	Therapeutic intervention for hypercholesterolemia. <b>1992</b> , 15, 18-21	4

1833	Cholesterol and lipoproteins: beyond atherogenesis. <b>1992</b> , 15, 883-90	5
1832	Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. <b>1992</b> , 13, 293-314	59
1831	Treatment strategies for daily life silent myocardial ischemia: a correlation with potential pathogenic mechanisms. <b>1992</b> , 35, 97-118	14
1830	Pathophysiology of ischemia in patients with coronary artery disease. <b>1992</b> , 35, 27-39	16
1829	Drug therapy of hyperlipidemia. <b>1992</b> , 17, 545-605	4
1828	Potential of digital flashing tomosynthesis for angiocardigraphic evaluation. <b>1992</b> , 5, 194-205	4
1827	Simvastatin but not pravastatin has a direct inhibitory effect on rat and human myocyte proliferation. <b>1992</b> , 25, 399-400	19
1826	Composition and classification of human atherosclerotic lesions. <b>1992</b> , 421, 277-90	147
1825	Approaches to the management of hypercholesterolaemia. <b>1992</b> , 17, 81-9	
1824	Quantitative and qualitative coronary angiographic analysis: review of methods, utility, and limitations. <b>1992</b> , 25, 110-31	93
1823	Genotype at a major locus with large effects on apolipoprotein B levels predicts familial combined hyperlipidemia. <b>1993</b> , 10, 257-70	22
1822	Drugs controlling triglyceride metabolism. <b>1993</b> , 13, 125-38	2
1821	The zaragozic acids: Structure elucidation of a new class of squalene synthase inhibitors. <b>1993</b> , 34, 399-402	47
1820	Polymeric sorbents for bile acids. <b>1993</b> , 20, 131-140	11
1819	Therapy of severe familial heterozygous hypercholesterolemia by low-density lipoprotein apheresis with immunoabsorption: effects of the addition of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to therapy. <b>1993</b> , 71, 908-12	8
1818	Coenzyme Q10 and coronary artery disease. <b>1993</b> , 71, S112-5	4
1817	Quantitative angiographic follow-up studies on the development of coronary artery disease: which coronary segments should be analyzed? Experience from INTACT. <b>1993</b> , 9, 29-37	1
1816	Progression and regression of coronary artery disease in one year. Quantitative angiographic assessment in patients with stable angina pectoris. <b>1993</b> , 9, 213-7	1

1815	The QUinapril Ischemic Event Trial (QUIET) design and methods: evaluation of chronic ACE inhibitor therapy after coronary artery intervention. <b>1993</b> , 7, 273-82	28
1814	Modifying serum lipids to prevent coronary heart disease: do we have a consensus?. <b>1993</b> , 7, 761-5	1
1813	Lowering blood lipids to treat atherosclerosis: vascular tone, plaques, events, and mortality. <b>1993</b> , 7, 767-74	2
1812	Cholesterol confusion in primary prevention of coronary artery disease. <b>1993</b> , 7, 779-84	2
1811	Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. <b>1993</b> , 44, 1124-9	69
1810	The pathogenesis of atherosclerosis: a perspective for the 1990s. <b>1993</b> , 362, 801-9	9289
1809	Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration. <b>1993</b> , 23, 240-5	30
1808	Symposium on regression of atherosclerosis. <b>1993</b> , 23, 385-98	22
1807	Retardation and arrest of progression or regression of coronary artery disease: a review. <b>1993</b> , 35, 435-54	43
1806	Effect of cholesterol reduction by simvastatin on progression of coronary atherosclerosis: Design, baseline characteristics, and progress of the Multicenter Anti-Atheroma Study (MAAS). <b>1993</b> , 14, 209-28	21
1805	Design features of a controlled clinical trial to assess the effect of an HMG CoA reductase inhibitor on the progression of coronary artery disease. Canadian Coronary Atherosclerosis Intervention Trial Investigators Montreal, Ottawa, and Toronto, Canada. <b>1993</b> , 14, 45-74	12
1804	The promotion of health through planned sociopolitical change: challenges for research and policy. <b>1993</b> , 36, 109-17	157
1803	Development of a program for identification of patients with familial hypercholesterolemia in British Columbia: a model for prevention of coronary disease. <b>1993</b> , 72, 25D-29D	4
1802	Who should treat familial hypercholesterolemia?. <b>1993</b> , 72, 38D-41D	0
1801	How effective is drug therapy in heterozygous familial hypercholesterolemia?. <b>1993</b> , 72, 54D-58D	19
1800	Expanding indications for thrombolytic therapy in acute myocardial infarction. How late is too late, and how early is early: the clinician's view of the first 100 minutes. <b>1993</b> , 72, 22G-29G	5
1799	Femoral and coronary angiographic trials. <b>1993</b> , 71, 20B-25B	3
1798	Antioxidants and lipid metabolism. Implications for the present and direction for the future. <b>1993</b> , 71, 32B-36B	7

1797	Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I). <b>1993</b> , 72, 31-5	43
1796	Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. <b>1993</b> , 71, 393-400	69
1795	Association of angiographically detected coronary artery disease with low levels of high-density lipoprotein cholesterol and systemic hypertension. <b>1993</b> , 71, 505-10	10
1794	Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group. <b>1993</b> , 71, 575-81	24
1793	Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. <b>1993</b> , 71, 45-52	92
1792	Natural history of coronary atherosclerosis using quantitative angiography in men, and implications for clinical trials of coronary regression. The Harvard Atherosclerosis Reversibility Project Study Group. <b>1993</b> , 71, 766-72	32
1791	Weekly treatment of diet/drug-resistant hypercholesterolemia with the heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) system by selective plasma low-density lipoprotein removal. <b>1993</b> , 71, 816-22	13
1790	The rapid reduction in cardiac events with lipid-lowering therapy: mechanisms and implications. <b>1993</b> , 72, 1072-3	15
1789	Getting cardiologists interested in lipids. <b>1993</b> , 72, 744-5	25
1788	In vivo validation of compensatory enlargement of atherosclerotic coronary arteries. <b>1993</b> , 71, 665-8	217
1787	Cholesterol lowering, low cholesterol, and mortality. <b>1993</b> , 72, 776-86	26
1786	Insulin resistance, glucose intolerance, hyperinsulinemia and dyslipidemia in patients with angiographically demonstrated coronary artery disease. <b>1993</b> , 72, 458-60	39
1785	Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks. The Principal Investigators. <b>1993</b> , 16, 317-22	10
1784	Host and environmental effects on plasma apolipoprotein B. <b>1993</b> , 23, 215-20	7
1783	Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. <b>1993</b> , 36, 1079-86	82
1782	Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. <b>1993</b> , 42, 888-94	77
1781	Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion. <b>1993</b> , 42, 497-503	61
1780	Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS). <b>1993</b> , 42, 1461-7	138

1779	Lipids, growth, and development. <b>1993</b> , 42, 36-44	27
1778	Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the induction of low-density lipoprotein receptor in HepG2 cells. <b>1993</b> , 1167, 223-5	24
1777	Low high-density lipoprotein cholesterol: what does it mean, what can we do about it, and what should we do about it?. <b>1993</b> , 94, 1-6	14
1776	Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol: a randomized, double-blind, placebo-controlled, crossover study. <b>1993</b> , 94, 7-12	43
1775	Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. <b>1993</b> , 94, 13-20	151
1774	The atherogenic potential of carbon monoxide. <b>1993</b> , 99, 137-49	18
1773	Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. <b>1993</b> , 102, 107-19	60
1772	The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. <b>1993</b> , 101, 61-8	78
1771	Pravastatin experience in elderly and non-elderly patients. <b>1993</b> , 101, 97-110	16
1770	Effects of fenofibrate on angiographically examined coronary atherosclerosis and left ventricular function in hypercholesterolemic patients. <b>1993</b> , 98, 127-38	18
1769	Effects of hydroxymethylglutaryl-coenzyme a reductase inhibitors on some blood coagulation parameters. <b>1993</b> , 53, 188-195	
1768	Epidemiology of hyperlipidemia and the efficacy of pravastatin therapy. <b>1993</b> , 54, 290-299	2
1767	Effect of pravastatin, a HMG CoA reductase inhibitor, on blood lipids and aortic lipidosis in cholesterol-fed White Carneau pigeons. <b>1993</b> , 1181, 279-86	4
1766	Digital flashing tomosynthesis: a promising technique for angiocardigraphic screening. <b>1993</b> , 12, 314-21	19
1765	Lipid-Lowering Drugs: Widely Used but Unproven in the Elderly. <b>1993</b> , 1, 7-10	
1764	Distribution of circumferential stress in ruptured and stable atherosclerotic lesions. A structural analysis with histopathological correlation. <b>1993</b> , 87, 1179-87	640
1763	Oestrogens and atherosclerotic vascular disease--lipid factors. <b>1993</b> , 7, 61-93	38
1762	Effect of pravastatin on fatty acid profile of low density lipoprotein in patients with hypercholesterolemia. <b>1993</b> , 48, 155-8	3

1761	Measurement of the ultrasonic intima-media complex thickness in normal subjects. <b>1993</b> , 17, 719-725	108
1760	LDL-apheresis: clinical experience and indications in the treatment of severe hypercholesterolemia. <b>1993</b> , 14, 249-59	12
1759	What is truth said Pontius Pilate and would not wait for an answer: a biological reply to Dr Stehbens. <b>1993</b> , 46, 1351-7; discussion 1359-64	1
1758	Immunoabsorption and dextran sulfate cellulose LDL-apheresis for severe hypercholesterolemia: the Rogosin Institute experience 1982-1992. <b>1993</b> , 14, 261-8	2
1757	Various intensities of leisure time physical activity in patients with coronary artery disease: effects on cardiorespiratory fitness and progression of coronary atherosclerotic lesions. <b>1993</b> , 22, 468-77	317
1756	Effects of exercise on coronary atherosclerotic lesions. <b>1993</b> , 22, 478-9	7
1755	Issues in contemporary cardiac rehabilitation: a historical perspective. <b>1993</b> , 21, 822-34	93
1754	Progression of coronary artery disease is dependent on anatomic location and diameter. The INTACT investigators. <b>1993</b> , 21, 1339-46	28
1753	Toward the quiescent coronary plaque. <b>1993</b> , 22, 1228-41	141
1752	Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. <b>1993</b> , 341, 1496-500	415
1751	Prevention of raised low-density lipoprotein cholesterol in a patient with familial hypercholesterolaemia and lipoprotein lipase deficiency. <b>1993</b> , 341, 1119-21	30
1750	Chromosome 11q13 and atopy underlying atopic eczema. <b>1993</b> , 341, 1121-2	72
1749	Lipids, lipoproteins and other coronary risk factors in Chinese male survivors of myocardial infarction. <b>1993</b> , 39, 195-202	15
1748	Atherosclerosis regression, plaque disruption, and cardiovascular events: a rationale for lipid lowering in coronary artery disease. <b>1993</b> , 44, 365-76	31
1747	Human type II hyperlipoproteinemia enhances platelet-collagen adhesion in flowing nonanticoagulated blood. <b>1993</b> , 13, 1650-3	9
1746	Familial hypoalphalipoproteinemia in premature coronary artery disease. <b>1993</b> , 13, 1728-37	88
1745	Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. <b>1993</b> , 69, 377-81	854
1744	Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. <b>1993</b> , 69, S30-7	252



1743	Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population. <b>1993</b> , 25, 41-5		79
1742	One-year reduction and longitudinal analysis of carotid intima-media thickness associated with colestipol/niacin therapy. <b>1993</b> , 24, 1779-83		110
1741	Explosive growth of coronary angioplasty. Success story of a less than perfect procedure. <b>1993</b> , 87, 1749-51		12
1740	Quantitative ultrasonic characterization of lesion composition and remodeling in atherosclerotic rabbit aorta. <b>1993</b> , 13, 1543-50		20
1739	HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. <b>1993</b> , 13, 571-8		197
1738	Genetics of LDL subclass phenotypes in women twins. Concordance, heritability, and commingling analysis. <b>1993</b> , 13, 687-95		71
1737	Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia. <b>1993</b> , 13, 427-34		77
1736	Relation of vessel wall shear stress to atherosclerosis progression in human coronary arteries. <b>1993</b> , 13, 310-5		217
1735	Treatment of and screening for hyperlipidemia. <i>New England Journal of Medicine</i> , <b>1993</b> , 329, 1124-5; author reply 1127-8	59.2	1
1734	Simultaneous detection of both coronary borders. <b>1993</b> , 12, 588-99		22
1733	B-mode ultrasound in clinical trials. Answers and questions. <b>1993</b> , 88, 319-21		64
1732	Triglycerides and disease. <b>1993</b> , 69, 679-95		6
1731	Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). <b>1993</b> , 119, 969-76		476
1730	Coronary angiography: more than meets the eye. <b>1993</b> , 87, 1399-401		16
1729	Prognostic significance of progression of coronary atherosclerosis. <b>1993</b> , 87, 1067-75		256
1728	Lipids. Workshop IV. AHA Prevention Conference III. Behavior change and compliance: keys to improving cardiovascular health. <b>1993</b> , 88, 1397-401		15
1727	Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. <b>1993</b> , 87, 1781-91		668
1726	Lesion-to-lesion independence of restenosis after treatment by conventional angioplasty, stenting, or directional atherectomy. Validation of lesion-based restenosis analysis. <b>1993</b> , 87, 1123-9		46

1725	Arteriographic view of treatment to achieve regression of coronary atherosclerosis and to prevent plaque disruption and clinical cardiovascular events. <b>1993</b> , 69, S48-53	34
1724	Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound. <b>1993</b> , 88, 20-8	308
1723	Rationale of the diet-heart statement of the American Heart Association. Report of the Nutrition Committee. <b>1993</b> , 88, 3008-29	83
1722	Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B. <b>1993</b> , 88, 2744-53	30
1721	Severe Reversible Hyperglycemia as a Consequence of Niacin Therapy. <b>1993</b> , 153, 2050	16
1720	Preventive Medicine for Our Ailing Health Care System. <b>1993</b> , 269, 616	23
1719	Lipoprotein[a] as a risk factor for preclinical atherosclerosis. <b>1993</b> , 13, 826-33	100
1718	Cholesterol Testing in Young Adults. <b>1993</b> , 269, 1426	1
1717	Nephrology and Urology in the Aged Patient. <b>1993</b> ,	
1716	Compliance with childhood cholesterol screening among members of a prepaid health plan. <b>1993</b> , 147, 382-5	6
1715	Factors Predicting Improvements in Lipid Values Following Cardiac Rehabilitation and Exercise Training. <b>1993</b> , 153, 982	34
1714	Cholesterol. Myth vs reality in pediatric practice. <b>1993</b> , 147, 371-3	2
1713	Inhibition of exercise-induced shortening of bleeding time by fish oil in familial hypercholesterolemia (type IIa). <b>1993</b> , 13, 98-104	25
1712	Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. <b>1993</b> , 13, 147-53	205
1711	Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. <b>1993</b> , 69, 359-69	85
1710	Plaque changes and arterial enlargement in atherosclerotic monkeys after manipulation of diet and social environment. <b>1993</b> , 13, 254-63	32
1709	Coronary atherosclerosis on angiography--progress or regress, and why?. <b>1993</b> , 88, 1358-60; author reply 1356-7	2
1708	Relation of plasma levels and composition of apolipoprotein B-containing lipoproteins to angiographically defined coronary artery disease in young patients with myocardial infarction. <b>1993</b> , 88, 2180-9	83

1707	Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials. <b>1993</b> , 119, 136-45	132
1706	Cholesterol lowering and mortality: the importance of considering initial level of risk. <b>1993</b> , 306, 1367-73	250
1705	Chapter 23. New Potential Therapies for the Treatment of Atherosclerosis. <b>1993</b> , 28, 217-226	2
1704	Plasma lipid concentrations and subsequent coronary occlusion after a first myocardial infarction. The POSCH Group. <b>1993</b> , 305, 139-44	15
1703	How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. <b>1993</b> , 306, 1313-8	84
1702	Correction: Diagnosis and treatment of malaria in Britain. <b>1993</b> , 306, 1318-1318	
1701	Detection and management of lipid disorders in diabetes. American Diabetes Association. <b>1993</b> , 16, 828-34	50
1700	The place of alpha blockers in the antihypertensive armamentarium. <b>1993</b> , 33, 260-3	1
1699	Lovastatin Treatment of Dyslipoproteinemia in Patients on Continuous Ambulatory Peritoneal Dialysis. <b>1993</b> , 13, 107-109	
1698	Dextran Sulphate Adsorption: Effects on Coronary Heart Disease. <b>1993</b> , 167-174	
1697	Combined Drug Regimens for Treating Hyperlipidemia: The Experience of a Lipid Clinic. <b>1993</b> , 93-98	
1696	Reversing coronary atherosclerosis. <b>1993</b> , 94, 50-65	
1695	Correction: Intraocular foreign body missed by radiography. <b>1993</b> , 306, 1318-1318	
1694	Pathogenesis of Atherothrombotic Brain Infarction: Role of Lipids. <b>1993</b> , 3, 338-342	
1693	Blind comparison of patient preference for Flavored Colestid Granules and Questran Light. <b>1993</b> , 27, 700-3	3
1692	Organization and Technical Problems of LDL-apheresis. <b>1993</b> , 16, 165-167	5
1691	Variability of lipid measurements: relevance for the clinician. <b>1993</b> , 39, 1495-1503	24
1690	Extracorporeal treatment of hypercholesterolaemia. <b>1993</b> ,	

1689	Essential Fatty Acids and Vascular Disease. <b>1993</b> , vnr-4, 259-271	0
1688	Efficacy Studies in Coronary Rehabilitation. <b>1993</b> , 11, 333-347	15
1687	Can lifestyle changes reverse coronary heart disease?. <b>1993</b> , 72, 38-48	13
1686	Lipoprotein(A): physiologic function, association with atherosclerosis, and effects of lipid-lowering drug therapy. <b>1994</b> , 28, 343-51	21
1685	The position of neuroimaging in the evaluation of stroke risk. <b>1994</b> , 13, 335-9	
1684	Comparative Efficacy and Safety of Micronized Fenofibrate and Simvastatin in Patients With Primary Type Ia or IIb Hyperlipidemia. <b>1994</b> , 154, 441	55
1683	Spinal Cord Stimulation. <b>1994</b> ,	
1682	Functional improvement precedes structural regression of atherosclerosis. <b>1994</b> , 89, 1810-8	306
1681	Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. <b>1994</b> , 89, 2519-24	531
1680	Inhalation of steady-state sidestream smoke from one cigarette promotes arteriosclerotic plaque development. <b>1994</b> , 90, 1363-7	92
1679	Recombinant human macrophage colony-stimulating factor reduces plasma cholesterol and carrageenan granuloma foam cell formation in Watanabe heritable hyperlipidemic rabbits. <b>1994</b> , 14, 70-6	27
1678	Genetic predictors of FCHL in four large pedigrees. Influence of ApoB level major locus predicted genotype and LDL subclass phenotype. <b>1994</b> , 14, 1687-94	65
1677	A Comparison of the Efficacy and Toxic Effects of Sustained- vs Immediate-Release Niacin in Hypercholesterolemic Patients. <b>1994</b> , 271, 672	172
1676	Prevention and regression of coronary atherosclerosis. Is it safe and efficacious therapy?. <b>1994</b> , 105, 718-26	11
1675	Mechanical properties of model atherosclerotic lesion lipid pools. <b>1994</b> , 14, 230-4	195
1674	Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography. <b>1994</b> , 90, 808-17	277
1673	Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management. <b>1994</b> , 90, 1056-69	142
1672	Atherosclerotic plaque evolution in the descending thoracic aorta in familial hypercholesterolemic patients. A transesophageal echo study. <b>1994</b> , 14, 1723-9	11

1671 Recent advances in cardiology. **1994**, 70, 257-74

1670	Quantitative Coronary Angiography in Clinical Practice. <b>1994</b> ,	49
1669	Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. <b>1994</b> , 89, 2525-32	211
1668	Lipoprotein Responses to Treatment With Lovastatin, Gemfibrozil, and Nicotinic Acid in Normolipidemic Patients With Hypoalphalipoproteinemia. <b>1994</b> , 154, 73	31
1667	Efficacy and Safety of Once-Daily vs Twice-Daily Dosing With Fluvastatin, a Synthetic Reductase Inhibitor, in Primary Hypercholesterolemia. <b>1994</b> , 154, 2449	24
1666	George Lyman Duff Memorial Lecture. Arterial imaging and atherosclerosis reversal. <b>1994</b> , 14, 177-92	189
1665	Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. <b>1994</b> , 89, 1530-8	265
1664	Can any agreement be reached on cholesterol lowering?. <b>1994</b> , 71, 125-8	1
1663	Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. <b>1994</b> , 90, 1679-87	709
1662	Lysophosphatidylcholine upregulates the level of heparin-binding epidermal growth factor-like growth factor mRNA in human monocytes. <b>1994</b> , 91, 1069-73	120
1661	Reversal of coronary heart disease by lipid-lowering therapy. Observations and pathological mechanisms. <b>1994</b> , 89, 2928-33	13
1660	Determinants of severity of coronary artery disease in Australian men and women. <b>1994</b> , 89, 1974-81	103
1659	Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. <b>1994</b> , 90, 42-9	299
1658	Conjoint high triglycerides and low HDL cholesterol across generations. Analysis of proband hypertriglyceridemia and lipid/lipoprotein disorders in first-degree family members. <b>1994</b> , 90, 1177-84	13
1657	Optimal risk factor management in the patient after coronary revascularization. A statement for healthcare professionals from an American Heart Association Writing Group. <b>1994</b> , 90, 3125-33	55
1656	Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. <i>New England Journal of Medicine</i> , <b>1994</b> , 331, 1331-7	59.2 237
1655	Inflammation and coronary artery disease. <i>New England Journal of Medicine</i> , <b>1994</b> , 331, 468-9	59.2 309
1654	Regression of atherosclerosis. <b>1994</b> , 8, 303-17	1

1653	The effect of LDL apheresis on progression of coronary artery disease in patients with familial hypercholesterolemia. Results of a multicenter LDL apheresis study. <b>1994</b> , 72, 858-63	24
1652	Safety and efficacy of lifestrol upon four-week administration to patients with primary hypercholesterolaemia. <b>1994</b> , 47, 133-8	8
1651	Lipid-lowering therapy and violent death: Is depression a culprit?. <b>1994</b> , 10, 233-237	8
1650	Accuracy and precision of quantitative arteriography in the evaluation of coronary artery disease after coronary bypass surgery. A validation study. <b>1994</b> , 10, 243-52	17
1649	Clinical and angiographic variables affecting the progression of coronary artery disease as determined by quantitative angiography. <b>1994</b> , 10, 217-25	3
1648	Acute myocardial infarction in a young boy with nephrotic syndrome: a case report and review of the literature. <b>1994</b> , 8, 290-4	23
1647	The application of breath hold phase velocity mapping techniques to the measurement of coronary artery blood flow velocity: phantom data and initial in vivo results. <b>1994</b> , 31, 526-36	86
1646	Verbesserte Prognose durch Behandlung von Fettstoffwechselstörungen-Ergebnisse und Schlüsse aus Interventionsstudien. <b>1994</b> , 96, 13-16	
1645	On-line quantitative coronary analysis in clinical practice: one step closer to reality?. <b>1994</b> , 31, 102-9	7
1644	Lifestrol increases hepatic cholesterol 7 $\beta$ hydroxylase activity in sprague-dawley rats. <b>1994</b> , 33, 439-447	2
1643	Dyslipidemia and coronary artery disease. <b>1994</b> , 17, 519-27	11
1642	Drug control of reverse cholesterol transport. <b>1994</b> , 61, 289-324	30
1641	Molecular and cellular concepts in atherosclerosis. <b>1994</b> , 61, 109-53	50
1640	Indications for low-density lipoprotein apheresis. <b>1994</b> , 74, 1109-12	42
1639	Effects of cardiac rehabilitation and exercise training on low-density lipoprotein cholesterol in patients with hypertriglyceridemia and coronary artery disease. <b>1994</b> , 74, 1192-5	54
1638	Monitoring the quality of life in patients with coronary artery disease. <b>1994</b> , 74, 1240-4	328
1637	Updated clinical safety experience with fluvastatin. <b>1994</b> , 73, 18D-24D	37
1636	Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety. <b>1994</b> , 73, 25D-29D	23

1635	Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin. <b>1994</b> , 73, 42D-49D	17
1634	Low blood total cholesterol and mortality: causality, consequence and confounders. <b>1994</b> , 73, 80-5	22
1633	Association between lipoprotein(a) and progression of coronary artery disease in middle-aged men. <b>1994</b> , 73, 742-6	36
1632	Advantages and limitations of intracoronary ultrasound for the assessment of vascular dimensions. <b>1994</b> , 7, 43-56	2
1631	Effects of erythropoietin therapy on the lipid profile in end-stage renal failure. <b>1994</b> , 45, 897-902	33
1630	The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. The HELP Study Group. Hepatic-induced, but transient LDL-oxidation. <b>1994</b> , 24, 724-32	125
1629	Gemfibrozil treatment of the high triglyceride-low high-density lipoprotein cholesterol trait in men with established atherosclerosis. <b>1994</b> , 236, 377-84	8
1628	Plaque stabilization: a mechanism for the beneficial effect of lipid-lowering therapies in angiography studies. <b>1994</b> , 37, 107-20	26
1627	Serum lipoprotein changes after prolonged intralipid infusion in malnourished haemodialysis patients. <b>1994</b> , 13, 111-5	9
1626	Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. <b>1994</b> , 23, 899-906	50
1625	Development of new coronary atherosclerotic lesions during a 4-year multifactor risk reduction program: the Stanford Coronary Risk Intervention Project (SCRIP). <b>1994</b> , 24, 900-8	39
1624	Endothelial dysfunction and dyslipidemia: possible effects of lipid lowering and lipid modifying therapy. <b>1994</b> , 29, 261-72	19
1623	Role of platelets and leukocytes in modulation of vascular tone. <b>1994</b> , 714, 122-35	11
1622	Efficacy of drug intervention for lipids in the prevention of coronary artery disease. <b>1994</b> , 24, 107-12	5
1621	Cholesterol reduction and death from non-coronary causes: evidence from randomised controlled trials. <b>1994</b> , 24, 120-3	4
1620	Ischaemic heart disease. <b>1994</b> , 2, 14-20	
1619	Metabolic risk factors for atherosclerosis in heart transplant recipients. <b>1994</b> , 128, 68-72	44
1618	Pathobiology of atherosclerosis and plaque complications. <b>1994</b> , 128, 1300-4	41

1617	Calcium channel blockers and coronary atherosclerosis: from the rabbit to the real world. <b>1994</b> , 128, 1309-16	32
1616	Heart disease in the assessment and treatment of hypercholesterolemia: coronary artery disease and other atherosclerotic disease, family history, and left ventricular hypertrophy. <b>1994</b> , 96, 9S-18S	5
1615	Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate. <b>1994</b> , 96, 55S-63S	17
1614	Niacin: a therapeutic dilemma. "One man's drink is another's poison". <b>1994</b> , 97, 313-6	4
1613	Cholesterol-lowering intervention and coronary artery disease after cardiac transplantation. <b>1994</b> , 57, 353-6	9
1612	Dyslipidemias and the secondary prevention of coronary heart disease. <b>1994</b> , 40, 369-464	
1611	Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor. <b>1994</b> , 43, 293-8	58
1610	Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group. <b>1994</b> , 344, 1182-6	151
1609	Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). <b>1994</b> , 344, 633-638	480
1608	The effects of fibrates on lipoprotein and hemostatic coronary risk factors. <b>1994</b> , 111, 161-74	72
1607	Homozygous Tangier disease and cardiovascular disease. <b>1994</b> , 107, 85-98	214
1606	LDL apheresis using the liposorber <sup>®</sup> LA-15 system in coronary and peripheral vascular disease associated with severe hypercholesterolemia. <b>1994</b> , 55, 879-904	14
1605	Effects of etofibrate therapy on high lipoprotein(a) levels in patients with hypercholesterolemia. <b>1994</b> , 55, 988-996	3
1604	Simvastatin in the treatment of patients with hypercholesterolemia and associated coronary heart disease risk factors: An Italian multicenter study. <b>1994</b> , 55, 786-796	
1603	Fat and cholesterol in the diet of infants and young children: implications for growth, development, and long-term health. <b>1994</b> , 125, S69-77	41
1602	Continuous combined and sequential estradiol and norethindrone acetate treatment of postmenopausal women: effect of plasma lipoproteins in a two-year placebo-controlled trial. <b>1994</b> , 171, 132-8	31
1601	Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. <b>1994</b> , 89, 959-68	436
1600	Clinical pharmacokinetics of pravastatin. <b>1994</b> , 27, 94-103	57



1599	Analysis of angiographic trial data in women. <b>1994</b> , 47 Suppl 2, 11-5	3
1598	Physical activity and lipoprotein lipid disorders. <b>1994</b> , 17, 6-21	50
1597	Sick vessel syndrome. Can atherosclerotic arteries recover?. <b>1994</b> , 89, 2447-50	30
1596	Cardiac rehabilitation programs. A statement for healthcare professionals from the American Heart Association. <b>1994</b> , 90, 1602-10	142
1595	Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). <b>1994</b> , 89, 975-90	700
1594	Evolution of coronary stenoses is related to baseline severity--a prospective quantitative angiographic analysis in patients with moderate coronary disease. INTACT Investigators. International Nifedipine Trial on Antiatherosclerotic Therapy. <b>1994</b> , 15, 648-53	13
1593	Epidemiological assessment of hyperlipidaemia management in primary health care. <b>1994</b> , 4, 38-45	4
1592	Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. <b>1994</b> , 120, 1012-25	155
1591	A case-management system for coronary risk factor modification after acute myocardial infarction. <b>1994</b> , 120, 721-9	546
1590	Pathology of arterial thrombosis. <b>1994</b> , 50, 789-802	37
1589	The association between cholesterol and death from injury. <b>1994</b> , 120, 848-55	32
1588	Reversing Heart Disease. <b>1994</b> , 22, 91-5	1
1587	The biology of the artery wall in atherogenesis. <b>1994</b> , 78, 41-67	30
1586	The prevention of cardiovascular disease. Emphasis on secondary prevention. <b>1994</b> , 78, 69-98	23
1585	The effects of lowering serum cholesterol on coronary heart disease risk. <b>1994</b> , 78, 181-95	18
1584	Chronobiology of Acute Myocardial Infarction. <b>1994</b> , 25, 494-501	
1583	Reversal of coronary atherosclerosis. Clinical promise as the basis for noninvasive management of coronary artery disease. <b>1994</b> , 90, 1558-71	36
1582	Dyslipidemias in diabetic patients. <b>1994</b> , 95, 69-84	7

1581	Asymptomatic Carotid Artery Stenosis: Diagnosis and Management. <b>1994</b> , 4, 12-17	
1580	Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. <b>1995</b> , 29, 743-59	122
1579	Unrecognized myocardial infarction: epidemiology, clinical characteristics, and the prognostic role of angina pectoris. The Reykjavik Study. <b>1995</b> , 122, 96-102	168
1578	Progression and regression of the atherosclerotic plaque. <b>1995</b> , 16 Suppl I, 26-30	17
1577	Pharmacologic intervention to prevent graft failure. <b>1995</b> , 75, 761-72	12
1576	Rethinking utilization review. <i>New England Journal of Medicine</i> , <b>1995</b> , 333, 1353-4	59.2 13
1575	The effect of noncritical coronary artery disease on long-term survival. <b>1995</b> , 310, 7-13	13
1574	Effect of Cholesterol-Lowering Medications on Progression of Mild Atherosclerotic Lesions of the Carotid Arteries and on the Risk of Stroke. <b>1995</b> , 5, 171-177	24
1573	Prescribing patterns of antilipemic drugs and prevalence of hypercholesterolemia in the Nova Scotia population more than 65 years old. <b>1995</b> , 29, 576-81	3
1572	Atherogenic risk reduction in patients with dyslipidaemia. comparison between bezafibrate and lovastatin. <b>1995</b> , 16, 1491-501	7
1571	Difficulty accepting lifestyle limitations after the abrupt onset of end-stage renal disease. <b>1995</b> , 2, 246-54	3
1570	Lipoprotein oxidation as a mediator of atherogenesis: insights from pharmacological studies. <b>1995</b> , 29, 297-311	30
1569	Comparison of an immunoprecipitation method for direct measurement of LDL-cholesterol with beta-quantification (ultracentrifugation). <b>1995</b> , 104, 76-81	30
1568	Noninsulin-dependent diabetes mellitus. The prevention of complications. <b>1995</b> , 79, 287-98	8
1567	An update on coronary risk factors. <b>1995</b> , 79, 951-71	79
1566	Clinical perspectives on primary and secondary prevention of coronary atherosclerosis. <b>1995</b> , 79, 973-98	16
1565	Acute ischemic syndromes. <b>1995</b> , 79, 999-1024	2
1564	Contemporary approaches in medical management of patients with stable coronary artery disease. <b>1995</b> , 79, 1063-84	4

1563	Quantification of regional myocardial perfusion by PET: rationale and first clinical results. <b>1995</b> , 16 Suppl J, 84-91	10
1562	Rationale for Cholesterol-lowering Strategies. <b>1995</b> , 20, 286-357	1
1561	Coronary risk factors and their modification: Lipids, smoking, hypertension, estrogen, and the elderly. <b>1995</b> , 20, 539-610	8
1560	Lipid risk factors and the regression of atherosclerosis. <b>1995</b> , 76, 3A-7A	6
1559	Clustering of cardiovascular risk factors: targeting high-risk individuals. <b>1995</b> , 76, 8A-20A	97
1558	Pharmacokinetics of the combination of fluvastatin and gemfibrozil. <b>1995</b> , 76, 80A-83A	83
1557	Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. <b>1995</b> , 76, 122A-125A	82
1556	Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia. <b>1995</b> , 76, 129A-135A	23
1555	Coronary artery bypass grafting in familial hypercholesterolemia. <b>1995</b> , 109, 364-9	23
1554	Secondary Prevention of Coronary Heart Disease in Practice. <b>1995</b> , 81, 398	1
1553	Atherosclerosis, oxidative stress, and antioxidant protection in endothelium-derived relaxing factor action. <b>1995</b> , 38, 129-54	150
1552	Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. <b>1995</b> , 76, 480-4	62
1551	Influence of coronary angioplasty on the progression of coronary atherosclerosis. <b>1995</b> , 76, 1126-30	13
1550	Noninvasive tracking of coronary atherosclerosis by electron beam computed tomography: rationale and design of the Felodipine Atherosclerosis Prevention Study (FAPS). <b>1995</b> , 76, 1239-42	8
1549	Unresolved issues in early trials of cholesterol lowering. <b>1995</b> , 76, 5C-9C	5
1548	Cholesterol reduction and its impact on coronary artery disease and total mortality. <b>1995</b> , 76, 10C-17C	42
1547	Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study. <b>1995</b> , 76, 40C-46C	73
1546	Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study. <b>1995</b> , 76, 47C-53C	41

- 1545 Range of serum cholesterol values in the population developing coronary artery disease. **1995**, 76, 69C-77C 219
- 1544 The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Harvard Atherosclerosis Reversibility Project Research Group. **1995**, 76, 78C-85C 28
- 1543 Lipid-lowering interventions in angiographic trials. **1995**, 76, 86C-92C 73
- 1542 Management of the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study after the Scandinavian Simvastatin Survival Study (4S). **1995**, 76, 107C-112C 30
- 1541 Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. **1995**, 75, 34-9 92
- 1540 Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications. **1995**, 25, 559-67 47
- 1539 Tel Aviv-Heidelberg three-generation offspring study: genetic determinants of apolipoprotein A1 and apolipoprotein B. **1995**, 57, 410-6 9
- 1538 Lofibrol: a novel lipid-lowering drug for the therapy of hypercholesterolemia. Lofibrol Study Group. **1995**, 57, 73-88 18
- 1537 Effect of royal jelly on serum lipids in experimental animals and humans with atherosclerosis. **1995**, 51, 927-35 67
- 1536 Pravastatin intervention trial on carotid artery atherosclerosis in patients with mild hypercholesterolemia: the CAIUS study. **1995**, 11, 119-124 6
- 1535 Changes in serum lipoprotein(a) in hyperlipidemic subjects undergoing long-term treatment with lipid-lowering drugs. **1995**, 9, 677-84 15
- 1534 Relevance of vascular biology to the ischemic syndromes of coronary atherosclerosis. **1995**, 9, 13-19 10
- 1533 Effect of a synthetic prostaglandin E2 analogue, RS-86505-007, on plasma lipids and lipoproteins in patients with moderate hypercholesterolaemia: efficacy and tolerance of treatment and response in different apolipoprotein polymorphism groups. **1995**, 48, 97-102 3
- 1532 Does lowering of cholesterol levels influence functional properties of large arteries?. **1995**, 48, 217-23 53
- 1531 The treatment of myocardial infarction. **1995**, 8, 730-51
- 1530 Quantitative coronary cineangiography for the study of atherosclerosis. **1995**, 17, 356-65 5
- 1529 Efficient and stereoselective synthesis of J-104,118, a novel, potent inhibitor of squalene synthase. **1995**, 36, 7459-7462 13
- 1528 Cholesterol in patients with coronary heart disease: how low should we go?. **1995**, 10, 464-71 7

1527	New targets for lipid lowering and atherosclerosis prevention. <b>1995</b> , 67, 433-47		6
1526	Clinical implications of acute ischemic syndromes in coronary artery disease. <b>1995</b> , 4, 51-55		
1525	Update on the treatment of hypercholesterolemia, with a focus on HMG-CoA reductase inhibitors and combination regimens. <b>1995</b> , 18, 307-15		11
1524	Progression and regression of coronary artery disease--linkage of clinical, pathologic, and angiographic findings. <b>1995</b> , 18, 412-7		5
1523	Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia. <b>1995</b> , 18, 621-9		28
1522	Response of high-density lipoproteins to hypolipidemic drugs according to their initial level. <b>1995</b> , 75, 293-5		9
1521	Clinical significance of lipoprotein size and risk for coronary atherosclerosis. <b>1995</b> , 41, 147-152		42
1520	LDL physical and chemical properties in familial combined hyperlipidemia. <b>1995</b> , 15, 452-9		57
1519	Oxidized low-density lipoproteins facilitate leukocyte adhesion to aortic intima without affecting endothelium-dependent relaxation. Role of P-selectin. <b>1995</b> , 15, 2076-83		52
1518	Coronary Heart Disease. <b>1995</b> , 6, 37-53		
1517	Four Years Treatment Efficacy of Patients with Severe Hyperlipidemia. Lipid Lowering Drugs versus LDL-Apheresis. <b>1995</b> , 18, 786-793		6
1516	Niacin for lipid disorders. <b>1995</b> , 98, 185-193		13
1515	Metabolic Abnormalities in Cardiac Ischemia. <b>1995</b> , 13, 529-538		14
1514	Acute Myocardial Infarctions. <b>1995</b> , 6, 69-95		
1513	Physician Recognition of Hypercholesterolemia in Patients Undergoing Peripheral and Carotid Artery Revascularization. <b>1995</b> , 11, 336-341		6
1512	The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. <i>New England Journal of Medicine</i> , <b>1995</b> , 332, 488-93	59.2	968
1511	Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. <i>New England Journal of Medicine</i> , <b>1995</b> , 332, 481-7	59.2	1083
1510	The Role of Coronary Angiography and Coronary Revascularization Before Noncardiac Vascular Surgery. <b>1995</b> , 273, 1919		91

1509	Efficacy and Safety of Pravastatin in African Americans With Primary Hypercholesterolemia. <b>1995</b> , 155, 1900		20
1508	High-density lipoprotein cholesterol, plasma triglyceride, and coronary heart disease: pathophysiology and management. <b>1995</b> , 32, 375-426		20
1507	Spinocerebellar ataxias and ataxins. <i>New England Journal of Medicine</i> , <b>1995</b> , 333, 1351-3	59.2	7
1506	Regression of atherosclerosis. Does it occur and does it have clinical meaning?. <b>1995</b> , 16 Suppl E, 2-5		5
1505	Insights into the pathogenesis and prevention of coronary artery disease. <b>1995</b> , 70, 69-79		32
1504	Lowering cholesterol with drugs and diet. <i>New England Journal of Medicine</i> , <b>1995</b> , 333, 1350-1	59.2	38
1503	Our ailing public hospitals. Cure them or close them?. <i>New England Journal of Medicine</i> , <b>1995</b> , 333, 1348-9	59.2	23
1502	Classification and comparison of oral contraceptives containing new generation progestogens. <b>1995</b> , 1, 231-63		49
1501	Reducing Low-Density Lipoprotein Cholesterol Levels in an Ambulatory Care System. <b>1995</b> , 155, 2330		44
1500	Effect of lipid-lowering treatment on progression of atherosclerotic lesions--a duplex ultrasonographic investigation. <b>1995</b> , 46, 269-80		6
1499	Angiographic trials of lipid-lowering therapy: end of an era?. <b>1995</b> , 74, 343-7		13
1498	Cardiac rehabilitation for older people. <b>1995</b> , 5, 321-328		
1497	Lipids and atherosclerosis. <b>1995</b> , 16, 509-710		10
1496	Intervention in diabetic vascular disease by modulation of growth factors. <b>1995</b> , 44, 83-90		4
1495	Effect of age on the response of blood lipids, body composition, and aerobic power to physical conditioning and deconditioning. <b>1995</b> , 44, 161-5		29
1494	Application of quantitative coronary angiography in a cineless environment: in vivo assessment of a fully automated system for clinical use. <b>1995</b> , 129, 300-6		3
1493	Influence of the selection of angiographic projections on the results of coronary angiographic follow-up trials. International Nifedipine Trial on Antiatherosclerotic Therapy Investigators. <b>1995</b> , 130, 433-9		4
1492	Preventing and arresting coronary atherosclerosis. <b>1995</b> , 130, 580-600		46

1491	High dose of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, lowers plasma cholesterol levels in homozygous Watanabe-heritable hyperlipidemic rabbits. <b>1995</b> , 1259, 99-104		17
1490	Comparison of the effects of simvastatin versus hormone replacement therapy in the treatment of postmenopausal women with primary hypercholesterolemia. <b>1995</b> , 56, 515-529		2
1489	Comparison of the effects of gemfibrozil (600 mg twice daily and 900 mg once daily) on lipid and glucose levels in chinese patients with noninsulin-dependent diabetes mellitus. <b>1995</b> , 56, 1033-1040		2
1488	The prevalence of side effects with regular and sustained-release nicotinic acid. <b>1995</b> , 99, 378-85		46
1487	The acceptability of resin therapy to patients attending a hospital lipid clinic. <b>1995</b> , 40, 92-4		5
1486	Relation of saphenous vein graft obstruction to serum cholesterol levels. <b>1995</b> , 25, 193-7		36
1485	Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. <b>1995</b> , 25, 333-41		964
1484	Quantification of coronary artery calcium by electron beam computed tomography for determination of severity of angiographic coronary artery disease in younger patients. <b>1995</b> , 25, 626-32		62
1483	Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research Group. <b>1995</b> , 25, 1492-8		181
1482	Gene therapy for the vulnerable plaque. <b>1995</b> , 26, 826-35		28
1481	American Heart Association consensus panel statement on preventing heart attack and death in patients with coronary disease. <b>1995</b> , 26, 291		
1480	Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. <b>1995</b> , 26, 1133-9		353
1479	Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. <i>New England Journal of Medicine</i> , <b>1995</b> , 332, 512-21	59.2	571
1478	Effect of pravastatin on outcomes after cardiac transplantation. <i>New England Journal of Medicine</i> , <b>1995</b> , 333, 621-7	59.2	1062
1477	Daily life cardiac ischaemia. Should it be treated?. <b>1995</b> , 49, 176-95		4
1476	Low-density lipoprotein apheresis as long-term treatment for children with homozygous familial hypercholesterolemia. <b>1995</b> , 126, 728-35		29
1475	The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients. <b>1995</b> , 112, 223-35		11
1474	Exogenous supply of artificial lipoproteins does not decrease susceptibility to atherosclerosis in cholesterol-fed rabbits. <b>1995</b> , 113, 237-46		7

1473	Long-term efficacy and tolerability of simvastatin in a large cohort of elderly hypercholesterolemic patients. <b>1995</b> , 116, 153-62	14
1472	Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity. <b>1995</b> , 117, 189-98	45
1471	Atherosclerosis progression/regression: lipoprotein and vessel wall determinants. <b>1995</b> , 118, S29-S36	5
1470	Coronary atherosclerosis stabilization: an achievable goal. <b>1995</b> , 118, S91-S101	12
1469	Non-invasive management of coronary artery disease. Report of a meeting at the University of Texas Medical School at Houston. <b>1995</b> , 346, 750-3	5
1468	Low-density-lipoprotein apheresis. <b>1995</b> , 346, 116-118	1
1467	Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. <b>1995</b> , 345, 811-6	204
1466	Currently available hypolipidaemic drugs and future therapeutic developments. <b>1995</b> , 9, 825-47	23
1465	Lipoproteins and the progression/regression of atherosclerosis. <b>1995</b> , 9, 849-66	8
1464	Review of new guidelines for management of dyslipidaemia. <b>1995</b> , 9, 867-90	4
1463	Insights Into the Pathogenesis and Prevention of Coronary Artery Disease. <b>1995</b> , 70, 69-79	33
1462	Regression of transplant coronary artery disease during chronic HELP therapy: a case study. <b>1995</b> , 115, 1-8	8
1461	Lessons from coronary atherosclerosis "regression" trials. <b>1996</b> , 14, 31-50	9
1460	MULTIFIT: a new approach to risk factor modification. <b>1996</b> , 14, 143-57	28
1459	Pathophysiology and inflammatory aspects of plaque rupture. <b>1996</b> , 14, 211-20	28
1458	Lipid lowering: the case for identifying and treating the high-risk patient. <b>1996</b> , 14, 117-30	7
1457	Efficacy of interventions designed to inhibit the progression of coronary atherosclerosis. <b>1996</b> , 30 Suppl, 37-53	4
1456	Natural history of severe atheromatous disease of the thoracic aorta: a transesophageal echocardiographic study. <b>1996</b> , 27, 95-101	118



1455	Angiographically silent atherosclerosis detected by intravascular ultrasound in patients with familial hypercholesterolemia and familial combined hyperlipidemia: correlation with high density lipoproteins. <b>1996</b> , 27, 1562-70	82
1454	27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 4. Efficacy of risk factor management. <b>1996</b> , 27, 991-1006	43
1453	27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 7. Evaluation and management of risk factors for the individual patient (case management). <b>1996</b> , 27, 1030-9	12
1452	Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis. <b>1996</b> , 131, 663-7	65
1451	Uncoupling clinical outcomes and coronary angiography: a review and perspective of recent trials in coronary artery disease. <b>1996</b> , 132, 910-20	5
1450	Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. <b>1996</b> , 100, 605-10	149
1449	The clinical and economic significance of atherosclerosis. <b>1996</b> , 101, 6S-9S	26
1448	Pathogenetic mechanisms of atherosclerosis: effect of lipid lowering on the biology of atherosclerosis. <b>1996</b> , 101, 10S-16S	21
1447	Review of cholesterol-lowering therapy: coronary angiographic and events trials. <b>1996</b> , 101, 4A34S-38S; discussion 39S	18
1446	Lipid management: current diet and drug treatment options. <b>1996</b> , 101, 4A40S-48S; discussion 48S-49S	44
1445	Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. <b>1996</b> , 100, 197-204	137
1444	Drug therapy of severe hypercholesterolemia in patients with coronary artery disease. <b>1996</b> , 20, 286-91	1
1443	Extracorporeal removal of lipids by dextran sulfate cellulose adsorption. <b>1996</b> , 20, 332-5	6
1442	Ex-vivo and in-vivo platelet function in patients with severe hypercholesterolemia undergoing LDL-apheresis. <b>1996</b> , 82, 291-301	18
1441	Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS). <b>1996</b> , 28, 1696-704	70
1440	Apolipoprotein B independently predicts progression of very-low-level albuminuria in insulin-dependent diabetes mellitus. <b>1996</b> , 45, 1101-7	30
1439	High density lipoproteins and coronary heart disease. <b>1996</b> , 121, 1-12	324
1438	Impaired radial artery compliance in normotensive subjects with familial hypercholesterolemia. <b>1996</b> , 124, 249-60	81

1437	Effects of vitamin E on endothelium-dependent coronary flow in hypercholesterolemic dogs. <b>1996</b> , 126, 43-51	2
1436	Lipoprotein(a) in renal disease. <b>1996</b> , 27, 1-25	205
1435	Clinical pharmacologic concepts for the rational selection and use of drugs for the management of dyslipidemia. <b>1996</b> , 18, 392-410; discussion 391	5
1434	The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study. <b>1996</b> , 18, 853-63	38
1433	Hyperlipidemia versus iron overload and coronary artery disease: yet more arguments on the cholesterol debate. <b>1996</b> , 49, 1353-8	7
1432	Differences in the response of serum lipoproteins to fenofibrate between women and men with primary hypercholesterolaemia. <b>1996</b> , 50, 365-9	3
1431	Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal. <b>1996</b> , 14, 11-24	74
1430	Age-related changes affecting atherosclerotic risk. Potential for pharmacological intervention. <b>1996</b> , 8, 275-98	8
1429	The 4S study. Implications for prescribing. <b>1996</b> , 51, 507-14	7
1428	Choosing the right lipid-regulating agent. A guide to selection. <b>1996</b> , 52, 649-61	34
1427	The 4S study and its pharmacoeconomic implications. <b>1996</b> , 9, 101-5	13
1426	Medical Management of Stable Angina and Unstable Angina in the Elderly With Coronary Artery Disease. <b>1996</b> , 12, 121-140	6
1425	Pathophysiology of Coronary Artery Disease. <b>1996</b> , 12, 1-21	6
1424	Management of Postmyocardial Infarction in the Elderly Patient. <b>1996</b> , 12, 169-180	3
1423	Treatment Effect of Niaspan, a Controlled-release Niacin, in Patients with Hypercholesterolemia: A Placebo-controlled Trial. <b>1996</b> , 1, 195-202	100
1422	Section Review: Cardiovascular & Renal: Treatment of severe and/or drug-resistant hyperlipidaemia. <b>1996</b> , 5, 513-520	
1421	Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group. <b>1996</b> , 16, 425-30	67
1420	Cholesterol screening in asymptomatic adults, revisited. Part 2. <b>1996</b> , 124, 518-31	76

1419	Do dietary phytochemicals with cytochrome P-450 enzyme-inducing activity increase high-density-lipoprotein concentrations in humans?. <b>1996</b> , 64, 706-11	9
1418	Treatment of dyslipidemias. <b>1996</b> , 2, 30-6	
1417	Effectiveness of Low-Dose Crystalline Nicotinic Acid in Men With Low High-Density Lipoprotein Cholesterol Levels. <b>1996</b> , 156, 1081	24
1416	Atherosclerosis and Risk Factor Modification: Does It Really Make a Difference?. <b>1996</b> , 9, 75-94	
1415	Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). <b>1996</b> , 17 Suppl F, 37-42	33
1414	Effect of a combination of gemfibrozil and niacin on lipid levels. <b>1996</b> , 36, 696-700	9
1413	Cardiac rehabilitation in the elderly: improving effectiveness. <b>1996</b> , 21, 182-6, 195	17
1412	Advances in treatment of cholesterol abnormalities. The role of HMG-CoA reductase inhibitors. <b>1996</b> , 100, 61-5, 70-2	
1411	Reversal of atherosclerosis with therapy: update of coronary angiographic trials. <b>1996</b> , 35, 307-20	1
1410	Dyslipidemia and coronary artery disease. Prevalence and treatment in patients referred for coronary arteriography. <b>1996</b> , 87, 497-501	1
1409	Prevention and regression of atherosclerosis: effects of HMG-CoA reductase inhibitors. <b>1996</b> , 30, 1304-15	4
1408	Beyond Low-Density Lipoprotein Cholesterol. <b>1996</b> , 156, 1278	22
1407	Cholesterol-lowering therapy: is there really a controversy?. <b>1996</b> , 30, 539-42	5
1406	Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease. <b>1996</b> , 19, 683-9	23
1405	A review of the use of risk factor modification in the management of atherosclerotic arterial disease. <b>1996</b> , 5, 226-232	
1404	Comprehensive lifestyle interventions in the community: A preliminary analysis. <b>1996</b> , 19, 91-100	3
1403	Relationship between total mortality and cholesterol reduction as found by meta-regression analysis of randomized cholesterol-lowering trials. <b>1996</b> , 17, 13-22	8
1402	Is the presence of hyperlipidemia associated with impairment of endothelium-dependent neointimal relaxation after percutaneous transluminal coronary angioplasty?. <b>1996</b> , 11, 255-61	6

1401	The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group. <b>1996</b> , 39, 1655-61	77
1400	Predictive value of lipid profile for salutary coronary angiographic changes in patients on a low-fat diet and physical exercise program. <b>1996</b> , 78, 163-7	15
1399	Effects of nonpharmacologic therapy with cardiac rehabilitation and exercise training in patients with low levels of high-density lipoprotein cholesterol. <b>1996</b> , 78, 1286-9	39
1398	Current concepts in the management of hypercholesterolemia with an update on fluvastatin. Introduction. <b>1996</b> , 78, 1-3	6
1397	Rationale for effective treatment of hypercholesterolemia. <b>1996</b> , 78, 4-12	23
1396	Review of the major intervention trials of lowering coronary artery disease risk through cholesterol reduction. <b>1996</b> , 78, 13-9	19
1395	Unstable angina: new insights into pathophysiologic characteristics, prognosis, and management strategies. <b>1996</b> , 21, 669-731	6
1394	The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. <b>1996</b> , 17, 550-83	28
1393	Familial hypercholesterolaemia with severe cardiac involvement in a boy: successful management and mid-term follow-up. <b>1996</b> , 85, 254-7	3
1392	Progression of atherosclerosis in middle-aged men: effects of multifactorial intervention. <b>1996</b> , 239, 425-33	18
1391	Genetic diagnosis of familial hypercholesterolemia in affected relatives using pedigree tracing. <b>1996</b> , 29, 371-7	4
1390	Human and porcine smooth muscle cells share similar proliferation dependence on the mevalonate pathway: implication for in vivo interventions in the porcine model. <b>1996</b> , 26, 1023-32	29
1389	Marine lipids normalize cholesteryl ester transfer in IDDM. <b>1996</b> , 39, 487-91	11
1388	A Prospective Study of Triglyceride Level, Low-Density Lipoprotein Particle Diameter, and Risk of Myocardial Infarction. <b>1996</b> , 276, 882	498
1387	Current and future therapeutic approaches to hyperlipidemia. <b>1996</b> , 35, 79-114	9
1386	The influence of angiographic endpoints on the outcome of lipid intervention studies. A proposal for standardization. REGRESS study group. <b>1996</b> , 47, 633-42	4
1385	Lead intoxication in children with pervasive developmental disorders. <b>1996</b> , 34, 177-81	37
1384	The cholesterol controversy. <b>1996</b> , 30, 495-500	9

1383	Delayed progression or regression of coronary atherosclerosis with intensive risk factor modification. Effects of diet, drugs, and exercise. <b>1996</b> , 22, 306-20		33
1382	Meta-analysis, Clinical Trials, and Transferability of Research Results Into Practice. <b>1996</b> , 156, 1158		30
1381	Practical aspects of preventing and managing atherosclerotic disease in post-menopausal women. <b>1996</b> , 17 Suppl D, 32-7		17
1380	Advances in coronary angioplasty. <i>New England Journal of Medicine</i> , <b>1996</b> , 335, 1290-302	59.2	206
1379	Cholesterol Lowering With Statin Drugs, Risk of Stroke, and Total Mortality. <b>1997</b> , 278, 313		420
1378	Long-term Cholesterol-Lowering Effects of 4 Fat-Restricted Diets in Hypercholesterolemic and Combined Hyperlipidemic Men. <b>1997</b> , 278, 1509		112
1377	Patients' Attitudes Toward Detection of Heterozygous Familial Hypercholesterolemia. <b>1997</b> , 157, 553		23
1376	Pharmacological treatment of ischaemic heart disease. Monotherapy vs combination therapy. <b>1997</b> , 18 Suppl B, B27-34		4
1375	Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia. <b>1997</b> , 2, 7-16		43
1374	The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. <i>New England Journal of Medicine</i> , <b>1997</b> , 336, 153-62	59.2	819
1373	Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation. <b>1997</b> , 112, 931-6		9
1372	Screening for risk factors for cardiovascular disease: a psychological perspective. <b>1997</b> , 42, 178-81		6
1371	Evolution of coronary atherosclerosis in patients with mild coronary artery disease studied by serial quantitative coronary angiography at 2 and 4 years follow-up. The Multicenter Anti-Atheroma Study (MAAS) Investigators. <b>1997</b> , 18, 1081-9		20
1370	Restenosis: is there a pharmacologic fix in the pipeline?. <b>1997</b> , 39, 313-51		1
1369	Binding of Bile Acids by Polymerized Cyclodextrin Resins. <b>1997</b> , 34, 335-347		17
1368	A randomized cross-over study comparing pharmacodynamic and metabolic variables of a new combiphasic and a well-established triphasic oral contraceptive. <b>1997</b> , 2, 173-80		7
1367	[Myocardial perfusion reserve studied by single-photon emission-computed tomography with thallium-201 and a drug stress test with adenosine triphosphate in patients with cardiovascular risk factors]. <b>1997</b> , 50, 696-708		
1366	Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. <b>1997</b> , 54, 615-33		103

1365	Low-Dose Simvastatin in the Treatment of Mild to Moderate Hypercholesterolaemia. <b>1997</b> , 13, 237-241	1
1364	Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. <b>1997</b> , 130, 191-7	114
1363	A brief review paper of the efficacy and safety of atorvastatin in early clinical trials. <b>1997</b> , 131, 17-23	42
1362	Evidence-Based Performance and Outcome Measures for Diabetes Care. <b>1997</b> , 2, 124-133	4
1361	Endothelial dysfunction and atherothrombotic occlusive disease. <b>1997</b> , 54 Suppl 3, 41-9; discussion 49-50	11
1360	Management of lipid disorders in the elderly. <b>1997</b> , 10, 444-62	11
1359	Atorvastatin, a New HMG-CoA Reductase Inhibitor, Does Not Affect Glucocorticoid Hormones in Patients With Hypercholesterolemia. <b>1997</b> , 2, 243-249	1
1358	Stressor-induced alterations in immune response and viral clearance following infection with herpes simplex virus-type 1 in BALB/c and C57B1/6 mice. <b>1997</b> , 11, 9-23	32
1357	Angiographic deterioration of target coronary artery narrowing as a result of percutaneous balloon angioplasty. <b>1997</b> , 133, 575-9	
1356	Angiographic predictors of neointimal thickening after successful coronary wall healing following percutaneous revascularization. <b>1997</b> , 133, 210-20	5
1355	The secondary prevention of coronary artery disease. <b>1997</b> , 102, 572-81	33
1354	Cholesterol screening should be targeted. <b>1997</b> , 102, 26-30	8
1353	Healthcare decisions and product labeling: results of a consumer comprehension study of prototype labeling for proposed over-the-counter cholestyramine. <b>1997</b> , 102, 50-6	19
1352	Improvement of erythrocyte deformability by cholesterol-lowering therapy with pravastatin in hypercholesterolemic patients. <b>1997</b> , 46, 287-91	33
1351	Endothelial dysfunction: does it matter? Is it reversible?. <b>1997</b> , 30, 325-33	535
1350	Clinical outcome in venous coronary artery bypass grafting: a 15-year follow-up study. <b>1997</b> , 58, 119-26	14
1349	Lipid abnormalities in Greek patients with coronary artery disease. <b>1997</b> , 59, 177-84	7
1348	Limits of lipid-lowering therapy: the potential benefits of amlodipine as an antiatherosclerotic agent. <b>1997</b> , 62 Suppl 2, S119-24	12

- 1347 LDL-cholesterol lowering and atherosclerosis--clinical benefit and possible mechanisms: an update. **1997**, 51, 16-27
- 1346 Aggressive cholesterol management: role of the lipid nurse specialist. **1997**, 26, 337-44 15
- 1345 The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS). **1997**, 18, 226-34 73
- 1344 Comparison of two assays for measuring LDL cholesterol. **1997**, 43, 1040-1047 24
- 1343 Long-term low-density lipoprotein immunoapheresis in renal disease. **1997**, 120, 105-19 2
- 1342 Efeito dos ácidos graxos ômega-3 sobre o relaxamento-dependente do endotôlio em coelhos hipercolesterolêmicos. **1997**, 69, 13-18 1
- 1341 Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. **1997**, 17, 2020-8 172
- 1340 Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate. **1997**, 17, 1793-9 61
- 1339 beta-VLDL hypercholesterolemia relative to LDL hypercholesterolemia is associated with higher levels of oxidized lipoproteins and a more rapid progression of coronary atherosclerosis in rabbits. **1997**, 17, 2376-82 29
- 1338 Rapid reversal of endothelial dysfunction in hypercholesterolaemic rabbits treated with simvastatin and pravastatin. **1997**, 24, 948-53 20
- 1337 Post-transplant hyperlipidaemia: low-dose lovastatin lowers atherogenic lipids without plasma accumulation of lovastatin. **1997**, 242, 483-90 7
- 1336 LDL apheresis in clinical practice: long-term treatment of severe hyperlipidemia. **1997**, 1, 49-54 2
- 1335 Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: clinical results. **1997**, 1, 242-8 21
- 1334 The retardation of progression, stabilization, and regression of coronary and carotid atherosclerosis by low-density lipoprotein apheresis in patients with familial hypercholesterolemia. **1997**, 1, 260-70 12
- 1333 Serum lipid profiles and the presence of yellow plaque in coronary lesions in vivo. **1997**, 79, 676-9 6
- 1332 Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dl and angiographically documented coronary artery disease. Coronary Artery Regression Study (CARS) Group. **1997**, 79, 893-6 26
- 1331 Contemporary cardiac rehabilitation services. **1997**, 79, 1075-7 22
- 1330 Cell dysfunction in atherosclerosis and the ischemic manifestations of coronary artery disease. **1997**, 79, 17-23 38

1329	Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol . <b>1997</b> , 80, 111-5	88
1328	Effects of Lipid Lowering on Coronary Plaques and Coronary Events. <b>1997</b> , 80, 8H-9H	
1327	Implementing quality assurance programs in multigroup practices for treating hypercholesterolemia in patients with coronary artery disease. <b>1997</b> , 80, 57H-61H	16
1326	Putting low-density lipoproteins at center stage in atherogenesis. <b>1997</b> , 79, 64-7	46
1325	A study to determine the response of coronary atherosclerosis to raising low high density lipoprotein cholesterol with a fibric-acid derivative in men after coronary bypass surgery. The rationale, design, and baseline characteristics of the LOCAT Study. Lipid Coronary Angiography Trial. <b>1997</b> , 18, 93-119	21
1324	A comparison of quantitative computerized and human panel coronary endpoint measures: implications for the design of angiographic trials. <b>1997</b> , 18, 168-79	10
1323	Variability in the measurement of intracoronary ultrasound images: implications for the identification of atherosclerotic plaque regression. <b>1997</b> , 20, 11-5	7
1322	Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials. <b>1997</b> , 11 Suppl 1, 257-63	19
1321	Acute Coronary Syndromes: Molecular Basis for Cardiac Risk Factors. <b>1997</b> , 4, 167-175	3
1320	Atherosclerotic Risk Factors Are Less Intensively Treated in Patients with Peripheral Arterial Disease Than in Patients with Coronary Artery Disease. <b>1997</b> , 12, 209-215	167
1319	Cardiac rehabilitation (CR) : Use of manual materials handling. <b>1997</b> , 20, 93-99	3
1318	Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. <b>1997</b> , 12, 591-6	57
1317	Metabolic and genetic aspects of familial combined hyperlipidaemia with emphasis on low-density lipoprotein heterogeneity. <b>1997</b> , 27, 802-11	32
1316	Secondary prevention of heart disease amongst patients with lipid abnormalities: practice and trends in the United States. <b>1997</b> , 241, 283-94	20
1315	DMP 504, a novel hydrogel bile acid sequestrant: III. Safety, tolerability, and cholesterol-lowering in healthy hypercholesterolemic subjects. <b>1997</b> , 41, 76-84	5
1314	Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis. <b>1998</b> , 12 Suppl 1, 111-8	11
1313	Comparison of the effect of bezafibrate on improvement of atherogenic lipoproteins in Japanese familial combined hyperlipidemic patients with or without impaired glucose tolerance. <b>1998</b> , 12, 3-12	6
1312	Treatment challenges in hypercholesterolemia. <b>1998</b> , 12, 325-37	2



1311	Cerivastatin (BAY w 6228): A Novel HMG-CoA Reductase Inhibitor. <b>1998</b> , 16, 236-263	16
1310	Shortcomings of the randomized controlled trial: a view from the boondocks. <b>1998</b> , 4, 283-6	8
1309	Dyslipidemias have a detrimental effect on left ventricular systolic function in patients with a first acute myocardial infarction. <b>1998</b> , 81, 531-7	34
1308	Aggressive lipid lowering in postcoronary angioplasty patients with elevated cholesterol (the Lovastatin Restenosis Trial). <b>1998</b> , 81, 632-6	10
1307	The new cholesterol education imperative and some comments on niacin. <b>1998</b> , 81, 492-4	5
1306	Use of Niacin, Statins, and Resins in Patients With Combined Hyperlipidemia. <b>1998</b> , 81, 52B-59B	37
1305	Impact of injection rate on the Thrombolysis in Myocardial Infarction (TIMI) trial frame count. <b>1998</b> , 81, 1268-70	53
1304	Relation of angiographic and ultrasound assessment of plaque progression to clinical outcomes. <b>1998</b> , 81, 69F-72F	4
1303	Current and future treatment of hyperlipidemia: the role of statins. <b>1998</b> , 82, 3J-10J	123
1302	Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. <b>1998</b> , 82, 737-43	182
1301	Clinical trial endpoints: angiograms, events, and plaque instability. <b>1998</b> , 82, 5M-11M	48
1300	Coronary arteriography and lipid lowering: limitations, new concepts, and new paradigms in cardiovascular medicine. <b>1998</b> , 82, 12M-21M	4
1299	Relation of clinical benefit to metabolic effects in lipid-lowering therapy. <b>1998</b> , 82, 22M-25M	1
1298	A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. <b>1998</b> , 82, 29U-34U; discussion 39U-41U	114
1297	Effect of niacin on atherosclerotic cardiovascular disease. <b>1998</b> , 82, 18U-23U; discussion 39U-41U	45
1296	Low-density lipoproteins and risk for coronary artery disease. <b>1998</b> , 82, 3Q-12Q	270
1295	Triglyceride as a risk factor for coronary artery disease. <b>1998</b> , 82, 22Q-25Q	311
1294	Did grandma give you heart disease? The new battle against coronary artery disease. <b>1998</b> , 82, 34Q-46Q	42

1293	Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. <b>1998</b> , 82, 35U-38U; discussion 39U-41U	75
1292	Treatment of hyperlipidemia with combined niacin-statin regimens. <b>1998</b> , 82, 82U-84U; discussion 85-86U	74
1291	State-of-the-art update and review: clinical trials of lipid-lowering agents. <b>1998</b> , 82, 3U-17U; discussion 39U-41U	38
1290	Treatment strategies for management of serum lipids: lessons learned from lipid metabolism, recent clinical trials, and experience with the HMG CoA reductase inhibitors. <b>1998</b> , 41, 95-116	12
1289	Cholesterol, cholesterol lowering, and endothelial function. <b>1998</b> , 41, 117-36	55
1288	Lipid-lowering drugs in the management of hyperlipidaemia. <b>1998</b> , 79, 205-30	52
1287	Lipid- and glucose-lowering efficacy of Plantago Psyllium in type II diabetes. <b>1998</b> , 12, 273-8	92
1286	Coronary artery injection technique: a quantitative in vivo investigation using modern catheters. <b>1998</b> , 44, 34-9	5
1285	Diabetes Atherosclerosis Intervention Study (DAIS): quantitative coronary angiographic analysis of coronary artery atherosclerosis. <b>1998</b> , 44, 249-56	16
1284	Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia. <b>1998</b> , 28, 192-5	37
1283	Inhibitors of acyl-CoA:cholesterol O-acyltransferase (ACAT). Part 1: identification and structure-activity relationships of a novel series of substituted N-alkyl-N-biphenylmethyl-N'-arylureas. <b>1998</b> , 6, 15-30	25
1282	Lipoprotein(a) apheresis in severe coronary heart disease: an immunoadsorption method. <b>1998</b> , 22, 135-9	13
1281	Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia. <b>1998</b> , 244, 143-7	15
1280	Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. <b>1998</b> , 47, 863-8	41
1279	Secondary prevention of coronary heart disease. <b>1998</b> , 79, 1006-17	8
1278	Cholesterol mobilization and regression of atheroma in cholesterol-fed rabbits induced by large unilamellar vesicles. <b>1998</b> , 1368, 306-20	43
1277	The mechanism of high-density lipoprotein cholesterol elevation in patients treated with simvastatin. <b>1998</b> , 59, 773-784	
1276	Aggressive medical therapy for the prevention and treatment of coronary artery disease. <b>1998</b> , 44, 1-40	1

1275	Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. <b>1998</b> , 31, 684-91	311
1274	Critical analysis of coronary artery bypass graft surgery: a 30-year journey. <b>1998</b> , 31, 1B-63B	82
1273	Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). <b>1998</b> , 32, 1648-56	140
1272	Decreased blood oxygen diffusion in hypercholesterolemia. <b>1998</b> , 124, 692-8	14
1271	Control of lipid disorders in patients with atherosclerotic vascular disease. <b>1998</b> , 78, 431-46	1
1270	Do lipid lowering drugs reduce the risk of coronary heart disease?. <b>1998</b> , 35, 603-21	15
1269	Risk indicators for recurrence among patients with coronary artery disease. Problems associated with their modification. <b>1998</b> , 32, 9-16	1
1268	Impact of dyslipidaemia. Lessons from clinical trials. <b>1998</b> , 14 Suppl 3, 1-9	1
1267	Clinical positioning of HMG-CoA reductase inhibitors in lipid management protocols. <b>1998</b> , 14 Suppl 3, 29-38	5
1266	Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials. <b>1998</b> , 104, 2S-5S	71
1265	Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization. <b>1998</b> , 104, 14S-18S	99
1264	New concepts and paradigms in cardiovascular medicine: the noninvasive management of coronary artery disease. <b>1998</b> , 104, 2S-17S	145
1263	The future: screening and effective intervention. <b>1998</b> , 104, 54S-59S	0
1262	The lipoprotein and coronary atherosclerosis study (LCAS): lipid and metabolic factors related to atheroma and clinical events. <b>1998</b> , 104, 42S-49S	14
1261	Benefit of aggressive lipid-lowering therapy: insights from the post coronary artery bypass graft study and other trials. <b>1998</b> , 105, 63S-68S	7
1260	Effect of HELP-LDL-apheresis on outcomes in patients with advanced coronary atherosclerosis and severe hypercholesterolemia. <b>1998</b> , 139, 401-9	18
1259	Improvement in the endothelium-dependent relaxation in hypercholesterolemic rabbits treated with vitamin E. <b>1998</b> , 140, 333-9	10
1258	Inhibitors of acyl-CoA:cholesterol O-acyltransferase. 3. Discovery of a novel series of N-alkyl-N-[(fluorophenoxy)benzyl]-N'-arylureas with weak toxicological effects on adrenal glands. <b>1998</b> , 41, 4408-20	19

1257	Differential effects of lovastatin on the trafficking of endogenous and lipoprotein-derived cholesterol in human monocyte-derived macrophages. <b>1998</b> , 18, 1322-9	29
1256	Inhibition of ileal Na <sup>+</sup> /bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits. <b>1998</b> , 18, 1304-11	63
1255	Cholesterol reduction yields clinical benefit: impact of statin trials. <b>1998</b> , 97, 946-52	351
1254	Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease. <b>1998</b> , 49, 339-48	8
1253	Suppressive effect of simvastatin on intramural small coronary arterial lesions in cholesterol-fed rabbits. <b>1998</b> , 49, 211-20	
1252	Vasodilatory capacity of forearm resistance vessels is augmented in hypercholesterolemic patients after treatment with fluvastatin. <b>1998</b> , 49, 743-8	12
1251	Cholesterol lowering and coronary artery disease: mechanisms of risk reduction. <b>1998</b> , 80, 543-7	14
1250	Echo-lucency of computerized ultrasound images of carotid atherosclerotic plaques are associated with increased levels of triglyceride-rich lipoproteins as well as increased plaque lipid content. <b>1998</b> , 97, 34-40	170
1249	Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. <b>1998</b> , 97, 1784-90	214
1248	Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. <b>1998</b> , 32, 1030-43	36
1247	IDL composition and angiographically determined progression of atherosclerotic lesions during simvastatin therapy. <b>1998</b> , 18, 577-83	11
1246	Multiple Risk Factors in Cardiovascular Disease. <b>1998</b> ,	
1245	Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol. <b>1998</b> , 18, 1723-9	164
1244	Present status of HMG reductase inhibitors in treatment of dyslipidemia. <b>1998</b> , 49, 801-5	1
1243	LDL hypercholesterolemia is associated with accumulation of oxidized LDL, atherosclerotic plaque growth, and compensatory vessel enlargement in coronary arteries of miniature pigs. <b>1998</b> , 18, 415-22	93
1242	Intensive lifestyle changes for reversal of coronary heart disease. <b>1998</b> , 280, 2001-7	1045
1241	Cardiac rehabilitation. <b>1998</b> , 19, 1004-10	14
1240	Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias. <b>1998</b> , 158, 1253-61	87

1239	Short-term efficacy and tolerability of combination therapy with lovastatin and acipimox in Chinese patients with type 2 diabetes mellitus and mixed dyslipidemia. <b>1998</b> , 38, 912-7	3
1238	Contemporary Practice: Treatment Gap in Lipid-Lowering Therapy. <b>1998</b> , 11, 318-322	
1237	Long-term intake of soy protein improves blood lipid profiles and increases mononuclear cell low-density-lipoprotein receptor messenger RNA in hypercholesterolemic, postmenopausal women. <b>1998</b> , 68, 545-51	237
1236	Dental and gingival pain as side effects of niacin therapy. <b>1998</b> , 114, 1472-4	4
1235	Maximizing the cost-effectiveness of lipid-lowering therapy. <b>1998</b> , 158, 1977-89	54
1234	Effectiveness of a dietary intervention strategy in general practice: effects on blood lipids, health and well-being. <b>1998</b> , 1, 273-81	8
1233	Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin cost-effective?. <b>1998</b> , 158, 375-81	23
1232	[Combined therapy with cholestyramine and HMG-CoA reductase inhibitors in secondary prevention of coronary disease]. <b>1998</b> , 70, 155-8	
1231	High level of lipoprotein(a) is a strong predictor for progression of coronary artery disease. <b>1998</b> , 5, 47-53	12
1230	Components of the insulin resistance syndrome are associated with progression of atherosclerosis in non-grafted arteries 5 years after coronary artery bypass surgery. <b>1998</b> , 19, 711-9	13
1229	Low serum cholesterol levels predict high perioperative mortality in patients supported by a left-ventricular assist system. <b>1998</b> , 89, 184-8	40
1228	Putative susceptibility markers of coronary artery disease: association between VDR genotype, smoking, and aromatic DNA adduct levels in human right atrial tissue. <b>1998</b> , 12, 1409-17	127
1227	Plasma apolipoprotein B levels predict platelet-dependent thrombosis in patients with coronary artery disease. <b>1999</b> , 92, 151-5	10
1226	Efficacy and safety of 300 micrograms and 400 micrograms cerivastatin once daily in patients with primary hypercholesterolaemia: a multicentre, randomized, double-blind, placebo-controlled study. <b>1999</b> , 27, 115-29	13
1225	An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program. <b>1999</b> , 282, 2051-7	75
1224	Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. <b>1999</b> , 19, 1051-9	107
1223	Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial (CLAPT). <b>1999</b> , 20, 1393-406	24
1222	A hepatic lipase gene promoter polymorphism attenuates the increase in hepatic lipase activity with increasing intra-abdominal fat in women. <b>1999</b> , 19, 2701-7	65

1221	Matching treatment to the genetic basis of (lipid) disorder in patients with coronary artery disease. <b>1999</b> , 82, 126-7	7
1220	Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. <b>1999</b> , 159, 1893-900	236
1219	Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial Data Issues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting. <b>1999</b> , 99, E1-7	64
1218	Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside. <b>1999</b> , 282, 2043-50	111
1217	Systematic review on the risk and benefit of different cholesterol-lowering interventions. <b>1999</b> , 19, 187-95	167
1216	Lipid-lowering and skin vascular responses in patients with hypercholesterolaemia and peripheral arterial obstructive disease. <b>1999</b> , 4, 233-8	54
1215	Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. <b>1999</b> , 99, 1959-64	230
1214	Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. <b>1999</b> , 99, 3227-33	433
1213	Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators. <b>1999</b> , 99, 3241-7	77
1212	Long-term follow-up after percutaneous transluminal coronary angioplasty was not performed based on intravascular ultrasound findings: importance of lumen dimensions. <b>1999</b> , 100, 256-61	183
1211	MRI of rabbit atherosclerosis in response to dietary cholesterol lowering. <b>1999</b> , 19, 1956-9	81
1210	Job-simulated phase II cardiac rehabilitation training program: Part A. A comparison with conventional phase II cardiac rehabilitation training program. <b>1999</b> , 24, 515-529	1
1209	Significance of graft occlusion and coronary atherosclerosis 5 years after coronary artery bypass grafting. A quantitative angiographic study with serial exercise testing. <b>1999</b> , 245, 545-52	3
1208	Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke. <b>1999</b> , 14, 763-74	26
1207	Tocotrienol: a review of its therapeutic potential. <b>1999</b> , 32, 309-19	251
1206	Lipid-Intervention und koronare Herzkrankheit bei Männern unter 56 Jahren Die Coronare Interventions-Studie: CIS. <b>1999</b> , 88, 270-282	
1205	[Short- and long-term effects of intensified versus conventional antilipidemic therapy in patients with coronary heart disease. Results from the Lipid-Coronary Artery Disease (L-CAD) Study]. <b>1999</b> , 88, 582-90	5
1204	Pathogenesis and pathology of coronary heart disease syndromes. <b>1999</b> , 8, 167-89	12

1203	[Prevention of coronary heart disease--"evidence-based medicine" of antilipemic therapy]. <b>1999</b> , 24, 3-12	2
1202	[Plaque stabilization by LDL apheresis?]. <b>1999</b> , 24, 57-61	5
1201	Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia. <b>1999</b> , 29, 22-5	42
1200	New developments in the treatment of low high-density lipoprotein cholesterol. <i>Current Atherosclerosis Reports</i> , <b>1999</b> , 1, 24-30	6 2
1199	Combination drug therapy for combined hyperlipidemia. <b>1999</b> , 1, 244-50	16
1198	Serial volumetric intravascular ultrasound assessment of arterial remodeling in left main coronary artery disease. <b>1999</b> , 83, 1427-32	45
1197	Coronary artery imaging in a 0.5-Tesla scanner: implementation of real-time, navigator echo-controlled segmented k-space FLASH and interleaved-spiral sequences. <b>1999</b> , 41, 392-9	27
1196	Screening for cardiovascular disease. Concepts, conflicts, and consensus. <b>1999</b> , 83, 1339-73	3
1195	Preventive pediatric cardiology. Tobacco, cholesterol, obesity, and physical activity. <b>1999</b> , 46, 253-62	10
1194	Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease. <b>1999</b> , 15, 47-74	60
1193	A comparative study of the effects of gestodene 60 microg/ethinylestradiol 15 microg and desogestrel 150 microg/ethinylestradiol 20 microg on hemostatic balance, blood lipid levels and carbohydrate metabolism. <b>1999</b> , 4 Suppl 2, 27-35	17
1192	Occlusions of epicardial arteries might not directly induce symptoms in ischemic heart disease. <b>1999</b> , 53, 533-42	9
1191	Efficacy and safety of atorvastatin and pravastatin in patients with hypercholesterolemia. <b>1999</b> , 10, 33-39	5
1190	Current perspectives on the benefits of HRT in menopausal women. <b>1999</b> , 33, 1-13	49
1189	Reflex testing I: algorithm for lipid and lipoprotein measurement in coronary heart disease risk assessment. <b>1999</b> , 280, 181-93	7
1188	Lipids and vascular disease: what we do and do not know. <b>1999</b> , 286, 7-22	5
1187	Interaction between lovastatin and cyclosporine A after heart and kidney transplantation. <b>1999</b> , 31, 2163-5	25
1186	Lack of regression of atherosclerotic lesions in phytosterol-treated apo E-deficient mice. <b>1999</b> , 64, 1029-36	41

1185	Reducción en las tasas de reestenosis después de una angioplastia coronaria con simvastatina y probucol. <b>1999</b> , 52, 778-784		
1184	Comparison of the Lipid-Lowering Effects of Fluvastatin, Lovastatin and Simvastatin in Patients with Hyperlipoproteinaemia. <b>1999</b> , 18, 209-215		1
1183	Drug treatment of lipid disorders. <i>New England Journal of Medicine</i> , <b>1999</b> , 341, 498-511	59.2	718
1182	Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. <b>1999</b> , 33, 1294-304		164
1181	Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). <b>1999</b> , 144, 409-17		78
1180	The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. <b>1999</b> , 144, 263-70		102
1179	Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma. <b>1999</b> , 145, 405-13		21
1178	Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs. <b>1999</b> , 146, 259-70		60
1177	Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. <b>1999</b> , 147, 253-61		289
1176	Effect of red wine consumption on low-density lipoprotein oxidation and atherosclerosis in aorta and coronary artery in Watanabe heritable hyperlipidemic rabbits. <b>1999</b> , 47, 4724-30		11
1175	Low-density and high-density lipoprotein subspecies and risk for premature coronary artery disease. <b>1999</b> , 107, 165-185		15
1174	Lipid reactivity to stress: I. Comparison of chronic and acute stress responses in middle-aged airline pilots.. <b>1999</b> , 18, 241-250		62
1173	The proving of the lipid hypothesis. <b>1999</b> , 10, 201-5		8
1172	Despite good compliance, very low fat diet alone does not achieve recommended cholesterol goals in outpatients with coronary heart disease. <b>1999</b> , 20, 1020-9		25
1171	Modification of coronary artery disease progression by cholesterol-lowering therapy: the angiographic studies. <b>1999</b> , 10, 527-34		10
1170	Forecasting patient outcomes in the management of hyperlipidemia. <b>1999</b> , 159, 569-75		3
1169	Cholesterol reduction and stroke occurrence: an overview of randomized clinical trials. <b>2000</b> , 10, 85-92		79
1168	Lipoprotein(a) is a potential coronary risk factor. <b>2000</b> , 64, 51-6		13



1167	Effect of long-term cholesterol-lowering treatment with HMG-CoA reductase inhibitor (simvastatin) on myocardial perfusion evaluated by thallium-201 single photon emission computed tomography. <b>2000</b> , 64, 177-82	7
1166	Risk factors that discriminate 'high- risk' from 'low-risk' Japanese patients with coronary artery disease. <b>2000</b> , 64, 825-30	13
1165	Triglycerides and coronary heart disease: implications of recent clinical trials. <b>2000</b> , 7, 339-45	53
1164	Prediction of angiographic stabilization/regression of coronary atherosclerosis by a risk factor graph. <b>2000</b> , 7, 415-23	5
1163	Pyridine nucleotides in glucose metabolism and diabetes: a review. <b>2000</b> , 16, 33-42	21
1162	Bile Salt Anion Sorption by Polymeric Resins: Comparison of a Functionalized Polyacrylamide Resin with Cholestyramine. <b>2000</b> , 232, 282-288	18
1161	Effect of plasma cholesterol on red blood cell oxygen transport. <b>2000</b> , 27, 951-5	33
1160	Debate: Are surrogate end-point studies worth the effort?. <b>2000</b> , 1, 72-75	1
1159	Bioconversion of compactin to pravastatin by <i>Actinomadura</i> sp. ATCC 55678. <b>2000</b> , 10, 151-156	13
1158	The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. <b>2000</b> , 21, 257-85	66
1157	Coronary artery bypass surgery with arterial grafts in familial hypercholesterolemia. <b>2000</b> , 119, 1008-13; discussion 1013-4	7
1156	Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group. <b>2000</b> , 86, 1176-81	31
1155	Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). <b>2000</b> , 86, 1293-8	122
1154	Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review. <b>2000</b> , 86, 46L-50L	188
1153	Evaluating niacin in its various forms. <b>2000</b> , 86, 51L-56L	76
1152	Efficacy of two lipid-lowering treatments on quantitative coronary angiographic endpoints. <b>2000</b> , 14, 411-8	1
1151	Reliability of mechanical and phased-array designs for serial intravascular ultrasound examinations--animal and clinical studies in stented and non-stented coronary arteries. <b>2000</b> , 16, 365-75	18
1150	FUNCTIONALIZED CYCLODEXTRIN POLYMERS FOR THE SORPTION OF BILE SALTS. <b>2000</b> , 37, 677-690	25

1149	Niacin dosing: relationship to benefits and adverse effects. <i>Current Atherosclerosis Reports</i> , <b>2000</b> , 2, 64-76	69
1148	Natural history of calcium deposits in atherosclerosis progression and regression. <b>2000</b> , 89 Suppl 2, 28-35	100
1147	Indications for Treatment of Asymptomatic Carotid Stenosis. <b>2000</b> , 11, 247-264	2
1146	Niacin protects the isolated heart from ischemia-reperfusion injury. <b>2000</b> , 279, H764-71	30
1145	References. <b>2000</b> , 173, S83	
1144	Population screening in hereditary hemochromatosis. <b>2000</b> , 21, 65-79	21
1143	Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). <b>2000</b> , 102, 1748-54	216
1142	Coronary Circulation and Myocardial Ischemia. <b>2000</b> ,	
1141	Cholesterol-lowering treatment is associated with improvement in coronary vascular remodeling and endothelial function in patients with normal or mildly diseased coronary arteries. <b>2000</b> , 20, 737-43	46
1140	Coronary Artery Disease Risk Predicted by Insulin Resistance, Plasma Lipids, and Hypertension In People without Diabetes. <b>2000</b> , 319, 84-88	11
1139	Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. <b>2000</b> , 284, 1263-70	379
1138	Effect of weight loss with reduction of intra-abdominal fat on lipid metabolism in older men. <b>2000</b> , 85, 977-82	108
1137	In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. <b>2000</b> , 20, 689-97	107
1136	Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). <b>2000</b> , 101, 477-84	462
1135	Competition between a sterol biosynthetic enzyme and tRNA modification in addition to changes in the protein synthesis machinery causes altered nonsense suppression. <b>2000</b> , 97, 61-6	52
1134	Beneficial effects of statins in coronary artery disease--beyond lowering cholesterol. <b>2000</b> , 34, 1432-9	45
1133	High-density lipoprotein and coronary heart disease: lessons from recent intervention trials. <b>2000</b> , 3, 33-39	3
1132	The antilipidemic effects of plain and extended-release niacin. <b>2000</b> , 3, 131-135	3

1131	Protective effect of high density lipoprotein on endothelium-dependent vasodilatation. <b>2000</b> , 73, 231-6	96
1130	Lipid lowering improves endothelial functions. <b>2000</b> , 74 Suppl 1, S3-S10	28
1129	Comparison of the risk factors for coronary artery spasm with those for organic stenosis in a Japanese population: role of cigarette smoking. <b>2000</b> , 72, 121-6	73
1128	Familial hypercholesterolaemia. <b>2000</b> , 4, 192-197	1
1127	Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. <b>2000</b> , 140, 792-803	19
1126	Preventing, stopping, or reversing coronary artery disease--triglyceride-rich lipoproteins and associated lipoprotein and metabolic abnormalities: the need for recognition and treatment. <b>2000</b> , 46, 421-503	5
1125	Management of Dyslipidaemias. <b>2000</b> , 7, 83-109	3
1124	Accelerating the return to work (RTW) chances of coronary heart disease (CHD) patients: part 1--development and validation of a training programme. <b>2000</b> , 22, 604-20	28
1123	Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent. <b>2000</b> , 9, 2663-71	41
1122	Pharmacotherapy of hypercholesterolaemia: statins in clinical practice. <b>2000</b> , 1, 683-95	23
1121	Prevention of coronary artery disease. <b>2000</b> , 27, 525-40,v	4
1120	Focus on HDL: a new treatment paradigm for athero-thrombotic vascular disease. <b>2000</b> , 9, 2139-46	4
1119	Guías de práctica clínica de la Sociedad Española de Cardiología en prevención cardiovascular y rehabilitación cardíaca. <b>2000</b> , 53, 1095-1120	36
1118	Current, new and future treatments in dyslipidaemia and atherosclerosis. <b>2000</b> , 60, 55-93	53
1117	Serum level of vascular endothelial growth factor is decreased by hormone replacement therapy in postmenopausal women without hypercholesterolemia. <b>2000</b> , 148, 189-95	26
1116	Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. <b>2000</b> , 150, 121-7	157
1115	Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study. <b>2000</b> , 151, 575-83	35
1114	The evolving role of statins in the management of atherosclerosis. <b>2000</b> , 35, 1-10	458

1113	Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. <b>2000</b> , 35, 214-21		116
1112	The combined effects of novel tocotrienols and lovastatin on lipid metabolism in chickens. <b>2001</b> , 156, 39-47		34
1111	Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. <b>2001</b> , 37, 1351-8		92
1110	Use of statins in CNS disorders. <b>2001</b> , 187, 81-9		101
1109	Cardiac rehabilitation and secondary prevention of coronary heart disease. <i>New England Journal of Medicine</i> , <b>2001</b> , 345, 892-902	59.2	551
1108	Approach to the Patient with Hyperlipidemia. <b>2001</b> , 115-132		
1107	The evolving role of high-density lipoprotein in reducing cardiovascular risk. <b>2001</b> , 4, 65-72		2
1106	Perspectives: Benefits of a new, nonsystemic lipid-lowering agent: the clinician's perspective. <b>2001</b> , 4, 38-39		
1105	Efficacy and safety of combination simvastatin and colesvelam in patients with primary hypercholesterolemia. <b>2001</b> , 110, 352-60		166
1104	Clinical context: current concepts of coronary heart disease management. <b>2001</b> , 110 Suppl 6A, 3S-11S		28
1103	A means to an end: an overview of a hyperlipidemia outcomes management program. <b>2001</b> , 110 Suppl 6A, 12S-16S		50
1102	Clinically relevant differences between the statins: implications for therapeutic selection. <b>2001</b> , 111, 390-400		154
1101	Design and rationale of the ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)--a randomized trial comparing the effects of atorvastatin and pravastatin on carotid artery intima-media thickness. <b>2001</b> , 141, 342-7		17
1100	STATINS & NEWER HOPE FOR ATHEROSCLEROSIS ASSOCIATED DISEASES. <b>2001</b> , 57, 129-30		
1099	Plasma phospholipid transfer protein activity in patients with low HDL and cardiovascular disease treated with simvastatin and niacin. <b>2001</b> , 1537, 117-24		16
1098	Selective modulation of thyroid hormone receptor action. <b>2001</b> , 76, 31-42		105
1097	Preoperative lipid control with simvastatin reduces the risk for graft failure already 1 year after myocardial revascularization. <b>2001</b> , 9, 33-43		32
1096	A simple turbidimetric assay designed for the routine screening as well as therapeutic monitoring of native LDL particles. <b>2001</b> , 303, 155-65		1

1095	Therapeutic implications of inflammation in atherosclerotic cardiovascular disease. <b>2001</b> , 71, 2066-74	26
1094	Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. <b>2001</b> , 357, 905-910	711
1093	Exercise in the reduction of cardiovascular events. Lessons from epidemiologic trials. <b>2001</b> , 19, 347-55	11
1092	Efectividad del tratamiento hipocolesterolemizante a largo plazo. <b>2001</b> , 13, 118-120	
1091	Mejorã de la funci3n endotelial al reducir las concentraciones lip3dicas en pacientes con hipercolesterolemia y arterias coronarias normales. <b>2001</b> , 54, 685-692	7
1090	Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. <b>2001</b> , 76, 971-82	122
1089	Concentraciones s3ficas de apo B como marcador de aterosclerosis coronaria en varones. <b>2001</b> , 13, 63-67	1
1088	Statins in the 21st century: end of the simple story?. <b>2001</b> , 10, 1755-66	17
1087	Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. <i>New England Journal of Medicine</i> , <b>2001</b> , 345, 1583-92	59.2 1662
1086	Recognition, pathophysiology, and management of acute myocardial infarction. <b>2001</b> , 58, 1709-1718	10
1085	Achieving blood lipid goals in patients with coronary artery disease. <b>2001</b> , 58, 415-419	
1084	Hepatic lipase as a focal point for the development and treatment of coronary artery disease. <b>2001</b> , 49, 112-8	20
1083	Coronary Atherosclerosis and Restenosis. <b>2001</b> , 967-1009	
1082	Genetic predisposition to coronary artery disease. <b>2001</b> , 16, 251-60	40
1081	Lipids and risk assessment. <b>2001</b> , 9, 348-58	1
1080	Statin therapy and stroke prevention. <b>2001</b> , 16, 219-24	27
1079	Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study. <b>2001</b> , 41, 70-8	14
1078	High-density lipoprotein: epidemiology, metabolism, and antiatherogenic effects. <b>2001</b> , 47, 369-416	14

1077	Structure-activity relationships of N-(3,5-dimethoxy-4-n-octyloxycinnamoyl)-N'-(3,4-dimethylphenyl)piperazine and analogues as inhibitors of acyl-CoA: cholesterol O-acyltransferase. <b>2001</b> , 49, 830-9		9
1076	Perspectives on vascular biology and diabetes. <b>2001</b> , 49, 100-3		0
1075	Transforming exercise-based cardiac rehabilitation programs into secondary prevention centers: a national imperative. <b>2001</b> , 21, 263-72		40
1074	The Clinical Relevance and Management of High-Density Lipoprotein Deficiency. <b>2001</b> , 11, 16-25		1
1073	Current Lipid-lowering Strategies for the Treatment of Diabetic Dyslipidemia: An Integrated Approach to Therapy. <b>2001</b> , 11, 368-383		3
1072	Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. <b>2001</b> , 104, 2376-83		211
1071	The benefits of niacin in atherosclerosis. <i>Current Atherosclerosis Reports</i> , <b>2001</b> , 3, 74-82	6	81
1070	Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century. <i>Current Atherosclerosis Reports</i> , <b>2001</b> , 3, 373-82	6	23
1069	Targeting triglycerides as prognostic indicators and determining lowest values for patient benefit. <b>2001</b> , 3, 424-32		3
1068	Anti-atherogenic effects of fibrates in type 2 diabetes. <b>2001</b> , 2, 218-220		1
1067	Using an electronic medical record to identify opportunities to improve compliance with cholesterol guidelines. <b>2001</b> , 16, 531-7		45
1066	Effects of low-density lipoprotein apheresis on coronary and carotid atherosclerosis and diabetic scleredema in patients with severe hypercholesterolemia. <b>2001</b> , 5, 244-51		11
1065	Current topics on low-density lipoprotein apheresis. <b>2001</b> , 5, 293-300		17
1064	Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. <b>2001</b> , 44, 2870-8		227
1063	Low-dose combination therapy with colesvelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. <b>2001</b> , 24, 467-74		85
1062	Pharmacotherapy of dyslipidemia. <b>2001</b> , 15, 413-22		37
1061	Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients. <b>2001</b> , 7, 93-9		53
1060	Lessons from the post coronary artery bypass graft study in evaluating and controlling technical variability in angiographic trials. <i>Post CABG Investigators</i> . <b>2001</b> , 87, 40-3		4

1059	Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy. <b>2001</b> , 87, 1174-80; A4	45
1058	Electron-beam tomography coronary calcium scores are superior to Framingham risk variables for predicting the measured proximal stenosis burden. <b>2001</b> , 88, 23E-26E	25
1057	Developing a clinical strategy for cholesterol management in an era of unanswered questions. <b>2001</b> , 88, 25F-30F	2
1056	Preoperative lipid control with simvastatin protects coronary artery bypass grafts from obstructive graft disease. <b>2001</b> , 88, 896-9, A8	31
1055	The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease. <b>2001</b> , 4, 165-172	22
1054	Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. <b>2001</b> , 103, 792-8	104
1053	Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. <b>2001</b> , 21, 1623-9	238
1052	Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. <b>2001</b> , 21, 1320-6	161
1051	The role of risk factors in the development of atherosclerosis. <b>2001</b> , 38, 401-40	21
1050	Current approaches to therapy for vascular injury. <b>2001</b> , 2, 753-64	
1049	Risk factors for coronary disease: the time for a paradigm shift?. <b>2001</b> , 39, 907-19	7
1048	Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. <b>2001</b> , 285, 1585-91	708
1047	A comparison of clinical outcome studies among cholesterol-lowering agents. <b>2001</b> , 35, 1599-607	15
1046	Relationship of insulin sensitivity and ApoB levels to intra-abdominal fat in subjects with familial combined hyperlipidemia. <b>2001</b> , 21, 567-72	55
1045	The endothermic nature of the binding of anionic bile salts to a cationic adsorbent. <b>2002</b> , 80, 89-93	3
1044	Niacin extended-release/lovastatin: combination therapy for lipid disorders. <b>2002</b> , 3, 1763-71	20
1043	The effects of combination therapy with niaspan and pravastatin on hyperlipidaemia. <b>2002</b> , 30, 271-81	4
1042	Coronary collateral size, flow capacity, and growth: estimates from the angiogram in patients with obstructive coronary disease. <b>2002</b> , 105, 168-73	56

1041	The coronary angiogram and its seminal contributions to cardiovascular medicine over five decades. <b>2002</b> , 106, 752-6	56
1040	Long-term effect of lipid-lowering therapy on atherosclerosis of abdominal aorta in patients with hypercholesterolemia: noninvasive evaluation by a new image analysis program. <b>2002</b> , 53, 57-68	19
1039	Protruding atherosclerotic aortic plaques and dyslipidaemia: correlation to subtypes of ischaemic stroke. <b>2002</b> , 3, 8-12	11
1038	Combination therapy: its rationale and the role of ezetimibe. <b>2002</b> , 4, J19-J22	9
1037	Antioxidant vitamins and coronary disease. <i>New England Journal of Medicine</i> , <b>2002</b> , 346, 1092-3	59.2
1036	Clinical review 141: lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies. <b>2002</b> , 87, 423-37	56
1035	Improving health behaviors and outcomes after angioplasty: using economic theory to inform intervention. <b>2002</b> , 17, 606-18	15
1034	Angiographic intervention trial using HMG CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma in West Japan (ATHEROMA study): rationale, design and baseline. <b>2002</b> , 9, 7-16	3
1033	Effect of colesevelam on lovastatin pharmacokinetics. <b>2002</b> , 36, 392-7	21
1032	Obesity, hypertension, and insulin resistance. <b>2002</b> , 25, 2088-97	46
1031	Regression of atherosclerosis in monkeys reduces vascular superoxide levels. <b>2002</b> , 90, 277-83	69
1030	Anticoagulant responses to thrombin are enhanced during regression of atherosclerosis in monkeys. <b>2002</b> , 106, 842-6	17
1029	Vasorelaxation by L-arginine after L-NAME administration in rabbits consuming moderate amounts of red wine. <b>2002</b> , 48, 318-21	3
1028	Effects of a contemporary, exercise-based rehabilitation and cardiovascular risk-reduction program on coronary patients with abnormal baseline risk factors. <b>2002</b> , 122, 338-43	27
1027	Reducing cholesterol and atherosclerosis. <b>2002</b> , 95, 339-41	4
1026	The surveillance of cholesterol management in the cardiac rehabilitation setting. <b>2002</b> , 22, 245-50	3
1025	. <b>2002</b> , 9, 7-16	2
1024	Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia. <b>2002</b> , 4, 124-37	40



1023	An organizational model to translate nutritional recommendations into routine clinical practice in secondary prevention of coronary artery disease. <b>2002</b> , 34, 138-43	2
1022	Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). <b>2002</b> , 40, 220-7	137
1021	Dynamics of reverse cholesterol transport: protection against atherosclerosis. <b>2002</b> , 161, 245-54	116
1020	Who should receive HMG CoA reductase inhibitors?. <b>2002</b> , 62, 1707-15	11
1019	Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. <b>2002</b> , 62, 1909-44	86
1018	Pharmacotherapeutic options for the management of myocardial infarction. <b>2002</b> , 3, 1153-68	1
1017	Low-density lipoprotein apheresis: clinical results with different methods. <b>2002</b> , 26, 133-9	18
1016	Lipid compositional differences of small, dense low-density lipoprotein particle influence its oxidative susceptibility: possible implication of increased risk of coronary artery disease in subjects with phenotype B. <b>2002</b> , 51, 1081-7	43
1015	Number needed to treat: easily understood and intuitively meaningful? Theoretical considerations and a randomized trial. <b>2002</b> , 55, 888-92	60
1014	Is atherosclerotic vascular disease related to a high-fat diet?. <b>2002</b> , 55, 1064-72; discussion 1073-4	6
1013	Efecto antiaterogénico de la atorvastatina en pollos alimentados con una dieta rica en colesterol. <b>2002</b> , 14, 225-229	
1012	WOMEN & CORONARY HEART DISEASE: EXERCISE, WELLNESS AND RISK MODIFICATION. <b>2002</b> , 13, 13-16	
1011	Dietary counselling for dyslipidemia in primary care: results of a randomized trial. <b>2002</b> , 63, 169-75	12
1010	Colesevelam hydrochloride. <b>2002</b> , 59, 932-9	39
1009	Acute Coronary Syndrome and Early Statin Therapy: What Is the Evidence?. <b>2002</b> , 2, 246-250	
1008	Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP. <b>2002</b> , 25, 1180-8	39
1007	Increased intima-media thickness in familial combined hyperlipidemia associated with apolipoprotein B. <b>2002</b> , 22, 283-8	44
1006	New cholesterol guidelines, new treatment challenges. <b>2002</b> , 22, 853-63	10

1005	Modification of high-density lipoprotein cholesterol in the management of cardiovascular risk. <b>2002</b> , 22, 1266-77	4
1004	Pathophysiology of coronary thrombosis: role of plaque rupture and plaque erosion. <b>2002</b> , 44, 357-68	78
1003	The effects of simvastatin-niacin and antioxidant therapy on HDL. <b>2002</b> , 17, 102-3	
1002	Quantitative coronary angiography in regression trials: a review of methodologic considerations, endpoint selection, and limitations. <b>2002</b> , 89, 4B-9B	18
1001	Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. <b>2002</b> , 89, 672-8	201
1000	Coronary angiographic changes in patients with cardiac events in the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT). <b>2002</b> , 90, 776-8	3
999	Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. <b>2002</b> , 90, 30i-47i	122
998	Combination therapy for elevated low-density lipoprotein cholesterol: the key to coronary artery disease risk reduction. <b>2002</b> , 90, 8K-20K	44
997	Women's angiographic vitamin and estrogen trial: design and methods. <b>2002</b> , 23, 708-27	19
996	Serum apolipoprotein AI levels in atherosclerotic and diabetic patients. <b>2002</b> , 24, 161-5	12
995	Treatment of lipid disorders after stroke. <i>Current Atherosclerosis Reports</i> , <b>2002</b> , 4, 304-10	6
994	Pharmacogenetics of Lipid-lowering Therapies. <i>Current Atherosclerosis Reports</i> , <b>2002</b> , 4, 183-92	6 7
993	LDL receptor mutation genotype and vascular disease phenotype in heterozygous familial hypercholesterolaemia. <b>2002</b> , 61, 408-15	8
992	Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial. <b>2002</b> , 251, 490-9	40
991	Meaning of low-density lipoprotein-apheresis for hypercholesterolemic patients at high risk for recurrence of coronary heart disease. <b>2002</b> , 6, 372-80	4
990	Invasive assessment of the coronary circulation: intravascular ultrasound and Doppler. <b>2002</b> , 53, 561-75	7
989	Returning coronary heart disease patients to work: a modified perspective. <b>2002</b> , 12, 31-42	4
988	The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. <b>2003</b> , 17, 265-85	63

987	A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. <b>2003</b> , 26, 112-8		50
986	Comparing HMG-CoA reductase inhibitors. <b>2003</b> , 26, 115-20		14
985	Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events. <i>Current Atherosclerosis Reports</i> , <b>2003</b> , 5, 418-22	6	8
984	Coronary arterial remodeling: from bench to bedside. <i>Current Atherosclerosis Reports</i> , <b>2003</b> , 5, 150-4	6	23
983	Niacin, lipids, and heart disease. <b>2003</b> , 5, 470-6		42
982	Triglycerides and HDL-cholesterol in pediatric patients. <b>2003</b> , 17, 151-158		2
981	Managing the spectrum of dyslipidemia in primary care. <b>2003</b> , 21, 81-9; quiz 90-1		3
980	REFERENCES. <b>2003</b> , 41, S77-S91		
979	Treating dyslipidemic patients with lipid-modifying and combination therapies. <b>2003</b> , 23, 625-37		15
978	Prevention of stroke and dementia with statins: Effects beyond lipid lowering. <b>2003</b> , 91, 23B-29B		99
977	Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. <b>2003</b> , 91, 1421-6		122
976	Effectiveness of aggressive management of dyslipidemia in a collaborative-care practice model. <b>2003</b> , 91, 1427-31		9
975	From membrane differential filtration to lipidfiltration: technological progress in low-density lipoprotein apheresis. <b>2003</b> , 7, 350-8		31
974	Low-density lipoprotein apheresis: an overview. <b>2003</b> , 7, 382-90		56
973	Surrogate measures of atherosclerosis and implications for evaluating cardiovascular risk. <b>2003</b> , 5, 73-80		4
972	Efecto del etofibrato de liberaci3n sostenida en pacientes con concentraciones plasm3ticas de lipoprote3na(a) > 300 mg/l. <b>2003</b> , 15, 8-15		
971	Pathophysiology of plaque rupture and the concept of plaque stabilization. <b>2003</b> , 21, 303-14, v		26
970	Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry study. <b>2003</b> , 170, 73-8		45

969	Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes. <b>2003</b> , 41, 23S-30S	16
968	Mechanisms of plaque vulnerability and rupture. <b>2003</b> , 41, 15S-22S	352
967	New insights into the relationship between myocardial perfusion and lipid-lowering. <b>2003</b> , 42, 611-3	5
966	Pharmacological treatment of patients with peripheral arterial disease. <b>2003</b> , 63, 637-47	9
965	Elasticity imaging of atheroma with transcutaneous ultrasound: preliminary study. <b>2003</b> , 107, 3018-21	119
964	Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. <b>2003</b> , 115 Suppl 8A, 24S-28S	93
963	A randomized trial of aggressive lipid reduction for improvement of myocardial ischemia, symptom status, and vascular function in patients with coronary artery disease not amenable to intervention. <b>2003</b> , 114, 445-53	16
962	Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. <b>2003</b> , 6, 179-88	49
961	Statin-associated myopathy. <b>2003</b> , 289, 1681-90	1002
960	Antiatherothrombotic effects of nicotinic acid. <b>2003</b> , 171, 87-96	71
959	A randomized trial of laypersons' perception of the benefit of osteoporosis therapy: number needed to treat versus postponement of hip fracture. <b>2003</b> , 25, 2575-85	36
958	Ischemic optic neuropathy as the first manifestation of elevated cholesterol levels in young patients. <b>2003</b> , 110, 1041-6; discussion 1046	67
957	The pathophysiology of perioperative myocardial infarction: facts and perspectives. <b>2003</b> , 17, 90-100	143
956	Niacin as a component of combination therapy for dyslipidemia. <b>2003</b> , 78, 735-42	58
955	Relation between coronary artery disease, risk factors and intima-media thickness of carotid artery, arterial distensibility, and stiffness index. <b>2003</b> , 54, 261-7	48
954	Primary hypercholesterolemia: genetic causes and treatment of five monogenic disorders. <i>Expert Review of Cardiovascular Therapy</i> , <b>2003</b> , 1, 107-19	2.5 31
953	Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL. <b>2003</b> , 44, 800-6	61
952	Impact of dyslipidemia in end-stage renal disease. <b>2003</b> , 14, S315-20	77

951	New lipid-modifying therapies. <b>2003</b> , 12, 325-35	9
950	Anti-atherosclerotic effects of statins: lessons from prevention trials. <b>2003</b> , 10, 155-9	7
949	. <b>2003</b> , 14, 315-320	3
948	Electronic staining: elasticity imaging of atheroma with transcutaneous ultrasound.	
947	Optimal therapy of low levels of high density lipoprotein-cholesterol. <b>2003</b> , 3, 53-65	13
946	Improving the Prediction of Cardiovascular Risk: Interaction Between LDL and HDL Cholesterol. <b>2003</b> , 14, 315-320	14
945	Hepatic lipase: a marker for cardiovascular disease risk and response to therapy. <b>2003</b> , 14, 179-89	78
944	. <b>2003</b> , 10, 155-159	14
943	Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management. <b>2003</b> , 18, 278-85	16
942	Genetic evaluation for coronary artery disease. <b>2003</b> , 5, 269-85	48
941	Mikamo Lecture: a radical view on the 'superfamily' of cardiovascular risk factors. <b>2003</b> , 67, 805-9	9
940	Aggressive lipid management for cardiovascular prevention: evidence from clinical trials. <b>2003</b> , 228, 769-78	10
939	Niacin for dyslipidemia: considerations in product selection. <b>2003</b> , 60, 995-1005	42
938	Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. <b>2003</b> , 139, 996-1002	57
937	Advances in the understanding and management of dyslipidemia: using niacin-based therapies. <b>2003</b> , 60, S15-21; quiz S25	7
936	Preventing angiographic progression of coronary atherosclerosis with pravastatin. <b>2003</b> , 10, 25-31	4
935	Quantifying the effect of applying the NCEP ATP III criteria in a managed care population treated with statin therapy. <b>2004</b> , 10, 244-50	12
934	Beta-lactam cholesterol absorption inhibitors. <b>2004</b> , 11, 1873-87	115

933	Electron beam tomography as a non invasive method to monitor effectiveness of antiatherosclerotic therapy. <b>2004</b> , 4, 177-81	5
932	Extended-release niacin for modifying the lipoprotein profile. <b>2004</b> , 5, 1385-98	51
931	Correlation between CXCR4 and homing or engraftment of acute myelogenous leukemia. <b>2004</b> , 64, 6832 author reply 6832-3	15
930	Atherosclerosis imaging and the future of lipid management. <b>2004</b> , 110, 3509-11	15
929	Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. <b>2004</b> , 110, 3512-7	788
928	New perspectives on the use of niacin in the treatment of lipid disorders. <b>2004</b> , 164, 697-705	146
927	Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. <b>2004</b> , 110, 227-39	445 <sup>0</sup>
926	Lipid-altering drugs: decreasing cardiovascular disease at the expense of increasing cancer?. <b>2004</b> , 64, 6831; author reply 6831-2	1
925	Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. <b>2004</b> , 68, 860-7	48
924	Addressing cardiovascular disease in women: focus on dyslipidemia. <b>2004</b> , 17, 424-37	32
923	Intima-media thickness and arterial distensibility in Behçet's disease. <b>2004</b> , 55, 413-9	39
922	Lipids and lipoproteins in patients with type 2 diabetes. <b>2004</b> , 27, 1496-504	483
921	Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C. <b>2004</b> , 20, 1253-68	214
920	Review: Use of nicotinic acid in patients with elevated fasting glucose, diabetes, or metabolic syndrome. <b>2004</b> , 4, 78-85	16
919	Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. <b>2004</b> , 24, e149-61	181
918	Handbook of Drug Interactions. <b>2004</b> ,	11
917	Statins and Inhibition of Atherosclerosis: Human Studies. <b>2004</b> , 37-51	
916	Cardiovascular risk assessment and triptans. <b>2004</b> , 44 Suppl 1, S31-9	20

915	Cholesterol metabolism and its implications for therapeutic interventions in patients with hypercholesterolaemia. <b>2004</b> , 58, 859-66		34
914	Clinical update on the use of niacin for the treatment of dyslipidemia. <b>2004</b> , 16, 526-34		4
913	Comparative effects of lipid-lowering therapies. <b>2004</b> , 47, 73-104		83
912	Pharmacologic treatment of type 2 diabetic dyslipidemia. <b>2004</b> , 24, 1692-713		27
911	Quantitative angiographic and intravascular ultrasound study >5 years after directional coronary atherectomy. <b>2004</b> , 93, 543-8		1
910	Fluvastatin reduces cardiac mortality in patients with coronary heart disease. <b>2004</b> , 18, 67-75		7
909	The physiological role of triacylglycerol hydrolase in lipid metabolism. <b>2004</b> , 5, 303-9		18
908	Pathological changes in acute coronary syndromes: the role of statin therapy in the modulation of inflammation, endothelial function and coagulation. <b>2004</b> , 18, 89-101		32
907	[Lifelong after-care and secondary prevention after myocardial infarct]. <b>2004</b> , 99, 309-20; quiz 321		
906	High-density lipoprotein subfractions and risk of coronary artery disease. <i>Current Atherosclerosis Reports</i> , <b>2004</b> , 6, 359-65	6	63
905	Combination therapy of dyslipidemia in non-insulin-dependent diabetes mellitus and the metabolic syndrome. <b>2004</b> , 4, 330-4		1
904	Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. <b>2004</b> , 255, 188-205		260
903	Cost-effectiveness analysis based on the number-needed-to-treat: common sense or non-sense?. <b>2004</b> , 13, 9-19		27
902	Improvement of endothelium-dependent coronary vasodilation after a single LDL apheresis in patients with hypercholesterolemia. <b>2004</b> , 19, 11-6		29
901	Assessment of coronary flow reserve and microcirculation: a clinical perspective. <b>2004</b> , 11, 3-11		36
900	Advances in positron emission tomography. <b>2004</b> , 11, 719-32		37
899	Management of the metabolic syndrome-nicotinic acid. <b>2004</b> , 33, 557-75, vii		22
898	Management of atherogenic dyslipidemia of the metabolic syndrome: evolving rationale for combined drug therapy. <b>2004</b> , 33, 525-44, vi		12

897	Clinical application of genetic risk assessment strategies for coronary artery disease: genotypes, phenotypes, and family history. <b>2004</b> , 31, 711-37, xi-xii		13
896	Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. <b>2004</b> , 43, 717-24		182
895	Extended-release niacin/lovastatin: the first combination product for dyslipidemia. <i>Expert Review of Cardiovascular Therapy</i> , <b>2004</b> , 2, 485-501	2.5	21
894	Elasticity imaging of atheroma with transcutaneous ultrasound both in longitudinal-axis and short-axis planes. <b>2004</b> , 1274, 64-74		1
893	A comparison of HDL and LDL cholesterol for prevalent coronary calcification. <b>2004</b> , 95, 55-60		31
892	Can change in high-density lipoprotein cholesterol levels reduce cardiovascular risk?. <b>2004</b> , 147, 966-76		35
891	Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. <b>2004</b> , 137, 615-24		49
890	Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia. <b>2004</b> , 7, 176-81		13
889	Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. <b>2004</b> , 44, 720-32		1070
888	Insights from apoB: from better diagnosis & therapy to the Medusa Hypothesis. <b>2004</b> , 5, 19-24		9
887	A randomized, open-label, comparative study of simvastatin plus diet versus diet alone on angiographic retardation of coronary atherosclerosis in adult Japanese patients: Japanese utilization of simvastatin therapy (JUST) study. <b>2004</b> , 26, 878-88		7
886	Progression of coronary artery disease in non-ischemic dilated cardiomyopathy. <b>2004</b> , 15, 291-7		13
885	High-density lipoprotein cholesterol and coronary heart disease. <b>2004</b> , 12, 107-19		46
884	Niacin therapy in atherosclerosis. <b>2004</b> , 15, 659-65		131
883	Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration*1. <b>2004</b> , 137, 615-624		116
882	Diet and Plasma Lipoproteins in Elderly With and Without Cardiovascular Disease. <b>2004</b> , 19, 215-225		
881	HDL-raising strategies in the treatment of coronary artery disease: perspectives from the Armed Forces Regression Study. <b>2005</b> , 16, 652-7		5
880	Determinants of the effect of estrogen on the progression of subclinical atherosclerosis: Estrogen in the Prevention of Atherosclerosis Trial. <b>2005</b> , 12, 366-73		39



879	Statins and cardiovascular risks. <b>2005</b> , 43, 55-68	4
878	Niacin therapy in atherosclerosis. <b>2005</b> , 4, 20-26	
877	Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies. <b>2005</b> , 20, 307-12	11
876	Three-year follow-up results of angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study. <b>2005</b> , 69, 875-83	23
875	Effect of pravastatin on progression of coronary atherosclerosis in patients after coronary artery bypass surgery. <b>2005</b> , 69, 636-43	25
874	Assessing progression or regression of CAD: the role of perfusion imaging. <b>2005</b> , 12, 625-38	21
873	Pravastatin attenuates ceramide-induced cytotoxicity in mouse cerebral endothelial cells with HIF-1 activation and VEGF upregulation. <b>2005</b> , 1042, 357-64	17
872	Combination niacin and statin therapy in primary and secondary prevention of cardiovascular disease. <b>2005</b> , 28, 317-20	14
871	Medical management of peripheral arterial disease. <b>2005</b> , 3, 1628-37	43
870	Management of dyslipidemia in women in the post-hormone therapy era. <b>2005</b> , 20, 297-305	7
869	Genes and atherosclerosis: at the origin of the predisposition. <b>2005</b> , 59, 462-72	22
868	Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. <b>2005</b> , 258, 94-114	467
867	Acute effect of atorvastatin on coronary circulation measured by transthoracic Doppler echocardiography in patients without coronary artery disease by angiography. <b>2005</b> , 96, 89-91	26
866	Assessment of patients at intermediate cardiac risk. <b>2005</b> , 96, 2J-10J	17
865	Interstudy reproducibility of three-dimensional volume-selective fast spin echo magnetic resonance for quantifying carotid artery wall volume. <b>2005</b> , 21, 187-91	27
864	[Niacin--an additive therapeutic approach for optimizing lipid profile]. <b>2005</b> , 100, 186-92	1
863	Comparison of two methods of estimation of low density lipoprotein cholesterol, the direct versus friedewald estimation. <b>2005</b> , 20, 54-61	29
862	Comprehensive imaging of coronary artery disease: impact on contemporary treatment approaches. <b>2005</b> , 31, 159-65	

- 861 Effects of colesvelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. **2005**, 50, 1232-8 29
- 860 Atherosclerosis imaging and circulating blood biomarkers: insights into subclinical atherosclerotic plaque burden and disease activity. **2005**, 21, 443-5
- 859 Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention. **2005**, 19, 135-9 26
- 858 Ten-year follow-up of familial hypercholesterolemia patients after intensive cholesterol-lowering therapy. **2005**, 46, 833-43 31
- 857 Modern intervention strategies for managing dyslipidaemia: the case for combination therapy. **2005**, 5, S17-S23
- 856 Coronary Drug Project. **2005**, 1-11
- 855 Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: an Asian/Pacific consensus. **2005**, 5, S1-S15
- 854 A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. **2005**, 142, 95-104 178
- 853 The predictive value of lipid markers in vascular disease. **2005**, 11, 2209-24 8
- 852 Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels. **2005**, 25, 436-41 74
- 851 Apolipoprotein L-I is positively associated with hyperglycemia and plasma triglycerides in CAD patients with low HDL. **2005**, 46, 469-74 23
- 850 Contradicted and initially stronger effects in highly cited clinical research. **2005**, 294, 218-28 890
- 849 Anticipating the evolution of clinical cholesterol guidelines: implications of recent statin intervention trials. **2005**, 1, 461-71
- 848 Beyond statin therapy: why we need new thinking. **2005**, 21 Suppl 6, S3-8 6
- 847 Managing abnormal blood lipids: a collaborative approach. **2005**, 112, 3184-209 164
- 846 Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. **2005**, 21, 665-82 89
- 845 The potential role of HDL- and LDL-cholesterol modulation in atheromatous plaque development. **2005**, 21 Suppl 6, S17-22 12
- 844 The realities of dyslipidaemia: what do the studies tell us?. **2005**, 7, F27-F33 8

843	Maximizing coronary disease risk reduction using nicotinic acid combined with LDL-lowering therapy. <b>2005</b> , 7, F34-F40	15
842	Beyond LDL-cholesterol reduction: the way ahead in managing dyslipidaemia. <b>2005</b> , 7, F56-F62	9
841	Historia natural de la arteriosclerosis. Expresividad cl?nica. Complicaciones agudas y cr?nicas. <b>2005</b> , 9, 2525-2535	
840	¿Son necesarios los estudios angiogr?ficos para valorar la eficacia terap?utica del tratamiento hipolipemiante?. <b>2005</b> , 17, 7-15	0
839	The inflammation: lipoprotein cycle. <b>2005</b> , 6, 15-20	40
838	What is the most effective strategy for managing diabetic dyslipidaemia?. <b>2005</b> , 6, 21-7	7
837	Effects of exercise and diet on chronic disease. <b>2005</b> , 98, 3-30	351
836	Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?. <b>2005</b> , 21, 299-306	18
835	Global cardiovascular risk : the role of plasma lipids. <b>2005</b> , 12, 125-33	
834	Regimen to increase HDL cholesterol levels may improve cholesterol profiles. Commentary 2. <b>2005</b> , 9, 106-7, 109-11	
833	Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. <b>2005</b> , 149, 473	110
832	Diabetes and progression of coronary calcium under the influence of statin therapy. <b>2005</b> , 149, 695-700	64
831	[Selective cholesterol absorption inhibition as a new prospect in treatment of hypercholesterolemia]. <b>2005</b> , 125, 16-23	3
830	Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. <b>2005</b> , 65, 2719-40	73
829	Clinical Outcomes Associated with Pharmacist Involvement in Patients with Dyslipidemia. <b>2005</b> , 13, 31-42	8
828	Antioxidants and Cardiovascular Disease. <b>2006</b> ,	3
827	Colesevelam hydrochloride in the management of dyslipidemia. <i>Expert Review of Cardiovascular Therapy</i> , <b>2006</b> , 4, 283-91	2.5 15
826	Communicating treatment effectiveness in the context of chronic disease processes. <b>2006</b> , 6, 673-9	6

- 825 Lipoproteínas clásicas, terapéuticas modernas. Farmacología de las lipoproteínas de alta densidad. **2006**, 18, 10-19
- 824 Controversia terapéutica: clopidogrel y estatinas. **2006**, 18, 34-48
- 823 Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. **2006**, 185, 327-30 38
- 822 Paradoxical increase in lumen size during progression of coronary atherosclerosis: observations from the REVERSAL trial. **2006**, 189, 229-35 30
- 821 A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease. **2006**, 7, 21-9 4
- 820 Elevated lipoprotein(a)—a genetic risk factor for premature vascular disease in people with and without standard risk factors: a review. **2006**, 52, 5-50 49
- 819 Control of risk factors in atherosclerosis. POSCH Report. **1995**, 748, 342-55; discussion 355-6
- 818 Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease. Observations from the FATS Trial. Familial Atherosclerosis Treatment Study. **1995**, 748, 407-17; discussion 417-8 39
- 817 Plasmapheresis for prevention and regression of coronary atherosclerosis. **1995**, 748, 429-39; discussion 439-40 9
- 816 Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. **2006**, 47, 992-7 136
- 815 Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials. **2006**, 152, 1059-63 34
- 814 [Treatment of dyslipidemia: how and when to combine lipid lowering drugs]. **2006**, 50, 344-59 8
- 813 Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs. **2006**, 12, 745-51 27
- 812 Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. **2006**, 99, 257-73 212
- 811 Vascular imaging and the clinical development of new pharmaceuticals. 418-429
- 810 . **2006**, 1
- 809 PET Assessment of Myocardial Perfusion. 83-98
- 808 Therapeutic modalities following low-density lipoprotein cholesterol goal attainment. **2006**, 1, 131-133

807	Achieving the therapeutic benefits of Niaspan <sup>®</sup> in daily practice. <b>2006</b> , 8, F68-F73		3
806	Diabetic dyslipidaemia: the triad. <b>2006</b> , 8, F30-F33		1
805	High-density lipoprotein cholesterol-raising strategies. <b>2006</b> , 47, 196-204		11
804	Effect of niacin on lipoproteins and atherosclerosis. <b>2006</b> , 1, 549-557		18
803	Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. <b>2006</b> , 17, 631-6		117
802	Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment. <b>2006</b> , 60, 707-15		39
801	Management of lipid abnormalities associated with end-stage renal disease. <b>2006</b> , 19, 391-401		1
800	Number-needed-to-treat (NNT)--needs treatment with care. <b>2006</b> , 99, 12-6		38
799	Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. <b>2006</b> , 259, 247-58		351
798	Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy. <b>2006</b> , 259, 401-9		12
797	Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease. <b>2006</b> , 259, 473-80		30
796	Effect of ascorbic acid on prevention of hypercholesterolemia induced atherosclerosis. <b>2006</b> , 285, 143-7		9
795	Statins and the primary prevention of cardiovascular events. <i>Current Atherosclerosis Reports</i> , <b>2006</b> , 8, 390-6	6	20
794	Is the metabolic syndrome a real clinical entity and should it receive drug treatment?. <b>2006</b> , 6, 357-64		6
793	Effects of colesvelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. <b>2006</b> , 97, 1198-205		93
792	Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. <b>2006</b> , 98, 39i-49i		140
791	Effect of atherosclerotic regression on total luminal size of coronary arteries as determined by intravascular ultrasound. <b>2006</b> , 98, 23-7		23
790	Plaque stabilization: Can we turn theory into evidence?. <b>2006</b> , 98, 26P-33P		48

789	Niaspan <sup>®</sup> in the management of dyslipidaemia: the evidence. <b>2006</b> , 8, F60-F67	9
788	Management of perioperative myocardial infarction in noncardiac surgical patients. <b>2006</b> , 130, 584-96	47
787	Reducing risk by raising HDL-cholesterol: the evidence. <b>2006</b> , 8, F23-F29	11
786	Statins in the treatment of chronic heart failure: a systematic review. <b>2006</b> , 3, e333	39
785	Essential Physical Medicine and Rehabilitation. <b>2006</b> ,	4
784	Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin. <b>2006</b> , 40, 1274-9	21
783	NAUTILUS (Safety and tolerability of Niaspan <sup>®</sup> ): a subgroup analysis in patients with diabetes. <b>2006</b> , 6, 127-133	2
782	Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. <b>2006</b> , 295, 1556-65	1375
781	Swine models of type 2 diabetes mellitus: insulin resistance, glucose tolerance, and cardiovascular complications. <b>2006</b> , 47, 243-58	121
780	A COMPARISON OF PATIENT STATE INDEX, BISPECTRAL INDEX, AND MODIFIED RAMSAY SEDATION SCORES IN MECHANICALLY VENTILATED CRITICALLY ILL PATIENTS. <b>2006</b> , 130, 203S	10
779	Biochemistry of Atherosclerosis. <b>2006</b> ,	
778	The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). <b>2006</b> , 114, 2850-70	286
777	Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study. <b>2006</b> , 22, 417-25	51
776	The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. <b>2006</b> , 22, 2243-50	267
775	Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?. <b>2007</b> , 8, 2267-77	9
774	Pleiotropic effects of statins: stabilization of the vulnerable atherosclerotic plaque?. <b>2007</b> , 13, 1003-12	27
773	Tracking coronary calcification and atherosclerotic lesions in patients with stable angina pectoris undergoing nifedipine therapy. <b>2007</b> , 107, 165-71	7
772	High-density lipoprotein cholesterol: an emerging target for stroke treatment. <b>2007</b> , 38, 1104-9	43

771	Present-day uses of niacin: effects on lipid and non-lipid parameters. <b>2007</b> , 8, 1711-7	14
770	Biomarkers in the prevention and treatment of atherosclerosis: need, validation, and future. <b>2007</b> , 59, 40-53	53
769	Use of lipid-lowering agents for the prevention of age-related macular degeneration: a meta-analysis of observational studies. <b>2007</b> , 14, 367-74	27
768	New technology for noninvasive evaluation of coronary artery disease. <b>2007</b> , 115, 1464-80	240
767	Rational therapy of mixed dyslipidaemia in a patient with diabetes. <b>2007</b> , 7, 25-30	0
766	The unique character of cardiovascular disease in chronic kidney disease and its implications for treatment with lipid-lowering drugs. <b>2007</b> , 2, 766-85	25
765	High-density lipoprotein as a therapeutic target: a systematic review. <b>2007</b> , 298, 786-98	341
764	The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease. <b>2007</b> , 4, 136-42	33
763	Changing health behaviors to improve health outcomes after angioplasty: a randomized trial of net present value versus future value risk communication. <b>2008</b> , 23, 826-39	13
762	HDL and Atherosclerosis. 491-505	1
761	Differing effects of water-soluble and fat-soluble extracts from Japanese radish ( <i>Raphanus sativus</i> ) sprouts on carbohydrate and lipid metabolism in normal and streptozotocin-induced diabetic rats. <b>2007</b> , 53, 261-6	13
760	Rationale and design for a study using intravascular ultrasound to evaluate effects of rosuvastatin on coronary artery atheroma in Japanese subjects: COSMOS study (Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects). <b>2007</b> , 71, 271-5	23
759	The 'forgotten' bile acid sequestrants: is now a good time to remember?. <b>2007</b> , 14, 567-80	75
758	Molecular mechanisms of plaque instability. <b>2007</b> , 18, 492-9	83
757	Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels. <b>2007</b> , 8, 483-8	23
756	Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. <b>2007</b> , 18, 415-20	74
755	High-density lipoprotein cholesterol: a potential therapeutic target for prevention of coronary artery disease. <b>2007</b> , 10, 26-30	4
754	Coronary heart disease events preventable by control of blood pressure and lipids in US adults with hypertension. <b>2007</b> , 9, 436-43	15

753	Statins and C-reactive protein levels. <b>2007</b> , 9, 622-8		34
752	How Can the Mortality Rate of Chronic Dialysis Patients Be Reduced?. <b>2007</b> , 6, 97-100		
751	Treatment of Hypertriglyceridemia in Dialysis Patients Is Expensive and Unproven. <b>2007</b> , 6, 200-202		
750	Extent and distribution of coronary artery disease: a comparative study of invasive versus noninvasive angiography with computed angiography. <b>2007</b> , 153, 378-84		39
749	Testing the hypothesis of atherosclerotic plaque lipid depletion during lipid therapy by magnetic resonance imaging: study design of Carotid Plaque Composition Study. <b>2007</b> , 154, 239-46		39
748	Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?. <b>2007</b> , 29, 196-209		9
747	Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. <b>2007</b> , 29, 778-794		95
746	Treatment of essential hypertension and non-insulin dependent diabetes mellitus with vitamin C. <b>2007</b> , 68, 1126-33		2
745	To statin or to non-statin in coronary disease--considering absolute risk is the answer. <b>2007</b> , 195, 1-6		32
744	Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. <b>2007</b> , 195, 339-47		84
743	Endothelial dysfunction, lipid peroxidation and cholesterol level in rabbit arteries: relationship to progressive hypercholesterolemia. <b>2007</b> , 19, 293-299		2
742	Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol. <i>Current Atherosclerosis Reports</i> , <b>2007</b> , 9, 81-8	6	9
741	The use of colestevlam hydrochloride in the treatment of dyslipidemia: a review. <b>2007</b> , 8, 2569-78		28
740	Risk of cardiovascular events in patients at optimal values for combined lipid parameters. <b>2007</b> , 23, 553-63		41
739	Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients. <b>2007</b> , 23, 1707-13		26
738	The Rationale for Intervention to Reduce the Risk of Coronary Heart Disease. <b>2007</b> , 1, 10-19		5
737	Clinical practice. Hypertriglyceridemia. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 1009-17	59.2	226
736	Bile acid sequestrants and the treatment of type 2 diabetes mellitus. <b>2007</b> , 67, 1383-92		130



735	Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review. <b>2007</b> , 27, 591-604	15
734	Thrombosis and thrombolysis: platelet membrane glycoproteins. <b>2007</b> , 16, 176-9	6
733	Premature coronary artery disease and apolipoprotein B and apolipoprotein A-I. <b>2007</b> , 1303, 85-94	
732	Atherosclerosis regression, vascular remodeling, and plaque stabilization. <b>2007</b> , 49, 271-3	31
731	Is intravascular ultrasound the gold standard surrogate for clinically relevant atherosclerosis progression?. <b>2007</b> , 49, 933-8	21
730	High-density lipoprotein associations with coronary heart disease: Does measurement of cholesterol content give the best result?. <b>2007</b> , 1, 57-64	10
729	Effect of drugs on high-density lipoprotein. <b>2007</b> , 1, 74-87	3
728	Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence. <b>2007</b> , 1, 88-94	33
727	Pilot study of combined therapy with $\omega$ 3 fatty acids and niacin in atherogenic dyslipidemia. <b>2007</b> , 1, 211-7	7
726	Revisiting niacin: reviewing the evidence. <b>2007</b> , 1, 248-55	12
725	Effects of niacin and Niaspan on HDL lipoprotein cellular SR-BI-mediated cholesterol efflux. <b>2007</b> , 1, 614-9	8
724	Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study. <b>2007</b> , 3, 467-79	14
723	[Apolipoprotein B and A-I: cardiovascular risk factor?]. <b>2007</b> , 53, 276-82	4
722	Cardiovascular rehabilitation of patients with ischemic heart disease undergoing medical treatment, percutaneous transluminal coronary angioplasty, and coronary artery bypass grafting. <b>2007</b> , 88, 72-8	1
721	Are the beneficial cardiovascular effects of simvastatin and metformin also associated with a hormone-dependent mechanism improving insulin sensitivity?. <b>2007</b> , 40, 229-235	10
720	Update in Hyperlipidemia Clinical Trials. <b>2007</b> ,	
719	. <b>2007</b> ,	6
718	In Search of a Pathogenesis. <b>2007</b> , 89-124	

717	Assessment of the carotid artery by MRI at 3T: a study on reproducibility. <b>2007</b> , 25, 1035-43	50	
716	Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. <b>2007</b> , 81, 849-57	126	
715	Changes in 24-h area-under-the-curve ghrelin values following diet-induced weight loss are associated with loss of fat-free mass, but not with changes in fat mass, insulin levels or insulin sensitivity. <b>2007</b> , 31, 385-9	20	
714	Successful weight maintenance preserves lower levels of oxidized LDL achieved by weight reduction in obese men. <b>2007</b> , 31, 245-53	24	
713	Correction of low HDL cholesterol to reduce cardiovascular risk: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan). <b>2007</b> , 61, 1914-21	7	
712	HDL cholesterol: physiology, pathophysiology, and management. <b>2007</b> , 32, 268-314	56	
711	Expert commentary: niacin safety. <b>2007</b> , 99, 32C-34C	9	
710	Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke. <b>2007</b> , 99, 1E-35E	18	
709	Use of niacin in the prevention and management of hyperlipidemia. <b>2001</b> , 16, 14-20	4	
708	Subclinical cardiovascular disease markers applicable to studies of oral health: multiethnic study of atherosclerosis. <b>2007</b> , 1098, 269-87	15	
707	[Severe progression of coronary heart disease in a patient with elevated lipoprotein (a) level in spite of optimal LDL-C decrease]. <b>2007</b> , 32, 578-82		
706	Design and rationale of the ARBITER 6 trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)-6-HDL and LDL Treatment Strategies in Atherosclerosis (HALTS). <b>2007</b> , 21, 221-5	33	
705	The importance of managing hypertension and dyslipidemia to decrease cardiovascular disease. <b>2007</b> , 21, 297-309	37	
704	Deutsche Leitlinie zur Rehabilitation von Patienten mit Herz-Kreislaufkrankungen (DLL-KardReha). <b>2007</b> , 2, 1-54	24	
703	Do statins reduce events in patients with metabolic syndrome?. <i>Current Atherosclerosis Reports</i> , <b>2008</b> , 10, 39-44	6	7
702	Pleiotropic effects: should statins be considered an essential component in the treatment of dyslipidemia?. <i>Current Atherosclerosis Reports</i> , <b>2008</b> , 10, 45-52	6	11
701	Triglycerides and risk for coronary artery disease. <i>Current Atherosclerosis Reports</i> , <b>2008</b> , 10, 386-90	6	75
700	When high is low: raising low levels of high-density lipoprotein cholesterol. <b>2008</b> , 10, 488-96		11

699	HDL-C and LDL-C: their role in stroke pathogenesis and implications for treatment. <b>2008</b> , 10, 195-206	8
698	Strategies to reverse atherosclerosis: an imaging perspective. <b>2008</b> , 10, 283-93	10
697	Tendinous disorders attributed to statins: a study on ninety-six spontaneous reports in the period 1990-2005 and review of the literature. <b>2008</b> , 59, 367-72	129
696	Mapping spatial and temporal changes in carotid atherosclerosis from three-dimensional ultrasound images. <b>2008</b> , 34, 64-72	32
695	Nicotinic acid: pharmacological effects and mechanisms of action. <b>2008</b> , 48, 79-106	211
694	Is raising HDL a futile strategy for atheroprotection?. <b>2008</b> , 7, 143-55	111
693	Treatment of homozygous familial hypercholesterolemia with low density lipoprotein apheresis: a 4 year follow-up study. <b>1997</b> , 21, 364-8	5
692	The editor's roundtable: expanded versus standard lipid panels in assessing and managing cardiovascular risk. <b>2008</b> , 101, 828-42	6
691	Evidence to support aggressive management of high-density lipoprotein cholesterol: implications of recent imaging trials. <b>2008</b> , 101, 36B-43B	7
690	Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk. <b>2008</b> , 101, 48B-57B	19
689	Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. <b>2008</b> , 101, 58B-62B	107
688	The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. <b>2008</b> , 102, 1K-34K	280
687	[Use of prolonged-release nicotinic acid in patients treated with statins as a secondary prevention and a persistently low HDL-cholesterol level in France]. <b>2008</b> , 57, 121-6	
686	ApoA-I(Milano)/phospholipid complex: clinical implications of dose-response studies in rabbit atherosclerosis with intravascular ultrasound and magnetic resonance imaging. <b>2008</b> , 51, 1110-1	5
685	Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. <b>2008</b> , 51, 1512-24	387
684	Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. <b>2008</b> , 51, 1564-72	75
683	The effects of medications on myocardial perfusion. <b>2008</b> , 52, 401-16	70
682	Point: Statins, plant sterol absorption, and increased coronary risk. <b>2008</b> , 2, 304-5	5

681	Angiographic and pathological studies on regression of coronary atherosclerosis of FH patients who received LDL-apheresis treatment. <b>1992</b> , 16, 171-6		8
680	Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. <b>2008</b> , 26, 547-60		26
679	Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. <b>2008</b> , 24, 995-1009		36
678	A cerebrovascular perspective of atherosclerosis. <b>2009</b> , 92, 215-38		0
677	Investigation and management of hypertriglyceridaemia. <b>2008</b> , 61, 1174-83		20
676	Lipid management to reduce cardiovascular risk: a new strategy is required. <b>2008</b> , 117, 560-8; discussion 568		79
675	Promise of low-density lipoprotein-lowering therapy for primary and secondary prevention. <b>2008</b> , 117, 569-73; discussion 573		34
674	Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. <b>2008</b> , 117, 2458-66		148
673	Advances in the management of hyperlipidemia-induced atherosclerosis. <i>Expert Review of Cardiovascular Therapy</i> , <b>2008</b> , 6, 369-83	2.5	16
672	Niacin: a lipid polypill?. <b>2008</b> , 9, 2911-20		6
671	Colesevelam hydrochloride: a specifically engineered bile acid sequestrant. <b>2008</b> , 3, 237-255		13
670	Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. <b>2008</b> , 31, 811-22		439
669	Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. <b>2008</b> , 28, 1672-8		125
668	Estimation of LDL-associated apolipoprotein B from measurements of triglycerides and total apolipoprotein B. <b>2008</b> , 54, 907-10		6
667	Pathophysiology of Myocardial Infarction. <b>2008</b> , 15-28		
666	The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. <b>2008</b> , 5, 319-35		192
665	Metabolomic strategies to identify tissue-specific effects of cardiovascular drugs. <b>2008</b> , 4, 665-80		12
664	Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders. <i>Expert Review of Cardiovascular Therapy</i> , <b>2008</b> , 6, 1303-10	2.5	3

663	Current and emerging paradigms in the therapeutic management of atherosclerosis. <b>2008</b> , 12, 1523-46	1
662	Simvastatin with or without ezetimibe in familial hypercholesterolemia. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 529; author reply 532	59.2 4
661	Smoking and low serum testosterone associates with high concentration of oxidized LDL. <b>2008</b> , 40, 634-40	16
660	Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. <b>2008</b> , 94, 706-14	84
659	Use of extended-release niacin in clinical practice. <b>2008</b> , 3, 9-16	1
658	Beyond cholesterol lowering: pleiotropic effects of bile acid binding resins against cardiovascular disease risk factors in patients with metabolic syndrome. <b>2008</b> , 6, 271-81	13
657	Fibrate therapy: an update. <b>2008</b> , 16, 129-41	65
656	Endothelial function in the time of the giants. <b>2008</b> , 52, 385-92	8
655	Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes. <b>2008</b> , 51, 331-51	31
654	Coronary Drug Project. <b>2008</b> , 1	
653	Antiatherogenic functionality of high density lipoprotein: how much versus how good. <b>2008</b> , 15, 52-62	92
652	Optimal treatment of chronic constipation in managed care: review and roundtable discussion. <b>2008</b> , 14, 1-15	33
651	Obstructive Sleep Apnea and Cardiovascular Disease: Role of the Metabolic Syndrome and Its Components. <b>2008</b> , 04, 261-272	124
650	Nicotinic Acid. <b>2009</b> , 298-314	4
649	Lipid-Modifying and Antiatherosclerotic Drugs. <b>2009</b> , 341-372	2
648	Combination Therapy for Dyslipidemia. <b>2009</b> , 352-362	1
647	Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. <b>2009</b> , 32 Suppl 2, S237-45	211
646	Statins for asymptomatic middle cerebral artery stenosis: The Regression of Cerebral Artery Stenosis study. <b>2009</b> , 28, 18-25	25

645	The HALTS trial--halting atherosclerosis or halted too early?. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 2178-80	59.2	27
644	Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. <b>2009</b> , 16, 404-23		42
643	High-density lipoprotein cholesterol: current perspective for clinicians. <b>2009</b> , 60, 644-9		2
642	Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. <b>2009</b> , 338, b92		331
641	Lipid-lowering drugs acting at the level of the gastrointestinal tract. <b>2009</b> , 15, 490-516		41
640	Advanced lipoprotein testing and subfractionation are clinically useful. <b>2009</b> , 119, 2383-95		53
639	Adding exercise training to rosuvastatin treatment: influence on serum lipids and biomarkers of muscle and liver damage. <b>2009</b> , 58, 1030-8		28
638	Nonpharmacologic treatment of dyslipidemia. <b>2009</b> , 52, 61-94		45
637	The role of nutrition in the functioning of the cardiovascular system. <b>1992</b> , 50, 402-6		13
636	New recommendations for the diagnosis and treatment of plasma lipid abnormalities. <b>1993</b> , 51, 246-53		9
635	Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS). <b>2009</b> , 104, 1457-64		40
634	Effects of statins on the progression of cerebral white matter lesion: Post hoc analysis of the ROCAS (Regression of Cerebral Artery Stenosis) study. <b>2009</b> , 256, 750-7		72
633	Inflammation and plaque vulnerability. <b>2009</b> , 23, 31-40		90
632	Management of the statin-intolerant patient. <b>2009</b> , 11, 263-71		8
631	Clinical trials report. <i>Current Atherosclerosis Reports</i> , <b>2009</b> , 11, 3-8	6	1
630	Nicotinic acid: a new look at an old drug. <i>Current Atherosclerosis Reports</i> , <b>2009</b> , 11, 87-92	6	15
629	Treatment of chronic CAD--do the guidelines (ESC, AHA) reflect daily practice?. <b>2009</b> , 34, 39-54		3
628	Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome. <b>2009</b> , 63, 56-62		63

627	Does nicotinic acid (niacin) lower blood pressure?. <b>2009</b> , 63, 151-9	22
626	A program in contemplative self-healing: stress, allostasis, and learning in the Indo-Tibetan tradition. <b>2009</b> , 1172, 123-47	17
625	Apolipoprotein measurements: is more widespread use clinically indicated?. <b>2009</b> , 32, 482-6	63
624	Fluvastatin titrate-to-goal clinical practice study: Interim results. <b>2009</b> , 17, IV-16-IV-20	
623	A new statin: a new standard. <b>2001</b> , 24, III18-23	3
622	[Drug-associated tendon disorders: after fluoroquinolones ... here are statins!]. <b>2009</b> , 30, 307-10	13
621	Food insecurity and dyslipidemia among adults in the United States. <b>2009</b> , 48, 480-5	44
620	[HDL-cholesterol: from risk factor to therapeutic target]. <b>2009</b> , 133, 229-34	1
619	Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. <b>2009</b> , 53, 316-22	280
618	The SLIM Study: Slo-Niacin <sup>®</sup> and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia. <b>2009</b> , 3, 167-178	16
617	Atherosclerosis in a managed care plan: hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring. <b>2009</b> , 3, 385-92	2
616	Cost-Effectiveness Analysis of a Genetic Screening Program in the Close Relatives of Spanish Patients With Familial Hypercholesterolemia. <b>2009</b> , 62, 57-65	2
615	Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. <b>2009</b> , 38, 79-97	73
614	Extended-release niacin or ezetimibe and carotid intima-media thickness. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 2113-22	59.2 534
613	A comparison of the pharmacokinetics of two different formulations of extended-release niacin. <b>2009</b> , 25, 15-22	6
612	. <b>2009</b> ,	1
611	Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms. <b>2009</b> , 49, 416-22	16
610	Endothelium function, lipid peroxidation, plasmatic and tissue cholesterol evaluations in mixed dyslipidemia in rabbits treated with rosuvastatin and atorvastatin. <b>2009</b> , 21, 263-267	1

609	Análisis coste-efectividad de un programa de cribado genético en familiares directos de pacientes con hipercolesterolemia familiar en España. <b>2009</b> , 62, 57-65	25
608	A review of lipid management in primary and secondary prevention. <b>2009</b> , 29, 2-12	41
607	Computed tomography coronary angiography plaque burden in patients with suspected coronary artery disease. <b>2009</b> , 10, 913-20	1
606	Colesevelam hydrochloride: a bile acid sequestrant for glycemic control and treatment of dyslipidemia in Type 2 diabetes mellitus. <b>2009</b> , 6, 475-487	1
605	14. Dyslipidemia and Coronary Disease. <b>2009</b> , 98, 2355-2364	
604	On the road to better dyslipidemia outcomes. <b>2009</b> , 34, 14-21; quiz 22	
603	Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). <b>2009</b> , 73, 2110-7	158
602	Psyllium. <b>2009</b> ,	
601	Drug combinations for dyslipidemia and obesity treatment in metabolic syndrome. <b>2009</b> , 15, 3446-62	5
600	Effects of niacin on LDL particle number. <b>2009</b> , 4, 565-571	2
599	Triglycerides and vascular risk: insights from epidemiological data and interventional studies. <b>2009</b> , 10, 320-7	23
598	Combination regimens with statin, niacin, and intestinally active LDL-lowering drugs: alternatives to high-dose statin therapy?. <b>2010</b> , 21, 372-7	6
597	Targeting dyslipidemia in the metabolic syndrome: an update. <b>2010</b> , 8, 450-63	4
596	Therapy and clinical trials: HDL-cholesterol and niacin therapy--past, present, and future. <b>2010</b> , 21, 165-6	3
595	Exchanging Carbohydrate or Protein for Fat Improves Lipid-Related Cardiovascular Risk Profile in Overweight Men and Women When Consumed Ad Libitum. <b>2010</b> , 58, 711-719	3
594	Changes in hepatic gene expression associated with the hypocholesterolaemic activity of royal jelly. <b>2006</b> , 58, 1683-9	26
593	New evidence for nicotinic acid treatment to reduce atherosclerosis. <i>Expert Review of Cardiovascular Therapy</i> , <b>2010</b> , 8, 1457-67	2.5 12
592	Linkage and association analyses identify a candidate region for apoB level on chromosome 4q32.3 in FCHL families. <b>2010</b> , 127, 705-19	11



591	Systematic review on evidence of the effectiveness of cholesterol-lowering drugs. <b>2010</b> , 27, 348-64	18
590	High-density lipoprotein therapy: is there hope?. <b>2010</b> , 12, 315-28	8
589	Die Bedeutung von körperlicher Aktivität und körperlichem Training in der Prävention der koronaren Herzkrankheit. <b>2010</b> , 5, 165-179	
588	Effect of extended-release niacin or ezetimibe on carotid intimal thickness: the ARBITER-HALTS Study. <i>Current Atherosclerosis Reports</i> , <b>2010</b> , 12, 285-7	6 2
587	Atherosclerotic plaque regression: fact or fiction?. <b>2010</b> , 24, 311-7	15
586	Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. <b>2010</b> , 126, 314-45	161
585	Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. <b>2010</b> , 105, 487-94	22
584	Combined therapy in the treatment of dyslipidemia. <b>2010</b> , 24, 19-28	70
583	The Bile Acid Sequestrant Acceptability scale validation study. <b>2010</b> , 64, 1393-7	2
582	Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. <b>2010</b> , 12, 983-93	13
581	Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia. <b>2010</b> , 6, 183-90	6
580	Efficacy and Safety of Fluvastatin Sodium XL 80mg in Treatment of Hypercholesterolemic Patient with Risk Factor of Cardiovascular Disease. <b>2010</b> , 2, 147-155	
579	Low high-density lipoprotein cholesterol: current status and future strategies for management. <b>2010</b> , 6, 979-96	20
578	Lipoprotein(a) as a cardiovascular risk factor: current status. <b>2010</b> , 31, 2844-53	1100
577	Effects of statins on progression of subclinical brain infarct. <b>2010</b> , 30, 51-6	23
576	Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?. <b>2010</b> , 5, 811-826	20
575	High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease. <b>2010</b> ,	5
574	Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy. <b>2010</b> , 26, 365-75	11

573	Cardiovascular disease risk reduction with sleep apnea treatment. <i>Expert Review of Cardiovascular Therapy</i> , <b>2010</b> , 8, 995-1005	2.5	23
572	Influence of soy lecithin administration on hypercholesterolemia. <b>2010</b> , 2010, 824813		11
571	High-density lipoprotein cholesterol increase and non-cardiovascular mortality: a meta-analysis. <b>2010</b> , 96, 1345-51		13
570	Niacin: from mechanisms of action to therapeutic uses. <b>2010</b> , 10, 204-17		31
569	Atherosclerosis regression and high-density lipoproteins. <i>Expert Review of Cardiovascular Therapy</i> , <b>2010</b> , 8, 1325-34	2.5	11
568	Raising highly desirable lipoprotein versus lowering deleterious lipoprotein. <b>2010</b> , 3, 173-6		
567	High density lipoproteins-based therapies for cardiovascular disease. <b>2010</b> , 1, 99-103		9
566	A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. <b>2010</b> , 85, 365-79		35
565	High-density lipoprotein and coronary heart disease: current and future therapies. <b>2010</b> , 55, 1283-99		155
564	Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. <b>2010</b> , 55, 2399-407		327
563	Insights from recent meta-analysis: role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression. <b>2010</b> , 4, 365-70		14
562	Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs. <b>2010</b> , 70, 1363-79		38
561	[Global therapy of diabetic dyslipidemia: benefits and new therapeutic approaches]. <b>2010</b> , 134, 406-11		5
560	[Residual vascular risk: recommendations of the Spanish Initiative for the Reduction of Residual Risk]. <b>2010</b> , 135, 165-71		5
559	Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events. <b>2010</b> , 123, 892-8		30
558	Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. <b>2010</b> , 210, 353-61		222
557	Cholesterol diet and effect of long-term withdrawal on plaque development and composition in the thoracic aorta of New Zealand White rabbits. <b>2010</b> , 210, 407-13		14
556	[Importance of HDL cholesterol in atherothrombosis: how did we get here? Where are we going?]. <b>2010</b> , 63 Suppl 2, 20-35		18

555	Familial combined hyperlipidemia: an oligogenic disorder. <b>2010</b> , 22, 25-26	
554	Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer. <b>2010</b> , 6, 1897-913	12
553	The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. <b>2010</b> , 55, 2721-6	174
552	Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease. <b>2010</b> , 15, 158-66	49
551	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. <b>2011</b> , 32, 1345-61	793
550	Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease. <b>2011</b> , 29, 87-103	31
549	Search and Rescue for Hypotheses Surviving AIM-HIGH, the Niacin Therapy Earthquake. <b>2011</b> ,	
548	Opening a new lipid "apo-theary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk. <b>2011</b> , 86, 762-80	25
547	Comprehensive Cardiovascular Medicine in the Primary Care Setting. <b>2011</b> ,	
546	Pharmacogenomic Testing in Current Clinical Practice. <b>2011</b> ,	1
545	Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome. <b>2011</b> ,	6
544	Mipomersen, an antisense apolipoprotein B synthesis inhibitor. <b>2011</b> , 20, 265-72	48
543	Riesgo residual vascular de origen lipídico. Estrategias para el tratamiento del riesgo residual por dislipidemia aterogénica. <b>2011</b> , 23, 230-239	
542	The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes	95
541	Statins moderate coronary stenoses but not coronary calcification: results from meta-analyses. <b>2011</b> , 153, 31-5	40
540	[ESC/EAS Guidelines for the management of dyslipidaemias]. <b>2011</b> , 64, 1168.e1-1168.e60	37
539	ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <b>2011</b> , 32, 1769-818	2020
538	Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. <b>2011</b> , 104, 109-24	222

537	Treating statin-intolerant patients. <b>2011</b> , 4, 155-66	51
536	Anacetrapib: hope for CETP inhibitors?. <b>2011</b> , 29, 327-39	10
535	ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <b>2011</b> , 217 Suppl 1, S1-44	152
534	ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <b>2011</b> , 217, 3-46	459
533	Tratamiento de la hipercolesterolemia y prevención de las enfermedades cardiovasculares mediante la inhibición de la reabsorción de ácidos biliares con resincolestiramina. <b>2011</b> , 23, 9-16	1
532	Mechanism of Action of Niacin: Implications for Atherosclerosis and Drug Discovery. <b>2011</b> , 235-251	
531	. <b>2011</b> ,	1
530	Colesevelam hydrochloride powder for oral suspension versus cholestyramine powder for oral suspension: comparison of acceptability and tolerability. <b>2011</b> , 17, 218-25	5
529	Residual Vascular Risk in T2DM: The Next Frontier. <b>2011</b> ,	
528	Stabilisation of atherosclerotic plaques. Position paper of the European Society of Cardiology (ESC) Working Group on atherosclerosis and vascular biology. <b>2011</b> , 106, 1-19	110
527	Effects of niacin on atherosclerosis and vascular function. <b>2011</b> , 26, 66-70	24
526	Impact of low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio on long-term outcome in patients undergoing percutaneous coronary intervention. <b>2011</b> , 75, 905-10	25
525	'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia. <b>2011</b> , 65, 82-101	14
524	Effects of statins on progression of coronary artery disease as measured by intravascular ultrasound. <b>2011</b> , 13, 492-6	23
523	The epidemiological concept of residual risk. <b>2011</b> , 6 Suppl 1, 45-51	21
522	Residual cardiovascular risk in secondary prevention. <b>2011</b> , 6 Suppl 1, 61-8	5
521	Statins in combinations: from ARBITER-6 HALTS to ACCORD--what works?. <i>Current Atherosclerosis Reports</i> , <b>2011</b> , 13, 4-8	6
520	What combination therapy with a statin, if any, would you recommend?. <i>Current Atherosclerosis Reports</i> , <b>2011</b> , 13, 12-22	6 15

519	The beneficial effects of HDL-C on atherosclerosis: rationale and clinical results. <b>2011</b> , 6, 181-208	7
518	Important considerations for treatment with dietary supplement versus prescription niacin products. <b>2011</b> , 123, 70-83	11
517	Atherosclerosis: current status of prevention and treatment. <b>2011</b> , 20, 213-22	18
516	Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians. <b>2011</b> , 2, 307-23	14
515	Triglycerides and heart disease: still a hypothesis?. <b>2011</b> , 31, 1716-25	145
514	The facts behind niacin. <b>2011</b> , 5, 227-40	16
513	Atlas of Atherosclerosis and Metabolic Syndrome. <b>2011</b> ,	5
512	Medical angioplasty - hope and expectations: an optimistic overview. <b>2011</b> , 18, 101-10	
511	Bile acid sequestrants: more than simple resins. <b>2012</b> , 23, 43-55	60
510	Niacin-a critical component to the management of atherosclerosis: contemporary management of dyslipidemia to prevent, reduce, or reverse atherosclerotic cardiovascular disease. <b>2012</b> , 27, 303-16	1
509	Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. <b>2012</b> , 10, 260-6	10
508	Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cells. <b>2012</b> , 53, 941-950	35
507	Laboratory approaches for predicting and managing the risk of cardiovascular disease: postanalytical opportunities of lipid and lipoprotein testing. <b>2012</b> , 50, 1169-81	10
506	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <b>2012</b> , 123, 1354-471	537
505	Safety and tolerability of extended-release niacin with laropiprant. <b>2012</b> , 11, 151-9	5
504	Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis. <b>2012</b> , 2012, 430-432	
503	Vitamines hydrosolubles (I). Thiamine, riboflavine, niacine, acide pantothhique, vitamine B6 et biotine. <b>2012</b> , 9, 1-27	1
502	Attainment of combined optimal lipid values with the use of niacin: has AIM-HIGH closed the book on this debate?. <b>2012</b> , 7, 389-396	

501	Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. <b>2012</b> , 2012, 426-430	
500	Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. <b>2012</b> , 2012, 79-84	
499	Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients. <b>2012</b> , 76, 712-20	20
498	Virtual histology findings and effects of varying doses of atorvastatin on coronary plaque volume and composition in statin-naïve patients: the VENUS study. <b>2012</b> , 76, 2662-72	18
497	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <b>2012</b> , 60, e44-e164	1138
496	Lipid-lowering drugs and circulating adiponectin. <b>2012</b> , 90, 341-74	8
495	A multicenter study of nutraceutical drinks for cholesterol (evaluating effectiveness and tolerability). <b>2012</b> , 6, 150-8	15
494	Search and rescue for hypotheses surviving AIM-HIGH, the niacin therapy earthquake: still problematic after the primary publication. <b>2012</b> , 6, 312-7	8
493	Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels. <b>2012</b> , 6, 434-42	20
492	Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence. <b>2012</b> , 6, 413-26	68
491	Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety. <b>2012</b> , 13, 1345-62	24
490	American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. <b>2012</b> , 18 Suppl 1, 1-78	312
489	Niacin: another look at an underutilized lipid-lowering medication. <b>2012</b> , 8, 517-28	33
488	G protein-coupled receptors for energy metabolites as new therapeutic targets. <b>2012</b> , 11, 603-19	160
487	Documento Abordaje de la dislipidemia. Sociedad Española de Arteriosclerosis (parte II). <b>2012</b> , 24, 40-52	3
486	Niacin inhibits skin dendritic cell mobilization in a GPR109A independent manner but has no impact on monocyte trafficking in atherosclerosis. <b>2012</b> , 217, 548-57	8
485	The effect of hepatic lipase on coronary artery disease in humans is influenced by the underlying lipoprotein phenotype. <b>2012</b> , 1821, 365-72	42
484	Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials. <b>2012</b> , 59, 2058-64	54

483	Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. <b>2012</b> , 110, 1468-76		86
482	The role of statins in stroke. <b>2012</b> , 7, 305-11		4
481	Drugs targeting high-density lipoprotein cholesterol for coronary artery disease management. <b>2012</b> , 28, 667-77		4
480	Lipids as New Targets. <b>2012</b> , 279-308		
479	Ezetimibe therapy: mechanism of action and clinical update. <b>2012</b> , 8, 415-27		122
478	Atherosclerosis: from biology to pharmacological treatment. <b>2012</b> , 9, 305-17		36
477	Effects of simvastatin on the expression of heme oxygenase-1 in human RPE cells. <b>2012</b> , 53, 6456-64		15
476	Validity and variability in visual assessment of stenosis severity in phantom bifurcation lesions: a survey in experts during the fifth meeting of the European Bifurcation Club. <b>2012</b> , 79, 361-8		29
475	Niacin in cardiovascular disease: recent preclinical and clinical developments. <b>2012</b> , 32, 582-8		39
474	Intracoronary IVUS for Evaluation of Atherosclerosis Progression. <b>2012</b> , 5, 239-248		
473	Niacin: the evidence, clinical use, and future directions. <i>Current Atherosclerosis Reports</i> , <b>2012</b> , 14, 49-59	6	27
472	Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. <i>Current Atherosclerosis Reports</i> , <b>2012</b> , 14, 1-10	6	215
471	When clinical trials fail to address treatment gaps: the failure of niacin-laropiprant to reduce cardiovascular events. <i>Current Atherosclerosis Reports</i> , <b>2013</b> , 15, 332	6	4
470	High-density lipoproteins: a consensus statement from the National Lipid Association. <b>2013</b> , 7, 484-525		215
469	Rebuttal: Why statins have failed to reduce mortality in just about anybody. <b>2013</b> , 7, 228		
468	Counterpoint: statins do reduce fatal events. <b>2013</b> , 7, 225-7; discussion 228		
467	Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. <b>2013</b> , 14, 93-9		86
466	Evolution and involution of atherosclerosis and its relationship with vascular reactivity in hypercholesterolemic rabbits. <b>2013</b> , 65, 297-304		10

465	Cardiovascular risk and lipid management beyond statin therapy: the potential role of omega-3 polyunsaturated fatty acid ethyl esters. <b>2013</b> , 8, 329-344	2
464	Coronary anatomy to predict physiology: fundamental limits. <b>2013</b> , 6, 817-32	63
463	Lipoprotein(a), cardiovascular disease, and contemporary management. <b>2013</b> , 88, 1294-311	74
462	Recomendações da ESC/EAS para a abordagem clínica das dislipidemias. <b>2013</b> , 32, 81.e1-81.e50	
461	Through the looking-glass of conventional meta-regression: an alternative approach based on fractional polynomials to a meta-analysis of niacin. <b>2013</b> , 23, e23-5	
460	Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (. <b>2013</b> , 111, 352-5	18
459	The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. <b>2013</b> , 61, 440-446	142
458	Relationship between low-density lipoprotein levels on admission and 1-year outcome in patients with acute ST-segment-elevation myocardial infarction. <b>2013</b> , 29, 206-13	4
457	HDL cholesterol and cardiovascular outcomes: what is the evidence?. <b>2013</b> , 15, 349	13
456	[Statin-related inflammatory myopathy]. <b>2013</b> , 34, 333-6	1
455	High-density lipoprotein cholesterol raising: does it matter?. <b>2013</b> , 28, 464-74	17
454	Drugs for Elevated Low-Density Lipoprotein Cholesterol. <b>2013</b> , 421-433	
453	Therapy to Manage Low High-Density Lipoprotein Cholesterol and Elevated Triglycerides. <b>2013</b> , 434-441	
452	Steps Beyond Diet and Drug Therapy for Severe Hypercholesterolemia. <b>2013</b> , 454-462	
451	Niacin, an old drug with a new twist. <b>2013</b> , 54, 2586-94	34
450	Niacin: a long history, but a questionable future. <b>2013</b> , 24, 475-9	21
449	Lipid Lowering Therapy with Combination of Niacin and Statin in Women: Age-Related Endothelial Effects. <b>2013</b> , 2013, 1-7	
448	The role of simvastatin in the therapeutic approach of rheumatoid arthritis. <b>2013</b> , 2013, 326258	20



447	The effect of pioglitazone and extended-release niacin on HDL-cholesterol in diabetes patients in a real-world setting. <b>2013</b> , 67, 1151-8		1
446	Inhibition of neointima formation through DNA vaccination for apolipoprotein(a): a new therapeutic strategy for lipoprotein(a). <b>2013</b> , 3, 1600		5
445	Treatment B) drug therapy: executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version. <b>2013</b> , 20, 850-60		13
444	Facts and principles learned at the 39th Annual Williamsburg Conference on Heart Disease. <b>2013</b> , 26, 124-36		1
443	Hypertriglyceridemia. <b>2013</b> , 5, 981-1001		85
442	Coronary Drug Project. <b>2013</b> , 1		
441	The Effect of Simvastatin on the Expression of Catalase in Human Retinal Pigment Epithelial Cells. <b>2014</b> , 55, 1535		
440	Coronary Drug Project. <b>2014</b> , 273-284		
439	Therapeutic vaccines for hypertension and dyslipidemia. <b>2014</b> , 55, 96-100		14
438	Coronary Drug Project. <b>2014</b> ,		
437	Are add-on agents to statin therapy necessary in hypercholesterolemia?. <b>2014</b> , 9, 695-707		
436	Consensus statement on management of dyslipidemia in Indian subjects. <b>2014</b> , 66 Suppl 3, S1-51		35
435	Intermediate end point cardiovascular clinical trials: an excellent idea based on an obsolete paradigm. <i>Expert Review of Cardiovascular Therapy</i> , <b>2014</b> , 12, 161-5	2.5	1
434	Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus. <b>2014</b> , 34, 427-32		23
433	Cardiovascular disease risk factors in youth with diabetes mellitus: a scientific statement from the American Heart Association. <b>2014</b> , 130, 1532-58		118
432	A controversial step forward: A commentary on the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. <b>2014</b> , 25, 360-3		8
431	Imaging Coronary Atherosclerosis. <b>2014</b> ,		
430	Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound. <b>2014</b> , 14, 60		26

429	Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease. <b>2014</b> , 113, 1494-8		20
428	Dramatic lowering of very high Lp(a) in response to niacin. <b>2014</b> , 8, 448-50		7
427	Treatment of cholesterol in the elderly: statins and beyond. <i>Current Atherosclerosis Reports</i> , <b>2014</b> , 16, 385	6	7
426	Niacin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients. <b>2014</b> , 399-413		
425	Cholesterol Absorption Inhibitors (Ezetimibe) and Bile Acid Binding Resins (Colesevelam HCl) as Therapy for Dyslipidemia in Patients with Diabetes Mellitus. <b>2014</b> , 415-433		
424	Should low high-density lipoprotein cholesterol (HDL-C) be treated?. <b>2014</b> , 28, 353-68		48
423	High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies. <b>2014</b> , 114, 205-13		106
422	Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. <b>2014</b> , 349, g4379		297
421	Prolonged combination lipid therapy is associated with reduced carotid intima-media thickness: a case-control study of the 20-year Familial Atherosclerosis Treatment - Observational Study (FATS-OS). <b>2014</b> , 8, 489-93		7
420	The therapeutic role of niacin in dyslipidemia management. <b>2014</b> , 19, 141-58		41
419	HDL: to treat or not to treat?. <i>Current Atherosclerosis Reports</i> , <b>2014</b> , 16, 429	6	11
418	Modulation of adiponectin as a potential therapeutic strategy. <b>2014</b> , 233, 721-728		89
417	Impact of cardiac rehabilitation on angiographic outcomes after drug-eluting stents in patients with de novo long coronary artery lesions. <b>2014</b> , 113, 1977-85		6
416	Dietary modulators of statin efficacy in cardiovascular disease and cognition. <b>2014</b> , 38, 1-53		9
415	Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease. <b>2014</b> , 233, 713-720		63
414	Is HDL a prognostic biomarker for coronary atherosclerosis?. <b>2014</b> , 174, 465-7		6
413	Update in Hyperlipidemia Clinical Trials. <b>2014</b> ,		
412	Influence of material property variability on the mechanical behaviour of carotid atherosclerotic plaques: a 3D fluid-structure interaction analysis. <b>2015</b> , 31, e02722		16

411	Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control. <b>2015</b> , 11, 165-72	4
410	Bile Acid Sequestrants: Risk Benefits and Role in Treating Dyslipidemias. <b>2015</b> , 453-463	1
409	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. <b>2015</b> , 9, S1-122.e1	293
408	Is HPS2-THRIVE the death knell for niacin?. <b>2015</b> , 9, 343-50	8
407	Type 2 diabetes mellitus, metabolic syndrome, and mixed dyslipidemia: how similar, how different, and how to treat?. <b>2015</b> , 13, 1-21	21
406	Niacin and progression of CKD. <b>2015</b> , 65, 785-98	18
405	Safety and tolerability of extended-release niacin-laropiprant: Pooled analyses for 11,310 patients in 12 controlled clinical trials. <b>2015</b> , 9, 313-25	10
404	Combination Therapy In Dyslipidemia. <b>2015</b> ,	3
403	Therapeutic ultrasound: Increased HDL-Cholesterol following infusions of acoustic microspheres and apolipoprotein A-I plasmids. <b>2015</b> , 241, 92-9	10
402	Niacin ameliorates kidney warm ischemia and reperfusion injury-induced ventricular dysfunction and oxidative stress and disturbance in mitochondrial metabolism in rats. <b>2015</b> , 47, 1079-82	6
401	A pilot trial to examine the effect of high-dose niacin on arterial wall inflammation using fluorodeoxyglucose positron emission tomography. <b>2015</b> , 22, 600-9	3
400	Role for combination therapy in diabetic dyslipidemia. <b>2015</b> , 17, 32	21
399	Systematic review of CETP inhibitors for increasing high-density lipoprotein cholesterol: where do these agents stand in the approval process?. <b>2015</b> , 22, 147-58	11
398	Statins and Niacin: The End of Residual Risk Therapy?. <b>2015</b> , 37-43	1
397	[Progression of coronary atherosclerosis]. <b>2015</b> , 40, 835-6	
396	[Assessment of progression and regression of coronary atherosclerosis by coronary angiography]. <b>2015</b> , 40, 875-82	1
395	Effects of HDL-modifiers on cardiovascular outcomes: a meta-analysis of randomized trials. <b>2015</b> , 25, 9-23	26
394	Comprehensive Management of High Risk Cardiovascular Patients. <b>2016</b> ,	1

393	Cholesterol-Lowering Drugs and Therapies in Cardiovascular Disease. <b>2016,</b>	0
392	Differential Benefit of Statin in Secondary Prevention of Acute Myocardial Infarction according to the Level of Triglyceride and High Density Lipoprotein Cholesterol. <b>2016, 46, 324-34</b>	7
391	Therapeutic modulation of the natural history of coronary atherosclerosis: lessons learned from serial imaging studies. <b>2016, 6, 282-303</b>	10
390	Disorders of Lipid Metabolism. <b>2016, 1660-1700</b>	4
389	Regression of coronary atheroma with statin therapy. <b>2016, 23, 131-7</b>	9
388	Niacin is still beneficial. Implications from an updated meta-regression analysis. <b>2016, 71, 463-472</b>	5
387	Identifying stable coronary plaques with OCT technology. <b>2016, 2, 77-88</b>	2
386	All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT. <b>2016, 7, 1541-50</b>	1
385	Biochemistry of Statins. <b>2016, 73, 127-68</b>	16
384	Statin combination therapy and cardiovascular risk reduction. <b>2016, 12, 289-315</b>	9
383	Cardiac CT Imaging. <b>2016,</b>	4
382	High density lipoprotein and metabolic disease: Potential benefits of restoring its functional properties. <b>2016, 5, 321-327</b>	11
381	Angiographic progression of coronary atherosclerosis in patients with familial hypercholesterolaemia treated with non-statin therapy: Impact of a fat-modified diet and a resin. <b>2016, 252, 82-87</b>	7
380	Current statins show calcium channel blocking activity through voltage gated channels. <b>2016, 17, 43</b>	8
379	Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Study-Observational Study. <b>2016, 10, 1091-7</b>	4
378	Pleiotropic effects of niacin: Current possibilities for its clinical use. <b>2016, 66, 449-469</b>	11
377	The relationship between Lp(a) and CVD outcomes: a systematic review. <b>2016, 15, 95</b>	38
376	Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications: A joint position statement issued by eight medical societies. 2016 update. <b>2016, 128 Suppl 2, S216-28</b>	4

375	Effect of niacin on triglyceride-rich lipoprotein apolipoprotein B-48 kinetics in statin-treated patients with type 2 diabetes. <b>2016</b> , 18, 384-91		9
374	Reperfusion Therapy for Acute Myocardial Infarction. <b>2016</b> ,		
373	Longer duration of statin therapy is associated with decreased carotid plaque vascularity by magnetic resonance imaging. <b>2016</b> , 245, 74-81		17
372	Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part I: Alternative Niacin Regimens. <i>Current Atherosclerosis Reports</i> , <b>2016</b> , 18, 11	6	10
371	HDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation. <b>2016</b> , 20, 907-21		7
370	The pharmacokinetic characters of simvastatin after co-administration with Shexiang Baoxin Pill in healthy volunteers' plasma. <b>2016</b> , 1026, 162-167		3
369	Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin Mimetics. <i>Current Atherosclerosis Reports</i> , <b>2016</b> , 18, 17	6	19
368	Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. <b>2016</b> , 102, 198-203		39
367	Lipoprotein Metabolism and the Treatment of Lipid Disorders. <b>2016</b> , 715-736.e7		3
366	Lipoprotein (a): a Unique Independent Risk Factor for Coronary Artery Disease. <b>2016</b> , 31, 13-20		13
365	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. <b>2017</b> , 23, 1-87		535
364	Bile Acid as Therapeutic Agents. <b>2017</b> , 61-90		1
363	Niacin for primary and secondary prevention of cardiovascular events. <b>2017</b> , 6, CD009744		26
362	Dyslipidemia in diabetes mellitus and cardiovascular disease. <b>2017</b> , 6, 27-32		20
361	Niacin and heart disease prevention: Engraving its tombstone is a mistake. <b>2017</b> , 11, 1309-1317		25
360	Shared polymorphisms and modifiable behavior factors for myocardial infarction and high cholesterol in a retrospective population study. <b>2017</b> , 96, e7683		1
359	Is atherosclerosis imaging the most sensitive way to assess patients' risk and the best way to conduct future drug trials? A pros-and-cons debate. <b>2017</b> , 266, 229-233		3
358	Concerning Niacin in Current Clinical Practice. <b>2017</b> , 130, e347		

357	Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity. <b>2017</b> , 30, 166-173	19
356	Role of Niacin in Current Clinical Practice: A Systematic Review. <b>2017</b> , 130, 173-187	48
355	The Role of Interventional Cardiology to Our Understanding of Basic Mechanisms Related to Coronary Atherosclerosis: "Thinking outside the box". <b>2017</b> , 58, 110-114	5
354	The role of vitamins in the diet of the elderly II. Water-soluble vitamins. <b>2017</b> , 10, 146-166	2
353	Oxidative Stress-Mediated Atherosclerosis: Mechanisms and Therapies. <b>2017</b> , 8, 600	200
352	High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes. <b>2017</b> , 13, 168-182	4
351	A novel lipoprotein (a) lowering drug, D-47, decreases neointima thickening after vascular injury. <b>2017</b> , 64, 64-67	2
350	Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndromes and hypercholesterolemia not adequately controlled with statins: ODYSSEY J-IVUS rationale and design. <b>2018</b> , 71, 583-589	8
349	Lp(a) (Lipoprotein(a)) Levels Predict Progression of Carotid Atherosclerosis in Subjects With Atherosclerotic Cardiovascular Disease on Intensive Lipid Therapy: An Analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) Carotid Magnetic Resonance Imaging Substudy-Brief Report. <b>2018</b> , 38, 673-678	25
348	Diabetic Dyslipidemia: Epidemiology and Prevention of Cardiovascular Disease and Implications of Newer Therapies. <b>2018</b> , 20, 125	9
347	Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. <b>2018</b> , 25, 846-984	295
346	Primary and Secondary Prevention of Cardiovascular Disease. <b>2018</b> , 63-76	
345	Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events. <b>2018</b> , 20, 55	4
344	Atherosclerosis in cholesterol-fed rabbits and in homozygous and heterozygous LDL receptor-deficient humans. <b>2018</b> , 276, 148-154	4
343	Niacin. <b>2018</b> , 83, 83-149	36
342	Is high-density lipoprotein a modifiable treatment target or just a biomarker for cardiovascular disease?. <b>2019</b> , 8, 2048004019869736	1
341	Vulnerable Plaque, Characteristics, Detection, and Potential Therapies. <b>2019</b> , 6,	31
340	The Goal of Achieving Atherosclerotic Plaque Regression with Lipid-Lowering Therapy: Insights from IVUS Trials. <b>2019</b> , 26, 592-600	18

339	Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis. <b>2019</b> , 2, e192224	25
338	Niacin: an old lipid drug in a new NAD dress. <b>2019</b> , 60, 741-746	19
337	Altered Risk for Cardiovascular Events With Changes in the Metabolic Syndrome Status: A Nationwide Population-Based Study of Approximately 10 Million Persons. <b>2019</b> , 171, 875-884	38
336	Effect of Environmental and Occupational Exposures to Heavy Metals: The Health Implications. <b>2019</b> ,	
335	Nutrition, risk factors, prevention, and imaging: The 2018 Mario Verani Lecture. <b>2019</b> , 26, 86-91	
334	The role of mass spectrometry in studies of glycation processes and diabetes management. <b>2019</b> , 38, 112-146	11
333	Effect of statins on atherosclerotic plaque. <b>2019</b> , 29, 451-455	42
332	Management of Dyslipidemia. <b>2019</b> , 39-69	
331	Cholesterol Lowering and Stroke: No Longer Room for Pleiotropic Effects of Statins - Confirmation from PCSK9 Inhibitor Studies. <b>2020</b> , 133, 95-99.e6	9
330	Macrophages in Atherosclerosis Regression. <b>2020</b> , 40, 20-33	127
329	Effect of cholesterol re-supplementation and atorvastatin on plaque composition in the thoracic aorta of New Zealand white rabbits. <b>2020</b> , 20, 420	2
328	NAD Metabolism as an Emerging Therapeutic Target for Cardiovascular Diseases Associated With Sudden Cardiac Death. <b>2020</b> , 11, 901	10
327	Development and Validation of Prediction Model for Risk Reduction of Metabolic Syndrome by Body Weight Control: A Prospective Population-based Study. <b>2020</b> , 10, 10006	2
326	NAD homeostasis in health and disease. <b>2020</b> , 2, 9-31	141
325	Atherosclerosis: Making a U Turn. <b>2020</b> , 71, 191-201	16
324	Reversible Cardiomyopathies.	
323	Segmentation and Classification of Heart Angiographic Images Using Machine Learning Techniques. <b>2021</b> , 2021, 6666458	1
322	Concomitant use of tea catechins affects absorption and serum triglyceride-lowering effects of monoglucosyl hesperidin. <b>2021</b> , 12, 9339-9346	0

321	Organ and Metabolic Complications: Cardiac. <b>1996</b> , 990-1002	1
320	Coronary Artery Disease. <b>2012</b> , 179-216	2
319	Omega-3 Fatty Acids and Heart Disease. <b>1995</b> , 77-137	1
318	The Clinical Profile of Atherosclerosis. <b>1993</b> , 89-98	1
317	Hyperinsulinism and dyslipidemias as coronary heart disease risk factors in NIDDM. <b>1993</b> , 334, 295-301	9
316	Cutaneous microvascular responses are improved after cholesterol-lowering in patients with peripheral vascular disease and hypercholesterolaemia. <b>1997</b> , 428, 49-54	9
315	Usefulness of Intravascular Ultrasound for Detecting Atherosclerosis Progression Or Regression. <b>1997</b> , 239-250	1
314	Antioxidant Vitamins and Atherosclerosis. <b>2001</b> , 91-115	4
313	Cardiovascular Disease in Women. <b>2007</b> , 349-368	2
312	Niacin: Risk Benefits and Role in Treating Dyslipidemias. <b>2015</b> , 439-452	1
311	Cardiovascular Drugs. <b>2012</b> , 285-381	1
310	Use of Combination Statin and Bile Acid Sequestrant Therapy to Treat Dyslipidemia. <b>2015</b> , 1-10	2
309	Behandlung von Fettstoffwechselstörungen: Wann? Warum?. <b>1992</b> , 1-18	2
308	Lipid Apheresis. <b>1994</b> , 279-300	1
307	Nicotinic Acid and Derivatives. <b>1994</b> , 349-400	3
306	The Natural History of Saphenous Vein Grafts. <b>1994</b> , 3-15	4
305	Akuter Myokardinfarkt. <b>2000</b> , 393-442	1
304	The NHLBI Post-Coronary Artery Bypass Graft Clinical Trial (Post-CABG): angiographic outcomes. <b>1996</b> , 203-213	4



303	Modulation of the Mevalonate Pathway in Atherosclerosis and Tumors. <b>1996</b> , 111-118	1
302	Value and limitations of quantitative coronary angiography to assess progression or regression of coronary atherosclerosis. <b>1993</b> , 255-271	9
301	Progression and regression of coronary atherosclerosis: data from a controlled clinical trial with nicardipine. <b>1993</b> , 285-298	1
300	A maximum confidence strategy for measuring progression and regression of coronary artery disease in clinical trials. <b>1993</b> , 311-326	2
299	Lessons from Clinical Trials: LCAS and Other Studies. <b>1998</b> , 267-274	1
298	Applications of intravascular ultrasound in cardiology. <b>1998</b> , 133-148	3
297	Introduction to Invasive Assessment of the Coronary Circulation. <b>2000</b> , 25-49	1
296	Cardiovascular Disease. <b>1993</b> , 341-363	2
295	Relevance of Smooth Muscle Replication and Development to Vascular Disease. <b>1995</b> , 81-139	8
294	DYSLIPIDEMIAS. <b>2009</b> , 303-320	1
293	Lipids, Lipoproteins, Apolipoproteins, and Other Cardiovascular Risk Factors. <b>2012</b> , 731-805	4
292	The Contribution of Triglycerides and Triglyceride-Rich Lipoproteins to Atherosclerotic Cardiovascular Disease. <b>2011</b> , 230-251	1
291	Bile Acid Sequestrants. <b>2009</b> , 281-287	3
290	Transgenic mice expressing full-length human apolipoprotein B-100. Full-length human apolipoprotein B mRNA is essentially not edited in mouse intestine or liver.. <b>1992</b> , 267, 21412-21420	7
289	Regulation of human apolipoprotein A-I gene expression by equine estrogens. <b>2001</b> , 42, 1789-1800	19
288	Low density lipoproteins develop resistance to oxidative modification due to inhibition of cholesteryl ester transfer protein by a monoclonal antibody. <b>2000</b> , 41, 126-133	17
287	In vivo evidence of a role for hepatic lipase in human apoB-containing lipoprotein metabolism, independent of its lipolytic activity. <b>2000</b> , 41, 2094-2099	44
286	Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. <b>1993</b> , 34, 1637-1659	582

285	Effects of 2164U90 on ileal bile acid absorption and serum cholesterol in rats and mice.. <b>1995</b> , 36, 1098-1105	44
284	Prevalence of familial hypercholesterolemia among young north Karelian patients with coronary heart disease: a study based on diagnosis by polymerase chain reaction.. <b>1993</b> , 34, 269-277	45
283	The ansamycins: hypolipidemic agents stimulating cholesterol removal by nonclassical mechanisms.. <b>1994</b> , 35, 1524-1534	2
282	Trans-9-octadecenoic acid is biologically neutral and does not regulate the low density lipoprotein receptor as the cis isomer does in the hamster.. <b>1994</b> , 35, 1661-1673	42
281	The discovery and development of HMG-CoA reductase inhibitors.. <b>1992</b> , 33, 1569-1582	521
280	Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease. <b>1991</b> , 32, 383-394	165
279	Lipid Management. <b>2007</b> , 13, 40-47	0
278	Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. <b>1997</b> , 12, 209-15	45
277	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <b>2020</b> , 41, 2313-2330	301
276	Coronary artery disease risk predicted by insulin resistance, plasma lipids, and hypertension in people without diabetes. <b>2000</b> , 319, 84-8	24
275	Gender-based mortality follow-up from the Program on the Surgical Control of the Hyperlipidemias (POSCH) and meta-analysis of lipid intervention trials. Women in POSCH and other lipid trials. <b>1996</b> , 224, 486-98; discussion 498-500	4
274	The vulnerable coronary plaque. <b>2000</b> , 15, 1-12	8
273	Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia. <b>1996</b> , 27, 563-70	48
272	Effect of a reduced-fat diet with or without pravastatin on glucose tolerance and insulin sensitivity in patients with primary hypercholesterolemia. <b>1996</b> , 28, 595-602	8
271	Cholesterol awareness and treatment in patients with coronary artery disease participating in cardiac rehabilitation. <b>1996</b> , 16, 117-22	11
270	Comprehensive cardiac rehabilitation improves the control of dyslipidemia in secondary prevention. <b>1998</b> , 18, 408-15	18
269	Lipid lowering in the cardiac rehabilitation setting. <b>1999</b> , 19, 255-60	18
268	Review of the state of the art in cardiovascular endoscopy imaging of atherosclerosis using photoacoustic techniques with pulsed and continuous-wave optical excitations. <b>2019</b> , 24, 1-15	11

267	By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?. <b>1994</b> , 308, 367-72	813
266	Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) Report. <b>1995</b> , 15, 1049-56	67
265	A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. <b>1995</b> , 15, 1512-31	731
264	Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism. <b>1996</b> , 16, 236-49	17
263	Gemfibrozil stimulates apolipoprotein A-I synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell line (Hep G2). <b>1996</b> , 16, 1052-62	28
262	Improvement of atherosclerosis and stiffness of the thoracic descending aorta with cholesterol-lowering therapies in familial hypercholesterolemia. <b>1996</b> , 16, 955-62	46
261	Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. <b>1997</b> , 17, 265-72	239
260	Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). <b>1995</b> , 91, 2528-40	554
259	Cholesterol reduction yields clinical benefit. A new look at old data. <b>1995</b> , 91, 2274-82	132
258	Angiographic and clinical progression in unstable angina. From clinical observations to clinical trials. <b>1995</b> , 91, 2295-8	16
257	Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. <b>1995</b> , 92, 3172-7	280
256	Plasma HDL cholesterol, triglycerides, and adiposity. A quantitative genetic test of the conjoint trait hypothesis in the San Antonio Family Heart Study. <b>1995</b> , 92, 3240-8	73
255	Lipid lowering, regression, and coronary events. A review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council meeting. <b>1995</b> , 92, 646-56	45
254	A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. <b>1995</b> , 92, 1355-74	1704
253	Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. <b>1995</b> , 92, 1758-64	344
252	Late outcome after coronary artery bypass graft surgery in patients <b>1995</b> , 92, 1114-9	16
251	Effects of cholesterol lowering on the progression of coronary atherosclerosis in women. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy. <b>1995</b> , 92, 2404-10	38
250	Progression and regression of coronary stenosis in the long-term follow-up of vasospastic angina. <b>1995</b> , 92, 2446-56	49

249	Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. <b>1996</b> , 93, 34-41	138
248	LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. <b>1996</b> , 93, 1826-35	200
247	Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). <b>1996</b> , 94, 2381-8	104
246	Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Qubec cardiovascular study. <b>1996</b> , 94, 273-8	320
245	Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. CCAIT Study Group. <b>1996</b> , 94, 614-21	73
244	Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. <b>1996</b> , 94, 2146-53	117
243	Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease. <b>1997</b> , 95, 5-7	49
242	Clinical reality of lowering total and LDL cholesterol. <b>1997</b> , 95, 306-7	5
241	Hypobetalipoproteinemia is associated with low levels of hemostatic risk factors in the Framingham offspring population. <b>1997</b> , 95, 825-30	24
240	Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. <b>1997</b> , 95, 1126-31	674
239	Late regression of the dilated site after coronary angioplasty: a 5-year quantitative angiographic study. <b>1997</b> , 96, 468-74	54
238	Electron beam computed tomographic coronary calcium as a predictor of coronary events: comparison of two protocols. <b>1997</b> , 96, 1122-9	120
237	Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lipid Coronary Angiography Trial (LOCAT) Study Group. <b>1997</b> , 96, 2137-43	280
236	The intima. Soil for atherosclerosis and restenosis. <b>1995</b> , 77, 445-65	638
235	Echolucent carotid artery plaques are associated with elevated levels of fasting and postprandial triglyceride-rich lipoproteins. <b>1996</b> , 27, 2166-72	43
234	Lp A-I and Niacin. <b>2001</b> , 21, 1707-1709	1
233	Regulation of rat hepatic low density lipoprotein receptors. In vivo stimulation by growth hormone is not mediated by insulin-like growth factor I. <b>1996</b> , 97, 292-9	48
232	Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2. <b>1997</b> , 100, 2824-32	123

231	Vitamin Disorders. <b>2007</b> , 137-178	3
230	Section Review: Cardiovascular & Renal: Genetic therapies for vascular diseases and lipid disorders. <b>1995</b> , 4, 1129-1137	3
229	The effects of lipid-lowering therapy on graft patency in coronary bypass surgery patients. <b>2006</b> , 9, E626-9	3
228	Coronary heart disease in chronic renal insufficiency: some management considerations. <b>2000</b> , 11, 1948-1956	24
227	Optimal lipid modification: the rationale for combination therapy. <b>2005</b> , 1, 317-31	18
226	Lipid management in Type 2 diabetes: the case for combination therapy?. <b>2011</b> , 8, 129-141	2
225	Role of mitogen-activated protein kinases and protein kinase C in regulating low-density lipoprotein receptor expression. <b>2002</b> , 10, 153-64	7
224	Knowledge, Attitudes, Treatment Practices, and Health Behaviors of Nurses Regarding Blood Cholesterol. <b>1999</b> , 30, 13-19	7
223	Influence of non-Newtonian properties of blood on the wall shear stress in human atherosclerotic right coronary arteries. <b>2011</b> , 8, 73-90	17
222	Nicotinic acid: a lipid-lowering agent with unrealized potential. <b>2014</b> , 26, 1-5	1
221	Correlation of Friedewald's calculated low-density lipoprotein cholesterol levels with direct low-density lipoprotein cholesterol levels in a tertiary care hospital. <b>2017</b> , 7, 57-62	8
220	Cardiovascular and Perceived Exertion Response to Treadmill Running and Cycle Ergometer Exercise in Responder and Nonresponder Acute Coronary Syndrome Patients. <b>2008</b> , 18, 1263-1270	1
219	HDL2 can inhibit further oxidative modification of partially oxidized LDL. <b>2010</b> , 17, 229-34	3
218	Treatment--drug therapy. <b>2008</b> , 15, 167-78	3
217	Successful management of primary hypercholesterolaemia with simvastatin and low-dose colestipol. <b>1992</b> , 157, 455-9	11
216	Is regression of human atherosclerosis a clinical reality?. <b>1994</b> , 160, 531-532	1
215	The Effects of Niacin on Inflammation in Patients with Non-ST Elevated Acute Coronary Syndrome. <b>2015</b> , 31, 120-6	5
214	Anatomie und Pathologie des Koronargefäßsystems, Physiologie und Pathophysiologie der Koronardurchleitung, Pathogenese der Atherosklerose. <b>2000</b> , 295-326	

- 213 Klinik und Diagnostik der koronaren Herzkrankheit. **2000**, 327-353
- 212 Lipid-Lowering Drugs. **2000**, 155-177
- 211 Therapie der stabilen und instabilen Angina pectoris. **2000**, 355-391
- 210 Lipidsenkende Mittel. **2000**, 382-391
- 209 Lipid-Lowering Drugs. **2000**, 215-238
- 208 Hypertriglyceridemia and low high-density lipoprotein: risks for coronary artery disease?. **2000**, 14, 79-90 ○
- 207 ????????? : ????(?????????, ??????) : 8.?????????(?64? ?????????????). **2000**, 8, 315-318
- 206 Endothelial Cell and Smooth Muscle Cell Biology in Vascular Disease. **2001**, 971-987
- 205 Coronary Atherosclerosis: Chronic Coronary Syndromes. **2002**, 779-820
- 204 Diabetes: A Growing CHD Epidemic. **2002**, 109-114
- 203 Intracoronary Ultrasound Imaging. **2002**, 127-140
- 202 References. **2002**, 106, 3373-3421 1
- 201 Koronarinsuffizienz und Herzinfarkt. **2003**, 3-29
- 200 Antihyperlipidemic Agents. **2003**, 339-383
- 199 Lipid-Lowering Drugs. **2003**, 165-191
- 198 Atherosclerotic Regression—Myth or Reality. **2003**, 323-339
- 197 Hyperlipidaemia as a risk factor for vascular heart disease. **2003**, 1-18
- 196 Lipid control in the pre-statin era. **2003**, 19-31

195 Cardiovascular Drugs. **2004**, 219-292

194 Koronarangiographie, Herzkatheterisierung und Angiokardiographie. **2004**, 281-317

193 Bedside Platelet Monitoring. **2004**, 495-520

192 Cellular and Molecular Mechanisms of Plaque Rupture. **2004**, 1-17

191 Pharmacological Treatments of Lipid Abnormalities. **2005**, 183-212

190 Assessment of Coronary Artery Disease with Cardiac PET/CT. **2006**, 433-451

189 Triglycerides and Risk for Atherosclerotic Disease. **2006**, 341-388

188 The Metabolic Syndrome: Identification and Management of the Patient at High Risk for Cardiovascular Disease. **2006**, 409-440

187 Management of Elevated Low-Density Lipoprotein Cholesterol. **2006**, 255-294

186 Pharmacological Therapy for Cardiovascular Disease. **2007**, 121-148

185 The Steps Beyond Diet and Drug Therapy for Severe Hypercholesterolemia. **2007**, 555-566

184 Myocardial Perfusion Imaging with PET. **2007**, 151-159

183 Pharmacologic Therapy for Hypertriglyceridemia and Low HDL: Rationale for Combination Therapy. **2007**, 515-527

182 Utilization of Lipoprotein Subfractions. **2007**, 321-347

181 Drugs for Elevated LDL-Cholesterol. **2007**, 528-539

180 Reaching target lipid levels in patients at high risk of cardiovascular event: the experience of a Canadian tertiary care lipid clinic. **2007**, 15, 106-9

1

179 [New trends in lipidology: the increasing role of HDL-cholesterol]. **2008**, 149, 1395-404

178 Evolving Targets of Therapy. **2009**, 387-395

- 177 Lipid Disorders. **2009**, 65-75
- 176 Genetic Dyslipidemia. **2009**, 71-84
- 175 Endocannabinoid Receptor Blockers. **2009**, 339-351
- 174 Pathophysiology of Vascular Disease. **2010**, 11-28
- 173 Bewegungstherapie bei koronarer Herzkrankheit. **2010**, 115-142 1
- 172 Effects of Niacin on HDL Metabolism. **2010**, 145-149
- 171 Natural History and Impact of Interventions on Coronary Calcium. **2010**, 59-68
- 170 Lipoprotein Metabolism and the Treatment of Lipid Disorders. **2010**, 788-807
- 169 Residual Risk Reduction Initiative: vřva ke snıenıreziduıhıo vaskuluıhıo rizika u pacientıhıo dyslipidemiı**2010**, 52, 212-228
- 168 The Metabolic Syndrome: 2009. **2011**, 137-163
- 167 Management of Dyslipidemia. **2011**, 59-89
- 166 Strategies for Treating Abnormal Lipid Profiles with Drugs. **2011**, 163-193
- 165 Diabetic Dyslipidemia. **2011**, 213-238 1
- 164 The Statin Response Gene: KIF6. **2011**, 175-198
- 163 Drug Therapy and Follow-Up. **2011**, 563-631
- 162 Low-Density Lipoprotein Cholesterol. **2011**, 215-229
- 161 Disorders of Lipid Metabolism. **2011**, 1633-1674
- 160 Prevention of Coronary Artery Disease. **2012**, 497-508



159 Krankheiten des Herzens. **2012**, 335-393

158 Lipid-lowering therapy. **2012**, 68-77

157 The highs and lows of high-density lipoprotein. **2013**, 70-87

156 Evaluation of Medical Therapies and Intravascular Devices with Quantitative Coronary Angiography. **2014**, 41-49

155 Koronare Herzkrankheit. **1991**, 357-474

154 Hypercholesterinämie und kardiovaskuläre Risikofaktoren. **1991**, 82-86

153 Neue Strategien in der Therapie der Fettstoffwechselstörung. **1991**, 23-28

152 The Influence of Nifedipine on the Progression of Coronary Artery Disease in Man: The INTACT Study. **1991**, 203-221

1

151 Kontrolle von Risikofaktoren bei dokumentierter koronarer Herzkrankheit (KHK): Ist eine Regression möglich?. **1991**, 35-43

150 Progression der koronaren Herzerkrankung unter körperlichem Training und fettarmer Ernährung. **1991**, 29-34

149 Entwicklungsschwerpunkte der Rehabilitation in den 90ern. **1991**, 113-119

148 Lipids: Outstanding Questions. **1991**, 155-163

147 Neue Aspekte der Arteriosklerose. **1991**, 223-244

146 Pharmacological Approaches to the Regression of Atherosclerotic Lesions of the Carotid or Coronary Arteries. **1992**, 149-157

145 Korrektur von Übergewicht durch Ernährungsschulung und körperliches Training: Langzeitergebnisse bei mehrjähriger Behandlung. **1992**, 95-101

144 Cholesterol-Lowering Clinical Trials: Where Do We Go From Here?. **1992**, 167-176

143 Endothelium, Lipoproteins and Atherosclerosis. Effects of Lipid Lowering and Lipid Modification Therapy. **1993**, 103-119

142 Determinants for Coronary Atherosclerosis Regression. The Marburg Lipid Intervention Trial. **1993**, 197-204

- 141 Regression of Coronary Atherosclerosis by LDL-Apheresis. **1993**, 293-297
- 140 Hypercholesterolemia: Negotiating the Issues. **1993**, 309-315
- 139 Clinical Trials of Atherosclerosis Regression. **1993**, 241-249
- 138 Aktuelle Fragen zur Genese und Therapie der Atherosklerose. **1993**, 18-31
- 137 Calcium Antagonists and Lipid-Lowering Agents in the Protection of the Arterial Wall. **1993**, 125-132
- 136 Coronary Artery Disease. **1993**, 253-273 1
- 135 A Pathologist's view of quantitative coronary arteriography. **1993**, 3-14
- 134 Regression and Decrease in Progression of Coronary Artery Disease Through Lipid-Lowering Therapy. **1993**, 399-406
- 133 Treatment of hyperlipidemia in the elderly. **1993**, 67-70
- 132 Causes Underlying the Reduced Response to Simvastatin Treatment in Hypercholesterolemic Patients. **1993**, 207-229
- 131 The HMG-CoA Reductase Inhibitors Story. **1993**, 159-166
- 130 Antiatherosclerotic Drugs: A Critical Assessment. **1993**, 317-331 3
- 129 Apolipoprotein(a) and atherogenesis. **1993**, 25, 291-3
- 128 Zur LDL-Apherese. **1993**, 201-205
- 127 Drugs Affecting High-Density Lipoprotein and Triglyceride Metabolism. **1993**, 199-213
- 126 Combined Drug Treatment of Severe Hypercholesterolemia. **1993**, 283-292
- 125 Understanding the Initiating Factors in Atherosclerosis: Implications for Intervention. **1993**, 117-124
- 124 Pharmacotherapy of critical limb ischaemia. **1994**, 95-112

- 123 Progression or regression of coronary atherosclerosis: Assessment with quantitative coronary angiography. **1994**, 635-651
- 122 Antiplatelet Drugs. **1994**, 276-298
- 121 Coronary Intravascular Ultrasonography. **1994**, 465-479
- 120 Drugs for treatment of patients with high cholesterol blood levels and other dyslipidemias. **1994**, 43, 9-41 4
- 119 Low Density Lipoprotein Subclass Phenotypes. **1994**, 105-113 1
- 118 Coronary atherosclerosis intervention trials using serial quantitative angiography. **1994**, 653-665
- 117 Intravascular ultrasound: An evolving rival for quantitative coronary angiography. **1994**, 695-715
- 116 Diagnostics of Lipids and Lipoproteins. **1994**, 33-73
- 115 Quantitative and Qualitative Coronary Angiography. **1994**, 267-275
- 114 Endothelial function in atherosclerosis. **1994**, 19-30
- 113 An Introduction to the Biochemistry and Biology of Blood Lipids and Lipoproteins. **1994**, 3-27
- 112 Treatment of Severe Hypercholesterolemia in Patients with Coronary Heart Disease by Means of Lipoprotein Apheresis. **1994**, 259-275
- 111 Rationale to Treat. **1994**, 221-245
- 110 Ion Exchange Resins. **1994**, 401-427
- 109 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitors. **1994**, 303-324
- 108 Vascular mechanisms leading to myocardial ischemia and their relation to hypertension, left ventricular hypertrophy and arrhythmias. **1994**, 205-211
- 107 Koronare Herzerkrankung und akuter Herzinfarkt [Aktuelle Aspekte der Pathogenese, Symptomatologie und des klinischen Verlaufs. **1994**, 48-98
- 106 Lipid-lowering therapy--implications for the prevention of atherosclerosis. **1994**, 89 Suppl 1, 185-98

- 105 LIPIDS, ATHEROSCLEROSIS, AND THE POSTMENOPAUSAL WOMAN: A Clinical Perspective. **1994**, 21, 337-355 8
- 104 Lipid Risk Factors and the Regression of Atherosclerosis. **1995**, 1-5
- 103 HDLC as a therapeutic target in coronary disease: current concepts and future directions. **1995**, 29-42
- 102 Effects of Simvastatin Treatment on Thromboxane (TX) Biosynthesis and Platelet Function in Type II Hypercholesterolemia (HC). **1995**, 349-352
- 101 Cholesterol-Lowering Coronary Angiography Trials: An Overview. **1995**, 321-333
- 100 The Impact of High-Density Lipoprotein Cholesterol on Cardiovascular Risk: The Bezafibrate Infarction Prevention (BIP) Study. **1995**, 373-378
- 99 Lipid Accumulation and Plaque Disruption: Processes Triggering Clinical Instability in Coronary Disease. **1995**, 1-9
- 98 Atherosclerosis. **1995**, 135-150
- 97 Clinical efficacy and safety of pravastatin treatment in symptomatic patients [the REGRESS trial]. **1996**, 85-106
- 96 Koronarangiographie. **1996**, 375-400
- 95 Canadian coronary atherosclerosis study on the effect of lovastatin on the progression of coronary artery disease (CCAIT): why are results different?. **1996**, 167-178
- 94 Impact upon angiographic disease progression following step drug therapy in normolipidaemic patients: results of the Harvard Atherosclerosis Reversibility Project (HARP). **1996**, 179-191
- 93 The H.E.L.P. System: Clinical Experience of 10 Years. **1996**, 521-529
- 92 Quality control in quantitative coronary arteriography. **1996**, 45-63 6
- 91 Angiographic endpoints in progression trials. **1996**, 71-77 2
- 90 Familial Atherosclerosis Treatment Study. **1996**, 107-113
- 89 Effect of aggressive versus conventional lipid-lowering treatment on coronary and peripheral atherosclerosis: design and baseline characteristics of the LDL-Apheresis Atherosclerosis Regression Study (LAARS). **1996**, 193-202
- 88 Assessment of Myocardial Perfusion with <sup>13</sup>N-Ammonia or <sup>82</sup>Rb. **1996**, 121-146

87 Koronare Herzkrankheit und Herzinfarkt. **1996**, 421-554

86 Lessons from the Monitored Atherosclerosis Regression Study (MARS) and beyond: atherosclerosis progression/regression responses to therapy depend on lesion size and composition. **1996**, 131-141

85 The use of metabolic measurements in angiographic regression trials. **1996**, 31-43

84 The Multicenter Anti-Atheroma Study (MAAS). **1996**, 119-130

83 Gene therapy for the vulnerable atherosclerotic plaque. **1996**, 395-412

82 Drug Combinations in the Practice of a Lipid Clinic. **1996**, 505-511

81 Long-Term Effect of Ldl-Apheresis on Coronary Heart Disease. **1996**, 513-519

80 Angiographic Trials on Progression and Regression of Atherosclerosis by Plasma Lipid Reduction. **1996**, 125-136

79 Lessons learned from angiographic coronary atherosclerosis trials. **1996**, 119-132

2

78 Management of Peripheral Vascular Disease. **1997**, 391-409

77 Cardiovascular Changes of the Perimenopause and Menopause. **1997**, 210-232

76 Remodeling: Accelerator or Decelerator of Luminal Narrowing in Human Atherosclerotic Arteries. **1997**, 69-80

75 Assessment of Lipoproteins. **1997**, 170-217

1

74 Introduction to Invasive Assessment of the Coronary Circulation. **1997**, 25-47

73 Longterm renal function protection in renal transplantation by nonimmunological treatments. **1997**, 167-174

72 Intracoronary Ultrasound Imaging. **1997**, 260-280

71 Unstable Angina Pectoris. **1998**, 103-142

70 How well does angiographic progression correlate with clinical events?. **1998**, 113-117

- 69 Early Markers of Cardiovascular Damage. **1998**, 103-122
- 68 How should future angiographic trials be designed?. **1998**, 119-131
- 67 Pathophysiology of Atherosclerosis. **1998**, 3-58
- 66 Arteriosklerose. **1998**, 34-74 2
- 65 Borderline Indications for Heart Transplantation and Alternative Measures. **1998**, 99-108
- 64 Lipoproteins and Apoproteins. **1999**, 28-68
- 63 Pathophysiology of Vascular Disease. **1999**, 11-29
- 62 Cholesterol Lowering. **1999**, 571-592
- 61 Lipid Lowering Therapy. **1999**, 69-101
- 60 Koronarinsuffizienz und Herzinfarkt. **1999**, 3-31
- 59 Lipidsenkende Mittel. **1999**, 356-365
- 58 Statin therapy and atherosclerosis stabilization in carotid arteries. **2015**, 6, 36-45
- 57 Natural History and Impact of Interventions on CAC. **2016**, 121-132
- 56 Coronary atherosclerosis regression - theory, facts and clinical relevance. **2016**, 15, 179-182
- 55 Akut Miyokard İnfarkti Tanısında Kardiyak Markörlerin İlemi. 11-17 1
- 54 The Basis of Atherosclerotic Guidelines—Time for a Change?. **2018**, 08, 337-352 1
- 53 Evaluations of factors affecting the outcome of redo coronary bypass surgery and long term results: A retrospective observational study.
- 52 The Role of Aggressive Lipid Lowering Therapy for Coronary Artery Disease. **2019**, 65, 468-473

- 51 Intestinally Active Therapies for Hypercholesterolemia: Ezetimibe, Bile Acid Resins, and Plant Sterols. **2021**, 219-268
- 50 Krankheiten des Herzens. **2008**, 311-373
- 49 Antioxidants and Chronic Vascular Disease: Animal Studies. **2006**, 227-253
- 48 Natural History and Impact of Interventions on Coronary Calcium. **2006**, 97-106
- 47 Koronarinsuffizienz und Herzinfarkt. **2005**, 3-33
- 46 Pathogenesis of the Acute Coronary Syndromes: Hypotheses Generated from Clinical Experience. **1997**, 183-205
- 45 Gene therapy for the vulnerable plaque. **1997**, 547-560
- 44 Prevention of Atherosclerosis: Endothelial Function, Cholesterol, and Antioxidants. **1999**, 77-106
- 43 Risk Factors. **2005**, 475-516
- 42 Rehabilitation After Acute MI. **2005**, 531-541
- 41 The Unstable Plaque. **2006**, 3-17
- 40 Cardiac Rehabilitation. **2006**, 119-145 1
- 39 Lipoproteins in Diabetes: Risk and Opportunity. **2008**, 265-288
- 38 Marine lipids normalize cholesteryl ester transfer in IDDM. **1996**, 39, 487-491
- 37 Lipids, atherosclerosis, and restenosis after percutaneous transluminal coronary angioplasty. **1992**, 19, 54-61 3
- 36 Niacin--the long and the short of it. **1991**, 155, 424-6 2
- 35 Cardiac rehabilitation. Current status and future directions. **1992**, 156, 183-8 10
- 34 Why is cardiac rehabilitation not widely used?. **1992**, 156, 206-8 7

33	Drs malloy and kane respond. <b>1992</b> , 156, 209	0
32	Atherosclerosis--reversal with therapy. <b>1993</b> , 159, 172-9	14
31	Regression of atherosclerosis--an ounce of prevention. <b>1993</b> , 159, 208-10	
30	Why are low-density lipoproteins atherogenic?. <b>1994</b> , 160, 153-64	41
29	Low-density lipoprotein oxidation and the pathogenesis of atherosclerosis. <b>1994</b> , 160, 183-4	3
28	Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. <b>2000</b> , 162, 1441-7	46
27	Does lipid-lowering therapy promote regression of coronary atheroma?. <b>1994</b> , 44, 3-4	1
26	Apolipoproteins and risk of coronary heart disease. <b>1991</b> , 144, 1277	1
25	Preventive medicine in primary care: management of hyperlipidaemia. <b>1992</b> , 42, 47-50	1
24	Regression of atherosclerosis. <b>1991</b> , 144, 459	1
23	Rous-Whipple Award Lecture. Atherosclerosis: a defense mechanism gone awry. <b>1993</b> , 143, 987-1002	222
22	The coronary angiogram and its seminal contributions to cardiovascular medicine over five decades. <b>2002</b> , 113, 261-71	6
21	The Jeremiah Metzger Lecture. Pathogenesis of atherosclerosis: redox as a unifying mechanism. <b>2003</b> , 114, 273-304	9
20	Hypercholesterolemia screening. Does knowledge of blood cholesterol level affect dietary fat intake?. <b>1998</b> , 44, 1289-97	17
19	Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors. <b>2007</b> , 3, 733-42	10
18	Reductase inhibitor therapy of hypercholesterolemia. <b>1991</b> , 102, 153-63; discussion 163-5	1
17	Obstructive sleep apnea and cardiovascular disease: role of the metabolic syndrome and its components. <b>2008</b> , 4, 261-72	67
16	Obstructive sleep apnea and cardiovascular disease: evidence and underlying mechanisms. <b>2009</b> , 48, 277-293	29



15	Exchanging carbohydrate or protein for fat improves lipid-related cardiovascular risk profile in overweight men and women when consumed ad libitum. <b>2010</b> , 58, 711-9		
14	An overview of cholesterol management. <b>2008</b> , 1, 39-48		10
13	Impaired lipid levels and inflammatory response in rats exposed to cadmium. <b>2012</b> , 11, 677-687		17
12	Lipid profile and Atherogenic Indices in Nigerians Occupationally Exposed to e-waste: A Cardiovascular Risk Assessment Study. <i>Mdica</i> , <b>2020</b> , 15, 196-205		
11	Simvastatin with or without ezetimibe in familial hypercholesterolemia. <i>Current Atherosclerosis Reports</i> , <b>2009</b> , 11, 3-5, 8	6	
10	The Immunomodulatory Effects of Statins on Macrophages. <i>Immuno</i> , <b>2022</b> , 2, 317-343		2
9	Achieving coronary plaque regression: a decades-long battle against coronary artery disease.. <i>Expert Review of Cardiovascular Therapy</i> , <b>2022</b> ,	2.5	0
8	Lipid-modifying and antiatherosclerotic drugs. <b>2013</b> , 398-435		3
7	A small H <sub>2</sub> O-soluble ingredient of royal jelly lower cholesterol levels in liver cells by suppressing squalene epoxidase.		
6	NURSING INTERVENTIONS FOR RISK FACTOR REDUCTION. <b>1992</b> , 27, 257-270		1
5	THE EPIDEMIOLOGIC BASIS OF CORONARY DISEASE PREVENTION. <b>1992</b> , 27, 153-170		0
4	A Small H <sub>2</sub> O-Soluble Ingredient of Royal Jelly Lower Cholesterol Levels in Liver Cells by Suppressing Squalene Epoxidase.		0
3	Pleotropic effects of statins: the dilemma of wider utilization of statin. <b>2023</b> , 75,		1
2	Koronare Herzkrankheit [Begutachtung. <b>2022</b> , 1-25		0
1	Nephrotic syndrome and acute coronary syndrome in children, teenagers and young adults: Systematic literature review. <b>2023</b> ,		0